The Cancer Genome Atlas
Powered by SNPnexus
Overview
Help
Sex
Survival Status
Race
ER Status
HER2 Status
Survival Time (Years)
Age at Diagnosis
Genetic Ancestry
Loading...
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| BRCA1 | Q934* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | Q934* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | Q934* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | Q934* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | Q934* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | Q934* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | Q934* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | Q934* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | Q934* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | Q934* | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | Q934* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | Q934* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q944* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q944* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q944* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q944* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | H1047L | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047L | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047L | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047L | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047L | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047L | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047L | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047L | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| CDH1 | Q23* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ROS1 | P194S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | P194S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | P194S | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | P194S | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | P194S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| CDH1 | R63* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| NF1 | R366* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | R366* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | R366* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | R366* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | R366* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | R366* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | R366* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | R366* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | R366* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | R366* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | R366* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | R366* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | R366* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | R366* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | R366* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | R366* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | R366* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | R366* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | R366* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | R366* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | R366* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | R366* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | R366* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | R366* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | R366* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | R366* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | R366* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | R366* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | R366* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | R366* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | R366* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | R366* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | R366* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | R366* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | R366* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | R366* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | R366* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | R366* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | R366* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | R366* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | R366* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | R366* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | R366* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | R366* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | R366* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | R366* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | R366* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| PIK3CA | E542K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E542K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E542K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E542K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E542K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E542K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ARID1A | Q479* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q479* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q479* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q479* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB2 | V777L | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | V777L | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V777L | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V777L | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | V777L | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | V777L | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | V777L | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | V777L | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | V777L | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | V777L | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | V777L | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V777L | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | V777L | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V777L | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | V777L | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | V777L | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | V777L | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V777L | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | V777L | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | V777L | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | V777L | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | V777L | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | V777L | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | V777L | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | V777L | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | V777L | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | V777L | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | V777L | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | V777L | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | V777L | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | V777L | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | V777L | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| CDH1 | splice_donor_variant | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| RB1 | S829* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | S829* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | S829* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | S829* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | S829* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | S829* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | S829* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| TP53 | R175H | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R175H | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R175H | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R175H | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R175H | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R175H | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R175H | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R175H | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R175H | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R175H | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R175H | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R175H | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R175H | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R175H | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R175H | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (E726K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| AKT3 | L151F | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | Q393* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q393* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q393* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q393* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ERCC4 | R8* | Complete Match | Cisplatin (Chemotherapy) | Responsive | OV | Pre-clinical |
| NF1 | Q535* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | Q535* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | Q535* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q535* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q535* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q535* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | Q535* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | Q535* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | Q535* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q535* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q535* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | Q535* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q535* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q535* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q535* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | Q535* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q535* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q535* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q535* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q535* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q535* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q535* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q535* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q535* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q535* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | Q535* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q535* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q535* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q535* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | Q535* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q535* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q535* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q535* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q535* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | Q535* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q535* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q535* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q535* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q535* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q535* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q535* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q535* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q535* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q535* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q535* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q535* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| ESR1 | Q17H | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| JAK2 | R133P | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| BRAF | S112C | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | S112C | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | S112C | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | S112C | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| SETD2 | S461* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | S461* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E542K), PIK3CA MUT (R88Q | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PML | intron_variant | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | intron_variant | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | intron_variant | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| NF1 | W571* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | W571* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | W571* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W571* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | W571* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | W571* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | W571* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | W571* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | W571* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W571* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | W571* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | W571* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | W571* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W571* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W571* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | W571* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W571* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W571* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | W571* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | W571* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W571* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W571* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | W571* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W571* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | W571* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | W571* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | W571* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W571* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | W571* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W571* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | W571* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | W571* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W571* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W571* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W571* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | W571* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | W571* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W571* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W571* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | W571* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W571* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W571* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | W571* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | W571* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | W571* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | W571* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W571* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | V272M | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V272M | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V272M | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V272M | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V272M | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V272M | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V272M | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V272M | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V272M | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V272M | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V272M | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V272M | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V272M | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V272M | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V272M | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | H1047R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | M133K | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | M133K | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | M133K | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | M133K | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | M133K | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | M133K | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | M133K | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M133K | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M133K | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | M133K | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | M133K | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | M133K | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M133K | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | M133K | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M133K | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | G118D | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | G118D | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | G118D | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G118D | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | G118D | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G118D | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | G118D | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | G118D | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| KMT2A | V3015I | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | V3015I | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | V3015I | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | V3015I | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | V3015I | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | V3015I | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E542K), PIK3CA MUT (M1004I | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | R196* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R196* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R196* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R196* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R196* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R196* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R196* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R196* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R196* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R196* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R196* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R196* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R196* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R196* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R196* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| AKT3 | L274L | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | G1049R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | G1049R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | G1049R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G1049R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | G1049R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G1049R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | G1049R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | G1049R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| CHEK2 | Q69* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| CHEK2 | Q69* | Different Alteration | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| PTPRD | L1535* | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| TP53 | S183* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S183* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S183* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S183* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S183* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S183* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S183* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S183* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S183* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S183* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S183* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S183* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S183* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S183* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S183* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273L | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273L | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273L | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273L | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273L | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273L | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273L | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273L | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273L | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273L | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273L | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273L | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273L | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273L | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273L | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | splice_donor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | splice_donor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | splice_donor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | splice_donor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | splice_donor_variant | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| TP53 | Y220C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y220C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y220C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y220C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y220C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y220C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y220C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y220C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y220C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y220C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK1 | L196M | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | L196M | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | L196M | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | L196M | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| BRD4 | 3-UTRSNV | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| FGFR2 | V122M | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | V122M | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273H), TP53 MUT (D208G | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273H), TP53 MUT (D208G | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | L792L | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | L792L | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PIK3CA | H1047Y | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047Y | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047Y | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047Y | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047Y | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047Y | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047Y | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047Y | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | R88Q | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | R88Q | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | R88Q | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | R88Q | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | R88Q | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | R88Q | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | R88Q | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | R88Q | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PTEN | R130* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R130* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R130* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | R130* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | R130* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | R130* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R130* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R130* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R130* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | R130* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R130* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R130* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | R130* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R130* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R130* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R130* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | R130* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R130* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R130* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R130* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R130* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R130* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R130* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R130* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R130* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| CDH1 | G278* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | E545K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E545K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E545K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E545K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E545K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E545K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | Q331* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q331* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q331* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q331* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q331* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q331* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q331* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q331* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q331* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q331* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q331* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q331* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q331* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q331* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q331* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | Q511* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| BRCA2 | Y3308* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | Y3308* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | Y3308* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | Y3308* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | Y3308* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | Y3308* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | Y3308* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | Y3308* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | Y3308* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | Y3308* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | Y3308* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | Y3308* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | Y3308* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | Y3308* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| AKT3 | G265R | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| BCR | T634T | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | T634T | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | T634T | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | T634T | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | T634T | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | T634T | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| STAG2 | G540* | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| TP53 | G199V | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G199V | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G199V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G199V | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G199V | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G199V | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G199V | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G199V | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G199V | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G199V | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G199V | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G199V | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G199V | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G199V | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G199V | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | L206* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | L206* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | L206* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | L206* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | L206* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | L206* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | L206* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| PIK3CA | N345K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | N345K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | N345K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N345K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | N345K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N345K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | N345K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | N345K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| KMT2A | S2872L | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | S2872L | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | S2872L | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | S2872L | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | S2872L | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | S2872L | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| BCR | intron_variant | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | intron_variant | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | intron_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| TP53 | Y234C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y234C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y234C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y234C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y234C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y234C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y234C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y234C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y234C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y234C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y234C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y234C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y234C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y234C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y234C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RNF43 | S425* | Complete Match | Porcupine inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | G2381G | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | L824L | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | L824L | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | L824L | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| SF3B1 | K700E | Complete Match | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R342* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R342* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R342* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R342* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R342* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R342* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R342* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R342* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R342* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R342* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R342* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R342* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R342* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R342* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R342* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | K3048T | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | K3048T | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | K3048T | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | K3048T | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | K3048T | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | K3048T | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ATM | R3047* | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | R3047* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | R3047* | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | R3047* | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | R3047* | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | R3047* | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | R3047* | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | R3047* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | R3047* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | R3047* | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | R3047* | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | R3047* | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | R3047* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| FBXW7 | R479Q | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | R479Q | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | R479Q | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | R479Q | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| BRCA2 | L2926* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | L2926* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | L2926* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | L2926* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | L2926* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | L2926* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | L2926* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | L2926* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | L2926* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | L2926* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | L2926* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | L2926* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | L2926* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | L2926* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| SMARCA4 | E1611* | Complete Match | EZH2 inhibitor | Responsive | OVRT | Case report |
| SMARCA4 | E1611* | Complete Match | AURKA inhibitor | Responsive | NSCLC | Pre-clinical |
| SMARCA4 | E1611* | Complete Match | EZH2 inhibitor | Responsive | OV | Case report |
| SMARCA4 | E1611* | Different Alteration | EZH2 inhibitor | Responsive | OVRT | Case report |
| SMARCA4 | E1611* | Different Alteration | EZH2 inhibitor | Responsive | OV | Case report |
| PDGFRA | R981P | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| CDH1 | splice_acceptor_variant | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | Q546R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | Q546R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | Q546R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Q546R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | Q546R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Q546R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | Q546R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | Q546R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | L755W | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | L755W | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | L755W | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | L755W | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | L755W | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | L755W | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | L755W | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | L755W | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | L755W | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | L755W | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | L755W | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755W | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | L755W | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | L755W | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | L755W | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | L755W | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | L755W | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | L755W | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | L755W | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | L755W | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755W | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | L755W | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | L755W | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | L755W | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | L755W | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | L755W | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| ERBB2 | R678Q | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | R678Q | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | R678Q | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | R678Q | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | R678Q | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | R678Q | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | R678Q | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | R678Q | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | R678Q | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | R678Q | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | R678Q | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | R678Q | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | R678Q | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | R678Q | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | R678Q | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | R678Q | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | R678Q | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | R678Q | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | R678Q | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | R678Q | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | R678Q | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | R678Q | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | R678Q | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | R678Q | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | R678Q | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| MET | I565M | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | P278L | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P278L | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P278L | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P278L | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P278L | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P278L | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P278L | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278L | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278L | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P278L | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P278L | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P278L | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278L | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P278L | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278L | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | W1048* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | W1048* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | W1048* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W1048* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | W1048* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | W1048* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | W1048* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | W1048* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | W1048* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W1048* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | W1048* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | W1048* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | W1048* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W1048* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W1048* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | W1048* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W1048* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W1048* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | W1048* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | W1048* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W1048* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W1048* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | W1048* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W1048* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | W1048* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | W1048* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W1048* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | W1048* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W1048* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | W1048* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | W1048* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W1048* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | W1048* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W1048* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | W1048* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | W1048* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | W1048* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W1048* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | W1048* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | W1048* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | W1048* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | W1048* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | W1048* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | W1048* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | W1048* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | W1048* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | Q554* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | Q554* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q554* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q554* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q554* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | Q554* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | Q554* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | Q554* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q554* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q554* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | Q554* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q554* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q554* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q554* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | Q554* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q554* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q554* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q554* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q554* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q554* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q554* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q554* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q554* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q554* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | Q554* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q554* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q554* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q554* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | Q554* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q554* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q554* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q554* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q554* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | Q554* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q554* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q554* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q554* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q554* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q554* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q554* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q554* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q554* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q554* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q554* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q554* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | Y163C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y163C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y163C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y163C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y163C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y163C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y163C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y163C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y163C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y163C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y163C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y163C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y163C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y163C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y163C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I255S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I255S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | I255S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | I255S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | I255S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | I255S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I255S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | I255S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | I255S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | I255S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | I255S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | Y835* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | E221* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E221* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E221* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E221* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E221* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E221* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E221* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E221* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E221* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E221* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E221* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E221* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E221* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E221* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E221* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C135R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C135R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C135R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C135R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C135R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C135R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C135R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C135R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C135R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C135R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C135R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | P920R | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| NOTCH1 | T887I | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | T887I | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | splice_donor_variant | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I195T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I195T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | I195T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | I195T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | I195T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | I195T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I195T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I195T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I195T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | I195T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | I195T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | I195T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I195T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | I195T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I195T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NPM1 | splice_acceptor_variant | Complete Match | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| NPM1 | splice_acceptor_variant | Complete Match | DOT1L inhibitor;MLL1 inhibitor | Responsive | AML | Pre-clinical |
| ATR | splice_acceptor_variant | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | splice_acceptor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | splice_acceptor_variant | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| KMT2A | P1367P | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | P1367P | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | P1367P | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | P1367P | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | P1367P | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | P1367P | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | K132E | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | K132E | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | K132E | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | K132E | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | K132E | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | K132E | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | K132E | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132E | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132E | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | K132E | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | K132E | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | K132E | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132E | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | K132E | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132E | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | D314G | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | D314G | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| RET | R330Q | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | R330Q | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | R330Q | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | R330Q | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | R330Q | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | R330Q | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | R330Q | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | R330Q | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | R330Q | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PIK3CA | N345T | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | N345T | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | N345T | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N345T | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | N345T | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N345T | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | N345T | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | N345T | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB2 | S310F | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | S310F | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | S310F | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | S310F | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | S310F | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | S310F | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | S310F | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | S310F | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | S310F | Complete Match | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | S310F | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | S310F | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | S310F | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | S310F | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | S310F | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | S310F | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | S310F | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | S310F | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | S310F | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | S310F | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | S310F | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | S310F | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | S310F | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | S310F | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | S310F | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | S310F | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | S310F | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | S310F | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | S310F | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | S310F | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | S310F | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | S310F | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| TP53 | C135F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C135F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C135F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C135F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C135F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C135F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C135F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C135F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C135F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C135F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C135F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB3 | G284R | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | G284R | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | G284R | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | G284R | Complete Match | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | G284R | Complete Match | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | G284R | Complete Match | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | G284R | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| STAG2 | splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| BRCA1 | E720* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | E720* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | E720* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | E720* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | E720* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | E720* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | E720* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | E720* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | E720* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | E720* | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | E720* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | E720* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| TP53 | R280S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R280S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R280S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R280S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R280S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R280S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R280S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R280S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R280S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R280S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R280S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | splice_acceptor_variant | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | splice_acceptor_variant | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | splice_acceptor_variant | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | splice_acceptor_variant | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | splice_acceptor_variant | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | splice_acceptor_variant | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | splice_acceptor_variant | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_acceptor_variant | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_acceptor_variant | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | splice_acceptor_variant | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | splice_acceptor_variant | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_acceptor_variant | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | splice_acceptor_variant | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | splice_acceptor_variant | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | splice_acceptor_variant | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | T155P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | T155P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | T155P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | T155P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | T155P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | T155P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | T155P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T155P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T155P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | T155P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | T155P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | T155P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T155P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | T155P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T155P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RET | V778I | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | V778I | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | V778I | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | V778I | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | V778I | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | V778I | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | V778I | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | V778I | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | V778I | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PTEN | I135K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | I135K | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | I135K | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | I135K | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | I135K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | I135K | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | I135K | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | I135K | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | I135K | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | I135K | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | I135K | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | I135K | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | I135K | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | I135K | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | I135K | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | I135K | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | I135K | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | I135K | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | I135K | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | I135K | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | I135K | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | I135K | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | I135K | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | I135K | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | I135K | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | Y220H | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y220H | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y220H | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y220H | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y220H | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y220H | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y220H | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220H | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220H | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y220H | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y220H | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220H | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220H | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y220H | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220H | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C238Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C238Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C238Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C238Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C238Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C238Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C238Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C238Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C238Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C238Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C238Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C238Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C238Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C238Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C238Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB2 | G309A | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | G309A | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | G309A | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | G309A | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | G309A | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | G309A | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | G309A | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | G309A | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | G309A | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | G309A | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | G309A | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | G309A | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | G309A | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | G309A | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | G309A | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | G309A | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | G309A | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | G309A | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | G309A | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | G309A | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | G309A | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | G309A | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | G309A | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | G309A | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | G309A | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | G309A | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | G309A | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | G309A | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | G309A | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | G309A | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | G309A | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| TSC2 | R1459* | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Case report |
| TSC2 | R1459* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | RA, GCA | FDA guidelines |
| TSC2 | R1459* | Complete Match | SRC inhibitor | Responsive | LAM | Pre-clinical |
| TSC2 | R1459* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | BLCA | Early trials |
| TSC2 | R1459* | Complete Match | MTOR inhibitor | Responsive | RA | Early trials |
| TSC2 | R1459* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | THCA | Case report |
| TSC2 | R1459* | Different Alteration | SRC inhibitor | Responsive | LAM | Pre-clinical |
| TP53 | C176F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C176F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C176F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C176F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C176F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C176F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C176F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C176F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C176F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C176F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C176F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C176F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C176F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C176F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C176F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | R1630G | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | R130Q | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R130Q | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R130Q | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | R130Q | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | R130Q | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | R130Q | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R130Q | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R130Q | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R130Q | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | R130Q | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R130Q | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R130Q | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | R130Q | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R130Q | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R130Q | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R130Q | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | R130Q | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R130Q | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R130Q | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R130Q | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R130Q | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R130Q | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R130Q | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R130Q | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R130Q | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | S1388T | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | M237I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | M237I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | M237I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | M237I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | M237I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | M237I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | M237I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M237I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M237I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | M237I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | M237I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | M237I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M237I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | M237I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M237I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | splice_donor_variant | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | splice_donor_variant | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | splice_donor_variant | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | splice_donor_variant | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | splice_donor_variant | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | splice_donor_variant | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | splice_donor_variant | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | splice_donor_variant | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | splice_donor_variant | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | splice_donor_variant | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E545K), PIK3CA MUT (E453K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E545K), PIK3CA MUT (E453K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | H179R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H179R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H179R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H179R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H179R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H179R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H179R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H179R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H179R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H179R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H179R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ESR1 | K472K | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | Q52* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q52* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q52* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q52* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q52* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q52* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q52* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q52* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q52* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q52* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q52* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q52* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q52* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q52* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q52* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RET | L963V | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | L963V | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | L963V | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | L963V | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | L963V | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | L963V | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L963V | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L963V | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L963V | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| EGFR | A147T | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | A147T | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | P250L | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P250L | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P250L | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P250L | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P250L | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P250L | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P250L | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P250L | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P250L | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P250L | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P250L | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P250L | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P250L | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P250L | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P250L | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ESR1 | P336P | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | G279E | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G279E | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G279E | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G279E | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G279E | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G279E | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G279E | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G279E | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G279E | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G279E | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G279E | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G279E | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G279E | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G279E | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G279E | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | splice_donor_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | splice_donor_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | splice_donor_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | splice_donor_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | splice_donor_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | G225D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| PDGFRA | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| BRCA1 | E272* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | E272* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | E272* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | E272* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | E272* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | E272* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | E272* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | E272* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | E272* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | E272* | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | E272* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | E272* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| BRD4 | K546N | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| TP53 | S215I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S215I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S215I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S215I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S215I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S215I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S215I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S215I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S215I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S215I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S215I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S215I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S215I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S215I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S215I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G266E | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G266E | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G266E | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G266E | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G266E | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G266E | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G266E | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G266E | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G266E | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G266E | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G266E | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G266E | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G266E | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G266E | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G266E | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRD4 | A264A | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ABL1 | Y440H | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | Y440H | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | Y440H | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | Y440H | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | Y440H | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | Y440H | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| EGFR | E282K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | E282K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| AKT1 | E17K | Complete Match | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | E17K | Complete Match | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | E17K | Complete Match | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | E17K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | E17K | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | E17K | Complete Match | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | E17K | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| ERBB2 | V842I | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | V842I | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V842I | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V842I | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | V842I | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | V842I | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | V842I | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | V842I | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | V842I | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | V842I | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | V842I | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V842I | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | V842I | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | V842I | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | V842I | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | V842I | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | V842I | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | V842I | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | V842I | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | V842I | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | V842I | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | V842I | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | V842I | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | V842I | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | V842I | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | V842I | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | V842I | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | V842I | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | V842I | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | V842I | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | V842I | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | V842I | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| KMT2A | Q1195* | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | Q1195* | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | Q1195* | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | Q1195* | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | Q1195* | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | Q1195* | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TMPRSS2 | P83P | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | P83P | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| JAK2 | Y44* | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | R1182S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | R1182S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | R1182S | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | R1182S | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | R1182S | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| FAT1 | Q1722* | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| BRCA2 | splice_donor_variant | Complete Match | PD1 Ab inhibitor | Responsive | CM | Case report |
| BRCA2 | splice_donor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | splice_donor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA2 | splice_donor_variant | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA2 | splice_donor_variant | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA2 | splice_donor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | PA | Case report |
| BRCA2 | splice_donor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA2 | splice_donor_variant | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA2 | splice_donor_variant | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | splice_donor_variant | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | splice_donor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA2 | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA2 | splice_donor_variant | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| BRCA2 | splice_donor_variant | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| JAK2 | Y132* | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| SETD2 | S470* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | S470* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047L), PIK3CA MUT (E726K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | E596K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | E596K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | E596K | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | E596K | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | E596K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| RB1 | E864* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | E864* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | E864* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | E864* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | E864* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | E864* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | E864* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| PIK3CA | Q546K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | Q546K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | Q546K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Q546K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | Q546K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Q546K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | Q546K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | Q546K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | C141Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C141Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C141Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C141Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C141Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C141Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C141Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C141Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C141Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C141Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C141Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C141Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C141Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C141Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C141Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR3 | H711H | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | H711H | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | H711H | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| TP53 | Q144* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q144* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q144* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q144* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q144* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q144* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q144* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q144* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q144* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q144* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q144* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q144* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q144* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q144* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q144* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | Q641* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PTEN | Y46* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Y46* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Y46* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | Y46* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | Y46* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | Y46* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Y46* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Y46* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Y46* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | Y46* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Y46* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Y46* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | Y46* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Y46* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Y46* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Y46* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | Y46* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Y46* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Y46* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Y46* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Y46* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Y46* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Y46* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Y46* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Y46* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | H193R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H193R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H193R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H193R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H193R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H193R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H193R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H193R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H193R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H193R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H193R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H193R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H193R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H193R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H193R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | splice_donor_variant | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | splice_donor_variant | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | splice_donor_variant | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| AKT3 | A373G | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| PML | L726L | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | L726L | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | L726L | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| PIK3CA | E726K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E726K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E726K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E726K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E726K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E726K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E726K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E726K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR2 | V113A | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | V113A | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| STAG2 | Q167* | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| KMT2A | S3380L | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | S3380L | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | S3380L | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | S3380L | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | S3380L | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | S3380L | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH1 | F1259F | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | F1259F | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PDGFRA | D985N | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| ALK | R1209P | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | R1209P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | R1209P | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | R1209P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | R1209P | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | R1209P | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | R1209P | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | R1209P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | R1209P | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | R1209P | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | R1209P | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | R1209P | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | R1209P | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | R1209P | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | R1209P | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | R1209P | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | R1209P | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | R1209P | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | R1209P | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| NTRK1 | S371F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | S371F | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | S371F | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | S371F | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | A2331S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ESR1 | L448L | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | D1051N), EGFR MUT* (intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | D1051N), EGFR MUT* (intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ABL1 | E588Q | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | E588Q | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | E588Q | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | E588Q | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | E588Q | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | E588Q | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ROS1 | H189Y), ROS1 MUT* (3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | H189Y), ROS1 MUT* (3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | H189Y), ROS1 MUT* (3-UTRSNV | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | H189Y), ROS1 MUT* (3-UTRSNV | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | H189Y), ROS1 MUT* (3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | R992T), MET MUT* (L581L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| BRAF | D449N | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | D449N | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | D449N | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | D449N | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ERBB4 | S184L), ERBB4 MUT* (E1144Q), ERBB4 MUT* (3-UTRSNV | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| SETD2 | S791* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | S791* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB2 | L755S | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | L755S | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755S | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755S | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | L755S | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | L755S | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | L755S | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | L755S | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | L755S | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | L755S | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | L755S | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755S | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | L755S | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755S | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | L755S | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | L755S | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | L755S | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | L755S | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | L755S | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | L755S | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | L755S | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | L755S | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | L755S | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | L755S | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | L755S | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | L755S | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | L755S | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | L755S | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | L755S | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | L755S | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | L755S | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | L755S | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| FGFR2 | S588C | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | S588C | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | M246I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | M246I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | M246I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | M246I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | M246I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | M246I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | M246I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M246I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M246I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | M246I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | M246I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | M246I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M246I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | M246I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M246I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| GNAS | R201C | Complete Match | JAK inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2D | L2255* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | LUSC | Pre-clinical |
| TP53 | D281Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | D281Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | D281Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | D281Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | D281Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | D281Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | D281Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | D281Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | D281Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | D281Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | D281Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | D281Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | D281Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | D281Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | D281Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | Q503* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| NTRK1 | G319D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | G319D | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | G319D | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | G319D | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | T2159T | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| RAF1 | V226D | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | V226D | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | V226D | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| ESR1 | 3-UTRSNV | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| SF3B1 | E622Q | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| RB1 | Y606* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | Y606* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Y606* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | Y606* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Y606* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Y606* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | Y606* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| ATM | Q2800* | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | Q2800* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | Q2800* | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | Q2800* | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | Q2800* | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | Q2800* | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | Q2800* | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | Q2800* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | Q2800* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | Q2800* | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | Q2800* | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | Q2800* | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | Q2800* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| KMT2A | P3959P | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | P3959P | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | P3959P | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | P3959P | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | P3959P | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | P3959P | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| CDH1 | Q647* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB4 | E1205K | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PIK3CA | E545A | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E545A | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E545A | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545A | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E545A | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545A | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E545A | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E545A | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| MET | A932A | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | R342P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R342P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R342P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R342P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R342P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R342P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R342P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R342P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R342P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R342P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R342P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R342P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R342P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R342P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R342P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| GATA3 | splice_acceptor_variant | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| CDH1 | R74* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ALK | N1544N | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | N1544N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | N1544N | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | N1544N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | N1544N | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | N1544N | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | N1544N | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | N1544N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | N1544N | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | N1544N | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | N1544N | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | N1544N | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | N1544N | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | N1544N | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | N1544N | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | N1544N | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | N1544N | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | N1544N | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | N1544N | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | G1121D | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G1121D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | G1121D | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | G1121D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | G1121D | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | G1121D | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | G1121D | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | G1121D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | G1121D | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | G1121D | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | G1121D | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | G1121D | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | G1121D | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G1121D | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G1121D | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | G1121D | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | G1121D | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | G1121D | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | G1121D | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| HIF1A | R463* | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| RB1 | splice_donor_variant | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | splice_donor_variant | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | splice_donor_variant | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | splice_donor_variant | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | splice_donor_variant | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | splice_donor_variant | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | splice_donor_variant | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| ERCC6 | R612* | Complete Match | Cisplatin (Chemotherapy) | Responsive | OV | Pre-clinical |
| PTEN | S59* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | S59* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | S59* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | S59* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | S59* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | S59* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | S59* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | S59* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | S59* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | S59* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | S59* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | S59* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | S59* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | S59* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | S59* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | S59* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | S59* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | S59* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | S59* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | S59* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | S59* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | S59* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | S59* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | S59* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | S59* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| FGFR2 | V635A | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | V635A | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| KMT2A | R3744Q), MLL MUT* (R652* | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | R3744Q), MLL MUT* (R652* | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | R3744Q), MLL MUT* (R652* | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | R3744Q), MLL MUT* (R652* | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | R3744Q), MLL MUT* (R652* | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | R3744Q), MLL MUT* (R652* | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| SMARCA4 | E1426* | Complete Match | EZH2 inhibitor | Responsive | OVRT | Case report |
| SMARCA4 | E1426* | Complete Match | AURKA inhibitor | Responsive | NSCLC | Pre-clinical |
| SMARCA4 | E1426* | Complete Match | EZH2 inhibitor | Responsive | OV | Case report |
| SMARCA4 | E1426* | Different Alteration | EZH2 inhibitor | Responsive | OVRT | Case report |
| SMARCA4 | E1426* | Different Alteration | EZH2 inhibitor | Responsive | OV | Case report |
| NF1 | E1734* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | E1734* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | E1734* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | E1734* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | E1734* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | E1734* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | E1734* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | E1734* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | E1734* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | E1734* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | E1734* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | E1734* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | E1734* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | E1734* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | E1734* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | E1734* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | E1734* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | E1734* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | E1734* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | E1734* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | E1734* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | E1734* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | E1734* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | E1734* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | E1734* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | E1734* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | E1734* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | E1734* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | E1734* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | E1734* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | E1734* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | E1734* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | E1734* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | E1734* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | E1734* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | E1734* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | E1734* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | E1734* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | E1734* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | E1734* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | E1734* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | E1734* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | E1734* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | E1734* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | E1734* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | E1734* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| BRD4 | P723P | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| ESR1 | A593D | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ROS1 | K1661Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | K1661Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | K1661Q | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | K1661Q | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | K1661Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NRG1 | R155I | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | R155I | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| APC | E109*), APC MUT (S2223* | Complete Match | Tankyrase inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3R1 | R557*), PIK3R1 MUT (R348* | Complete Match | AKT inhibitor | Responsive | G | Pre-clinical |
| PIK3R1 | R557*), PIK3R1 MUT (R348* | Complete Match | PI3K pathway inhibitor | Responsive | ED | Case report |
| PDGFRA | I139I | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| ERBB4 | F401L | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ATR | R1368* | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | R1368* | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | R1368* | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | Y1021C), PIK3CA MUT (R349* | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| RAF1 | S605F | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | S605F | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | S605F | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| NTRK3 | T369N | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | T369N | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | T369N | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | L194R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L194R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L194R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L194R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L194R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L194R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L194R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L194R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L194R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L194R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L194R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L194R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L194R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L194R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L194R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | splice_donor_variant | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | splice_donor_variant | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | splice_donor_variant | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | splice_donor_variant | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | splice_donor_variant | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | splice_donor_variant | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_donor_variant | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | splice_donor_variant | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_donor_variant | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | splice_donor_variant | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | splice_donor_variant | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_donor_variant | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | splice_donor_variant | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | splice_donor_variant | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | splice_donor_variant | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_donor_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | splice_donor_variant | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | splice_donor_variant | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | splice_donor_variant | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_donor_variant | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | P278S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P278S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P278S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P278S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P278S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P278S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P278S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P278S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P278S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P278S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P278S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2D | W1491* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | LUSC | Pre-clinical |
| RB1 | Q383* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | Q383* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Q383* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | Q383* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Q383* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Q383* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | Q383* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| FGFR2 | L262P | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | L262P | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E545G), PIK3CA MUT (E545K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E545G), PIK3CA MUT (E545K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ERBB4 | 3-UTRSNV | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | E780D | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E780D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | E780D | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | E780D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | E780D | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | E780D | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | E780D | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | E780D | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | E780D | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | E780D | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | E780D | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | E780D | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | E780D | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E780D | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E780D | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | E780D | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | E780D | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | E780D | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | E780D | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| NOTCH2 | V1015A | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| EGFR | S246S | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | S246S | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ROS1 | L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | L567L), ROS1 MUT* (I745I), ROS1 MUT* (3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | P485L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| PTEN | splice_acceptor_variant | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | splice_acceptor_variant | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | splice_acceptor_variant | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | splice_acceptor_variant | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | splice_acceptor_variant | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | splice_acceptor_variant | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | splice_acceptor_variant | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | splice_acceptor_variant | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | splice_acceptor_variant | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | splice_acceptor_variant | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | splice_acceptor_variant | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | splice_acceptor_variant | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | splice_acceptor_variant | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | splice_acceptor_variant | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | splice_acceptor_variant | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | splice_acceptor_variant | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | splice_acceptor_variant | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | splice_acceptor_variant | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | splice_acceptor_variant | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | splice_acceptor_variant | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | splice_acceptor_variant | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | splice_acceptor_variant | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | splice_acceptor_variant | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| KMT2A | P654P | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | P654P | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | P654P | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | P654P | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | P654P | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | P654P | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ERBB4 | splice_acceptor_variant | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CM | Pre-clinical |
| ERBB4 | splice_acceptor_variant | Different Mutation | ERBB2 inhibitor | Resistant | BRCA | Case report |
| ERBB4 | splice_acceptor_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | E294* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E294* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E294* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E294* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E294* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E294* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E294* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E294* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E294* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E294* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E294* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E294* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E294* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E294* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E294* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| DNMT3A | R882H | Complete Match | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| AKT1 | L52R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | L52R | Different Mutation | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | L52R | Different Mutation | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | L52R | Different Mutation | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | L52R | Different Mutation | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | L52R | Different Mutation | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | L52R | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| ESR1 | E380Q | Different Mutation | Fulvestrant (Hormonal therapy) | Resistant | BRCA | Pre-clinical |
| ESR1 | E380Q | Complete Match | novel ER degrader | Responsive | BRCA | Case report |
| ESR1 | E380Q | Complete Match | Tamoxifen (Hormonal therapy) | Resistant | BRCA | Early trials |
| ESR1 | E380Q | Complete Match | Exemestane (Hormonal therapy) | Resistant | BRCA | Late trials |
| ESR1 | E380Q | Complete Match | Fluvestrant (Hormonal therapy) | Responsive | BRCA | Late trials |
| ESR1 | E380Q | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| ALK | D525N | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | D525N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | D525N | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | D525N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | D525N | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | D525N | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | D525N | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | D525N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | D525N | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | D525N | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | D525N | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | D525N | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | D525N | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | D525N | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | D525N | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | D525N | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | D525N | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | D525N | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | D525N | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| PIK3CA | R108H | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | R108H | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | R108H | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | R108H | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | R108H | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | R108H | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | R108H | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | R108H | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| RAF1 | Q253* | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | Q253* | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | Q253* | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| BRAF | K698R | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | K698R | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | K698R | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | K698R | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| STAG2 | R216* | Complete Match | PARP inhibitor | Responsive | G | Pre-clinical |
| PTEN | Y88* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Y88* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Y88* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | Y88* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | Y88* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | Y88* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Y88* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Y88* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Y88* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | Y88* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Y88* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Y88* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | Y88* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Y88* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Y88* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Y88* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | Y88* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Y88* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Y88* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Y88* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Y88* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Y88* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Y88* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Y88* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Y88* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PIK3CA | E453K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E453K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E453K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E453K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E453K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E453K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E453K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E453K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | R282W | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R282W | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R282W | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R282W | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R282W | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R282W | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R282W | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R282W | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R282W | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R282W | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R282W | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R282W | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R282W | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R282W | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R282W | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | S359S | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | S359S | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | S359S | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| FAT1 | Q3825* | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| RB1 | R552* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | R552* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | R552* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | R552* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | R552* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | R552* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | R552* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| TP53 | V173M | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V173M | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V173M | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V173M | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V173M | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V173M | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V173M | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V173M | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V173M | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V173M | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V173M | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V173M | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V173M | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V173M | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V173M | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L265R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L265R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L265R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L265R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L265R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L265R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L265R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L265R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L265R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L265R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L265R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L265R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L265R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L265R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L265R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3R1 | splice_donor_variant | Complete Match | AKT inhibitor | Responsive | G | Pre-clinical |
| PIK3R1 | splice_donor_variant | Complete Match | PI3K pathway inhibitor | Responsive | ED | Case report |
| PTPRD | G574* | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| PDGFB | K155N | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| TP53 | R248W | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248W | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248W | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248W | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248W | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248W | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248W | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248W | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248W | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248W | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248W | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248W | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | N550K), FGFR2 MUT (N550K | Different Alteration | FGFR inhibitor | Resistant | CH | Early trials |
| FGFR2 | N550K | Different Mutation | FGFR inhibitor | Responsive | LUSC | Pre-clinical |
| FGFR2 | N550K | Complete Match | Dovitinib (FGFR inhibitor) | Resistant | ED | Pre-clinical |
| FGFR2 | N550K | Complete Match | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | ED | Pre-clinical |
| FGFR2 | N550K | Complete Match | FGFR inhibitor | Responsive | ED | Pre-clinical |
| FGFR2 | N550K | Different Mutation | FGFR inhibitor | Responsive | L | Pre-clinical |
| FGFR2 | N550K | Different Mutation | FGFR inhibitor | Responsive | ED | Pre-clinical |
| FGFR2 | N550K | Different Mutation | FGFR inhibitor | Responsive | BT | Case report |
| FGFR2 | N550K | Different Alteration | FGFR inhibitor | Responsive | ST | Early trials |
| FGFR2 | N550K | Different Alteration | FGFR inhibitor | Responsive | BRCA | Case report |
| FGFR2 | N550K | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | N550K | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| BRCA1 | G1788V | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | G1788V | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | G1788V | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | G1788V | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | G1788V | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | G1788V | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | G1788V | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | G1788V | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | G1788V | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | G1788V | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | G1788V | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | G1788V | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | R268S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | L252P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L252P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L252P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L252P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L252P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L252P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L252P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L252P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L252P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L252P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L252P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L252P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L252P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L252P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L252P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ABL1 | P112Q | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | P112Q | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | P112Q | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | P112Q | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | P112Q | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | P112Q | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | R213* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R213* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R213* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R213* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R213* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R213* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R213* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R213* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R213* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R213* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R213* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R213* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R213* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R213* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R213* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | K128N | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | K128N | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | K128N | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | K128N | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | K128N | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | K128N | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | K128N | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | K128N | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | K128N | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | K128N | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | K128N | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | K128N | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | K128N | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | K128N | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | K128N | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | K128N | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | K128N | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | K128N | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | K128N | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | K128N | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | K128N | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | K128N | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | K128N | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | K128N | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | K128N | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| EZH2 | S639* | Different Mutation | EZH2 inhibitor | Responsive | LY | Pre-clinical |
| EZH2 | S639* | Different Mutation | EZH2 inhibitor | Responsive | LY | Early trials |
| PML | P419P | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | P419P | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | P419P | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | C2068Y | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | C2068Y | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | C2068Y | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | C2068Y | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | C2068Y | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | C2068Y | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | G245D | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G245D | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G245D | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G245D | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G245D | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G245D | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G245D | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G245D | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G245D | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G245D | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G245D | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G245D | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G245D | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G245D | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G245D | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H193L | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H193L | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H193L | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H193L | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H193L | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H193L | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H193L | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H193L | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H193L | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H193L | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H193L | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H193L | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H193L | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H193L | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H193L | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | Q300H | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | Q300H | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | Q300H | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | Q300H | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | Q300H | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | Q300H | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ALK | M301I | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M301I | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | M301I | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | M301I | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | M301I | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | M301I | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | M301I | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | M301I | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | M301I | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | M301I | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | M301I | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | M301I | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | M301I | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M301I | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | M301I | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | M301I | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | M301I | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | M301I | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | M301I | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ERBB4 | N278S | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | V216M | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V216M | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V216M | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V216M | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V216M | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V216M | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V216M | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V216M | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V216M | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V216M | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V216M | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V216M | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V216M | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V216M | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V216M | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | C526S | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | C526S | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | R273P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | T2266R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | T2266R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | T2266R | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | T2266R | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | T2266R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| EGFR | Y900Y | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | Y900Y | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | E198* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E198* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E198* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E198* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E198* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E198* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E198* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E198* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E198* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E198* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E198* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E198* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E198* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E198* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E198* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (M1004I | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | E571K | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| ATM | splice_donor_variant | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | splice_donor_variant | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | splice_donor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | splice_donor_variant | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | splice_donor_variant | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | splice_donor_variant | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | splice_donor_variant | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | splice_donor_variant | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | splice_donor_variant | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | splice_donor_variant | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | splice_donor_variant | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | splice_donor_variant | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| TP53 | V197G | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V197G | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V197G | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V197G | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V197G | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V197G | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V197G | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V197G | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V197G | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V197G | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V197G | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V197G | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V197G | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V197G | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V197G | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SETD2 | S180* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | S180* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y205C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y205C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y205C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y205C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y205C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y205C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y205C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y205C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y205C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y205C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y205C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y205C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y205C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y205C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y205C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | Q900* | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | Q900* | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | Q900* | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | Q900* | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | Q900* | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | Q900* | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ATM | R2993* | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | R2993* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | R2993* | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | R2993* | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | R2993* | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | R2993* | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | R2993* | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | R2993* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | R2993* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | R2993* | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | R2993* | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | R2993* | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | R2993* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| PDGFRA | R822H | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| PDGFRA | R822H | Complete Match | Sunitinib (Pan-TK inhibitor) | Responsive | GIST | NCCN guidelines |
| PDGFRA | R822H | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | GIST | NCCN guidelines |
| PDGFRA | R822H | Complete Match | Regorafenib (Pan-kinase inhibitor) | Responsive | GIST | NCCN guidelines |
| PDGFRA | R822H | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | CM | Pre-clinical |
| PDGFRA | R822H | Different Mutation | Crenolanib (FLT3 inhibitor) | Responsive | CM | Pre-clinical |
| PDGFRA | R822H | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | HES | Case report |
| PDGFRA | R822H | Different Mutation | Crenolanib (FLT3 inhibitor) | Responsive | GIST | Early trials |
| PDGFRA | R822H | Different Mutation | HSP90 inhibitor | Responsive | GIST | Pre-clinical |
| PDGFRA | R822H | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | GIST | Pre-clinical |
| PDGFRA | R822H | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | GIST | Pre-clinical |
| PDGFRA | R822H | Different Mutation | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Late trials |
| PDGFRA | R822H | Different Mutation | PDGFR inhibitor | Responsive | GIST | Early trials |
| PDGFRA | R822H | Different Mutation | Sunitinib (Pan-TK inhibitor) | Resistant | GIST | Late trials |
| PDGFRA | R822H | Different Mutation | Sorafenib (Pan-TK inhibitor) | Responsive | GIST | Early trials |
| PDGFRA | R822H | Different Mutation | Sunitinib (Pan-TK inhibitor) | Responsive | GIST | Late trials |
| PDGFRA | R822H | Different Alteration | PDGFR inhibitor | No Responsive | G | Pre-clinical |
| PDGFRA | R822H | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| RB1 | S215* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | S215* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | S215* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | S215* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | S215* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | S215* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | S215* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| AKT3 | 3-UTRSNV | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| MET | Y390Y | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| EGFR | S198S | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | S198S | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ATM | Q2269* | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | Q2269* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | Q2269* | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | Q2269* | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | Q2269* | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | Q2269* | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | Q2269* | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | Q2269* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | Q2269* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | Q2269* | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | Q2269* | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | Q2269* | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | Q2269* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| TP53 | E51* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E51* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E51* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E51* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E51* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E51* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E51* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E51* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E51* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E51* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E51* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E51* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E51* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E51* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E51* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ARID1A | S711* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | S711* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | S711* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | S711* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| CDH1 | Q255* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| CDKN1A | S98* | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1A | S98* | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| BRD4 | P15L | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| PTEN | H123D | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | H123D | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | H123D | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | H123D | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | H123D | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | H123D | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | H123D | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | H123D | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | H123D | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | H123D | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | H123D | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | H123D | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | H123D | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | H123D | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | H123D | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | H123D | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | H123D | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | H123D | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | H123D | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | H123D | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | H123D | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | H123D | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | H123D | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | H123D | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | H123D | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | L566F | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| KRAS | G12C | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12C | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12C | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12C | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12C | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12C | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12C | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12C | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12C | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12C | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12C | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12C | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12C | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12C | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12C | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12C | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12C | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12C | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12C | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12C | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12C | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12C | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12C | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12C | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12C | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12C | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12C | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12C | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12C | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| FBXW7 | Y545C | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | Y545C | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | Y545C | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | Y545C | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| TP53 | F270I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | F270I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | F270I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | F270I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | F270I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | F270I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | F270I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | F270I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | F270I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | F270I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | F270I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | F270I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | F270I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | F270I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | F270I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273H | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R273H | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R273H | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R273H | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R273H | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R273H | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R273H | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R273H | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R273H | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R273H | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273H | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R273H | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R273H | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E285K | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E285K | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E285K | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E285K | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E285K | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E285K | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E285K | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E285K | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E285K | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E285K | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E285K | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E285K | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E285K | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E285K | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E285K | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK1 | P695P | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | P695P | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | P695P | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | P695P | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TP53 | D281V | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | D281V | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | D281V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | D281V | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | D281V | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | D281V | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | D281V | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | D281V | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | D281V | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | D281V | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | D281V | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | D281V | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | D281V | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | D281V | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | D281V | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB3 | V104L | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | V104L | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | V104L | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| KRAS | G12V | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12V | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12V | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12V | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12V | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12V | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12V | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12V | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12V | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12V | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12V | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12V | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12V | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12V | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12V | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12V | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12V | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12V | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12V | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12V | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12V | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12V | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12V | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12V | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12V | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12V | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12V | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12V | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12V | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| NOTCH1 | A2441T | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | A2441T | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | C124* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C124* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C124* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C124* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C124* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C124* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C124* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C124* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C124* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C124* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C124* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C124* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C124* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C124* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C124* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | D350G | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | D350G | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | D350G | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | D350G | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | D350G | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | D350G | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | D350G | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | D350G | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| MET | V797M | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| ERBB3 | D297Y | Different Mutation | PI3K pathway inhibitor;MEK inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | D297Y | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | D297Y | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | D297Y | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB3 | D297Y | Different Mutation | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB3 | D297Y | Different Mutation | ERBB3 mAb inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB3 | D297Y | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| MET | G1364G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| MET | Q830L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| EGFR | A1201V | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | A1201V | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ABL1 | splice_acceptor_variant | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | splice_acceptor_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | splice_acceptor_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | splice_acceptor_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | splice_acceptor_variant | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | splice_acceptor_variant | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ATM | splice_acceptor_variant | Different Mutation | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ATM | splice_acceptor_variant | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ATM | splice_acceptor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | ST, PRAD | Early trials |
| ATM | splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | ST | Early trials |
| ATM | splice_acceptor_variant | Complete Match | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | splice_acceptor_variant | Complete Match | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | splice_acceptor_variant | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATM | splice_acceptor_variant | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | splice_acceptor_variant | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ATM | splice_acceptor_variant | Different Alteration | DNA-PKc inhibitor | Responsive | LY | Pre-clinical |
| ATM | splice_acceptor_variant | Different Alteration | PARP inhibitor | Responsive | ST | Early trials |
| ATM | splice_acceptor_variant | Different Alteration | ATR inhibitor | Responsive | COREAD | Case report |
| ATM | splice_acceptor_variant | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (P539R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | C135Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C135Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C135Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C135Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C135Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C135Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C135Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C135Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C135Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C135Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C135Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248Q | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y220S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y220S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y220S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y220S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y220S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y220S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y220S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y220S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y220S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y220S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y220S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y220S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | V753G | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | V753G | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | V753G | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| FGFR2 | V342V | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | V342V | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| NOTCH1 | P2399S | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | P2399S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | C124S | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | C124S | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | C124S | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | C124S | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | C124S | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | C124S | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | C124S | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | C124S | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | C124S | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | C124S | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | C124S | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | C124S | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | C124S | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | C124S | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | C124S | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | C124S | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | C124S | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | C124S | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | C124S | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | C124S | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | C124S | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | C124S | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | C124S | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | C124S | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | C124S | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH1 | S2523L | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | S2523L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| EGFR | E114K | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | E114K | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | E114K | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | E114K | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | E114K | Different Mutation | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | E114K | Different Mutation | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | E114K | Different Mutation | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | E114K | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | E114K | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | E114K | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | E114K | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | E114K | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | E114K | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | E114K | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | E114K | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | E114K | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | E114K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | E114K | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | E114K | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | E114K | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | E114K | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | E114K | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | E114K | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | E114K | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | E114K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | E114K | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | E114K | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | E114K | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | E114K | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | E114K | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | E114K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | E114K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | E114K | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | E114K | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | E114K | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | E114K | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | E114K | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | E114K | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | E114K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | E114K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| AKT3 | S375* | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK1 | Q626K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | Q626K | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | Q626K | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | Q626K | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| ARID1A | Q2037* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q2037* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q2037* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q2037* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB4 | T703K | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | P278T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P278T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P278T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P278T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P278T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P278T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P278T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P278T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P278T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P278T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P278T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| HRAS | G13R | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CER | Pre-clinical |
| HRAS | G13R | Complete Match | MEK inhibitor +/- MTOR inhibitor | Responsive | AML | Pre-clinical |
| HRAS | G13R | Complete Match | MTOR inhibitor | Responsive | CESC | Pre-clinical |
| HRAS | G13R | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | Responsive | CANCER | Early trials |
| ABL1 | D482E | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | D482E | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | D482E | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | D482E | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | D482E | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | D482E | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | L265P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L265P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L265P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L265P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L265P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L265P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L265P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L265P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L265P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L265P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L265P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L265P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L265P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L265P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L265P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDKN1B | S27* | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | S27* | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P151H | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P151H | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P151H | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P151H | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P151H | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P151H | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P151H | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P151H | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P151H | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P151H | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P151H | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P151H | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P151H | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P151H | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P151H | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R248W), TP53 MUT (L114* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R248W), TP53 MUT (L114* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G245S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G245S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G245S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G245S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G245S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G245S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G245S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G245S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G245S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G245S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G245S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G245S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G245S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G245S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G245S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EPHA2 | CdsStopSNV | Different Mutation | MTOR inhibitor | Responsive | LUSC | Pre-clinical |
| EPHA2 | CdsStopSNV | Different Mutation | Dasatinib (BCR-ABL inhibitor) | Responsive | LUSC | Pre-clinical |
| EPHA2 | CdsStopSNV | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | CANCER | Pre-clinical |
| TP53 | F270S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | F270S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | F270S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | F270S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | F270S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | F270S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | F270S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | F270S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | F270S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | F270S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | F270S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | F270S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | F270S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | F270S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | F270S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| JAK2 | R115I | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| NOTCH2 | R1604S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BCOR | S3* | Complete Match | Enzastaurin (PKCb inhibitor) | Responsive | ST | Pre-clinical |
| PDGFRA | T361S | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| RET | T636T | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | T636T | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | T636T | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | T636T | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | T636T | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | T636T | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | T636T | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | T636T | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | T636T | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PIK3CA | Q546P | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | Q546P | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | Q546P | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Q546P | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | Q546P | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | Q546P | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | Q546P | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | Q546P | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ESR1 | 5-UTRBlockSubstitution | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | E453K), PIK3CA MUT (E81K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E453K), PIK3CA MUT (E81K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E453K), PIK3CA MUT (E81K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| CDKN1B | E105* | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | E105* | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| NRG1 | E579E | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | E579E | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| NOTCH2 | V1666F | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | K266* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | K266* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | K266* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | K266* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | K266* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | K266* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | K266* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | K266* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | K266* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | K266* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | K266* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | K266* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | K266* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | K266* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | K266* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | K266* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | K266* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | K266* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | K266* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | K266* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | K266* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | K266* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | K266* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | K266* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | K266* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| NOTCH2 | G476* | Different Mutation | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | G476* | Different Mutation | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | G476*), NOTCH2 MUT* (S955N | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRD4 | T296P | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| CDH1 | Q195* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| CDH1 | E494* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| NTRK1 | R342Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | R342Q | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | R342Q | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | R342Q | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| PIK3CA | C420R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | C420R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | C420R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | C420R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | C420R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | C420R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | C420R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | C420R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ESR1 | P222S | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | Q921Q | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | E258Q | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E258Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E258Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E258Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E258Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E258Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E258Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E258Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E258Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E258Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E258Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E258Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E258Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E258Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E258Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NTRK3 | R683S | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R683S | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R683S | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | E726G | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E726G | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E726G | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E726G | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E726G | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E726G | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E726G | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E726G | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (E726K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E545K), PIK3CA MUT (E726K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E545K), PIK3CA MUT (E726K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | V274F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V274F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V274F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V274F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V274F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V274F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V274F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V274F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V274F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V274F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V274F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V274F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V274F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V274F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V274F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ARID1A | R1989* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | R1989* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | R1989* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | R1989* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| PTEN | R130P | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R130P | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | R130P | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | R130P | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | R130P | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | R130P | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R130P | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R130P | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R130P | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | R130P | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R130P | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R130P | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | R130P | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R130P | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R130P | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R130P | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | R130P | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | R130P | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | R130P | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | R130P | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | R130P | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | R130P | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | R130P | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | R130P | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | R130P | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ALK | Q286Q | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | Q286Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | Q286Q | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | Q286Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | Q286Q | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | Q286Q | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | Q286Q | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | Q286Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | Q286Q | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | Q286Q | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | Q286Q | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | Q286Q | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | Q286Q | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | Q286Q | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | Q286Q | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | Q286Q | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | Q286Q | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | Q286Q | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | Q286Q | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | G187S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | G187S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | G187S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | G187S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | G187S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | G187S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | G187S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G187S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | G187S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | G187S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | G187S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | G187S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G187S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | G187S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | G187S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | splice_donor_variant | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | splice_donor_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | splice_donor_variant | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | splice_donor_variant | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | splice_donor_variant | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | splice_donor_variant | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| KMT2A | splice_acceptor_variant | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | splice_acceptor_variant | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | splice_acceptor_variant | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | splice_acceptor_variant | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | splice_acceptor_variant | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | splice_acceptor_variant | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | K132N | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | K132N | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | K132N | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | K132N | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | K132N | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | K132N | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | K132N | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132N | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132N | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | K132N | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | K132N | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | K132N | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132N | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | K132N | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132N | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | Q682* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | Q682* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | Q682* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q682* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q682* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q682* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | Q682* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | Q682* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | Q682* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q682* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q682* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | Q682* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q682* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q682* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q682* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | Q682* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q682* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q682* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q682* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q682* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q682* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q682* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q682* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q682* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q682* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | Q682* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q682* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q682* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q682* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | Q682* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q682* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q682* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q682* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q682* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | Q682* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q682* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q682* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q682* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q682* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q682* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q682* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q682* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q682* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q682* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q682* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q682* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| ROS1 | R1311Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | R1311Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | R1311Q | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | R1311Q | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | R1311Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| GATA3 | K358* | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| ALK | R1275* | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | R1275* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | R1275* | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | R1275* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | R1275* | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | R1275* | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | R1275* | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | R1275* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | R1275* | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | R1275* | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | R1275* | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | R1275* | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | R1275* | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | R1275* | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | R1275* | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | R1275* | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | R1275* | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | R1275* | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | R1275* | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | T125T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | T125T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | T125T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | T125T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | T125T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | T125T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | T125T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T125T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T125T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | T125T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | T125T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | T125T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T125T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | T125T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T125T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | G818G | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | G818G | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | R158G | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R158G | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R158G | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R158G | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R158G | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R158G | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R158G | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R158G | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R158G | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R158G | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R158G | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R158G | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R158G | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R158G | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R158G | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (P366R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | S2153A | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | P172R | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| RET | P117T | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | P117T | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | P117T | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | P117T | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | P117T | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | P117T | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | P117T | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | P117T | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | P117T | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| EGFR | D916D | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | D916D | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PTEN | splice_donor_variant | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | splice_donor_variant | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | splice_donor_variant | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | splice_donor_variant | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | splice_donor_variant | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | splice_donor_variant | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | splice_donor_variant | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | splice_donor_variant | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | splice_donor_variant | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | splice_donor_variant | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | splice_donor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | splice_donor_variant | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | splice_donor_variant | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | splice_donor_variant | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | splice_donor_variant | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | splice_donor_variant | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | splice_donor_variant | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | splice_donor_variant | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | splice_donor_variant | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | splice_donor_variant | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | splice_donor_variant | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | splice_donor_variant | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | splice_donor_variant | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | splice_donor_variant | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | splice_donor_variant | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PIK3CA | M1043I | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | M1043I | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | M1043I | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | M1043I | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | M1043I | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | M1043I | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | M1043I | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | M1043I | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | E286A | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E286A | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E286A | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E286A | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E286A | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E286A | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E286A | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E286A | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E286A | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E286A | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E286A | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E286A | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E286A | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E286A | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E286A | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | T1997T | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | T1997T | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ROS1 | N2234K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | N2234K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | N2234K | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | N2234K | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | N2234K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | F1004S | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| RAF1 | I122V | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | I122V | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | I122V | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| PDGFB | intron_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| ARID1A | Q723* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q723* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q723* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q723* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| KMT2A | P3059P | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | P3059P | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | P3059P | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | P3059P | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | P3059P | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | P3059P | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| EGFR | E257K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | E257K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PIK3R1 | R534* | Complete Match | AKT inhibitor | Responsive | G | Pre-clinical |
| PIK3R1 | R534* | Complete Match | PI3K pathway inhibitor | Responsive | ED | Case report |
| RET | 3-UTRSNV | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | 3-UTRSNV | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | 3-UTRSNV | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | 3-UTRSNV | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | 3-UTRSNV | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | 3-UTRSNV | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | 3-UTRSNV | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | 3-UTRSNV | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | 3-UTRSNV | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| KMT2A | S2170N), MLL MUT* (R613Q | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | S2170N), MLL MUT* (R613Q | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | S2170N), MLL MUT* (R613Q | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | S2170N), MLL MUT* (R613Q | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | S2170N), MLL MUT* (R613Q | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | S2170N), MLL MUT* (R613Q | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | A422T | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ROS1 | 3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | 3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | 3-UTRSNV | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | 3-UTRSNV | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | 3-UTRSNV | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | L165L), ALK MUT* (P213L | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| RAF1 | 3-UTRSNV | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | 3-UTRSNV | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | 3-UTRSNV | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| JAK2 | I77I | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| MET | R412G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| TP53 | S241C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S241C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S241C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S241C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S241C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S241C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S241C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S241C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S241C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S241C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S241C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S241C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S241C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S241C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S241C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | splice_acceptor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | splice_acceptor_variant | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | splice_acceptor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | splice_acceptor_variant | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | splice_acceptor_variant | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| AKT3 | R66* | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | Q548* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q548* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q548* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q548* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ERBB4 | L1008L | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| SF3B1 | K666E | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C135W | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C135W | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C135W | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C135W | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C135W | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C135W | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C135W | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135W | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C135W | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C135W | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C135W | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C135W | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135W | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C135W | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C135W | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | G1007R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | G1007R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | G1007R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G1007R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | G1007R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G1007R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | G1007R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | G1007R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | R1630H | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NOTCH1 | Q2487L | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | Q2487L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | E56* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E56* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E56* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E56* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E56* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E56* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E56* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E56* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E56* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E56* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E56* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E56* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E56* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E56* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E56* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (Q546K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | E1037K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E1037K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E1037K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E1037K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E1037K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E1037K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E1037K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E1037K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | L1717I | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ROS1 | S551F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | S551F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | S551F | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | S551F | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | S551F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ROS1 | R1910* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | R1910* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | R1910* | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | R1910* | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | R1910* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | R280T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R280T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R280T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R280T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R280T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R280T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R280T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R280T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R280T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R280T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R280T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RB1 | Q93* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | Q93* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Q93* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | Q93* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Q93* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | Q93* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | Q93* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| IDH1 | R132C | Complete Match | Venetoclax (BCL2 inhibitor) | Responsive | AML | Early trials |
| IDH1 | R132C | Complete Match | IDH1 inhibitor | Responsive | AML | Early trials |
| IDH1 | R132C | Complete Match | AG-120 (IDH1 inhibitor) | Responsive | G | Early trials |
| IDH1 | R132C | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | CH | Early trials |
| IDH1 | R132C | Complete Match | Ivosidenib (IDH1 inhibitor) | Responsive | AML | Early trials |
| IDH1 | R132C | Complete Match | BCL2 inhibitor | Responsive | AML | Pre-clinical |
| IDH1 | R132C | Complete Match | BCL2 inhibitor (BCL2 inhibitor) | Responsive | AML | Pre-clinical |
| IDH1 | R132C | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | BT | Pre-clinical |
| IDH1 | R132C | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| PTEN | N48I | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | N48I | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | N48I | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | N48I | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | N48I | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | N48I | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | N48I | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | N48I | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | N48I | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | N48I | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | N48I | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | N48I | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | N48I | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | N48I | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | N48I | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | N48I | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | N48I | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | N48I | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | N48I | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | N48I | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | N48I | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | N48I | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | N48I | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | N48I | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | N48I | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| ESR1 | L370F | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| BCR | E771Q | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | E771Q | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | E771Q | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | E771Q | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | E771Q | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | E771Q | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (E365V | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3R1 | I559T | Complete Match | AKT inhibitor | Responsive | G | Pre-clinical |
| PIK3R1 | I559T | Complete Match | PI3K pathway inhibitor | Responsive | ED | Case report |
| TP53 | V173L | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V173L | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V173L | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V173L | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V173L | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V173L | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V173L | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V173L | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V173L | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V173L | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V173L | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V173L | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V173L | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V173L | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V173L | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | K111E | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | K111E | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | K111E | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | K111E | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | K111E | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | K111E | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | K111E | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | K111E | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | N247I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | N247I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | N247I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | N247I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | N247I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | N247I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | N247I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | N247I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | N247I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | N247I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | N247I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | N247I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | N247I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | N247I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | N247I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB2 | D769Y | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | D769Y | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769Y | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769Y | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | D769Y | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | D769Y | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | D769Y | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | D769Y | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | D769Y | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | D769Y | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769Y | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | D769Y | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769Y | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | D769Y | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | D769Y | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | D769Y | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769Y | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | D769Y | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | D769Y | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | D769Y | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | D769Y | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | D769Y | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | D769Y | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | D769Y | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | D769Y | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769Y | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | D769Y | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | D769Y | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | D769Y | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | D769Y | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | D769Y | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| TP53 | Y126C | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y126C | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y126C | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y126C | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y126C | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y126C | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y126C | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y126C | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y126C | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y126C | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y126C | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y126C | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y126C | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y126C | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y126C | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C238F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C238F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C238F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C238F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C238F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C238F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C238F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C238F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C238F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C238F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C238F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C238F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C238F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C238F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C238F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S127P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S127P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S127P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S127P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S127P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S127P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S127P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S127P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S127P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S127P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S127P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S127P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S127P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S127P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S127P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| LRP1B | Q400* | Complete Match | Liposomal Doxorubicin (Chemotherapy) | Resistant | OV | Early trials |
| LRP1B | Q400* | Different Alteration | Liposomal Doxorubicin (Chemotherapy) | Resistant | OV | Early trials |
| ROS1 | S2326F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | S2326F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | S2326F | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | S2326F | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | S2326F | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH2 | S801L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | S287* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | S287* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | S287* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | S287* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | S287* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | S287* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | S287* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | S287* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | S287* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | S287* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | S287* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | S287* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | S287* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | S287* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | S287* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | S287* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | S287* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | S287* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | S287* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | S287* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | S287* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | S287* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | S287* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | S287* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | S287* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | Y205N | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y205N | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y205N | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y205N | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y205N | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y205N | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y205N | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y205N | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y205N | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y205N | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y205N | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y205N | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y205N | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y205N | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y205N | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | Y217F | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| BRAF | E309* | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | E309* | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | E309* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | E309* | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ERBB4 | intron_variant | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PTEN | L146* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | L146* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | L146* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | L146* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | L146* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | L146* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | L146* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | L146* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | L146* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | L146* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | L146* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | L146* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | L146* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | L146* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | L146* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | L146* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | L146* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | L146* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | L146* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | L146* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | L146* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | L146* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | L146* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | L146* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | L146* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| TP53 | H193Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H193Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H193Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H193Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H193Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H193Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H193Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H193Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H193Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H193Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H193Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H193Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H193Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H193Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H193Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | L1169L | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L1169L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | L1169L | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | L1169L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | L1169L | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | L1169L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | L1169L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | L1169L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | L1169L | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | L1169L | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | L1169L | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | L1169L | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | L1169L | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L1169L | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L1169L | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | L1169L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | L1169L | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | L1169L | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | L1169L | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | L1048L | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L1048L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | L1048L | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | L1048L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | L1048L | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | L1048L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | L1048L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | L1048L | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | L1048L | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | L1048L | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | L1048L | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | L1048L | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | L1048L | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L1048L | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | L1048L | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | L1048L | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | L1048L | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | L1048L | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | L1048L | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ERBB2 | D769H | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | D769H | Complete Match | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769H | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769H | Complete Match | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | D769H | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | D769H | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | D769H | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | D769H | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | D769H | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | D769H | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769H | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | D769H | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769H | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | D769H | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | D769H | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | D769H | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | D769H | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | D769H | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | D769H | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | D769H | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | D769H | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | D769H | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | D769H | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | D769H | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | D769H | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | D769H | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | D769H | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | D769H | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | D769H | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | D769H | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | D769H | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| RET | L1101V | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | L1101V | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | L1101V | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | L1101V | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | L1101V | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | L1101V | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L1101V | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L1101V | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L1101V | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| ERCC4 | E359* | Complete Match | Cisplatin (Chemotherapy) | Responsive | OV | Pre-clinical |
| JAK2 | R138P | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| RB1 | C853* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | C853* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | C853* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | C853* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | C853* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | C853* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | C853* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| TP53 | L194P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L194P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L194P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L194P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L194P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L194P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L194P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L194P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L194P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L194P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L194P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L194P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L194P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L194P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L194P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H179Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H179Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H179Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H179Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H179Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H179Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H179Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H179Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H179Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H179Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H179Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C141R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C141R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C141R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C141R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C141R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C141R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C141R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C141R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C141R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C141R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C141R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C141R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C141R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C141R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C141R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | T847K | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | T847K | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | T847K | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | T847K | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | T847K | Different Mutation | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | T847K | Different Mutation | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | T847K | Different Mutation | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | T847K | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | T847K | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | T847K | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | T847K | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | T847K | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | T847K | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | T847K | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | T847K | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | T847K | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | T847K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | T847K | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | T847K | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | T847K | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | T847K | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | T847K | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | T847K | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | T847K | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | T847K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | T847K | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | T847K | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | T847K | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | T847K | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | T847K | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | T847K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | T847K | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | T847K | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | T847K | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | T847K | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | T847K | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | T847K | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | T847K | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | T847K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | T847K | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ERBB2 | I767M | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, BRCA, GEJA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) | Responsive | SOLID | Early trials |
| ERBB2 | I767M | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | I767M | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | I767M | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER, BRCA | Pre-clinical |
| ERBB2 | I767M | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | CANCER | Early trials |
| ERBB2 | I767M | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Case report |
| ERBB2 | I767M | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | BRCA, LUAD | Case report |
| ERBB2 | I767M | Different Mutation | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | L | Early trials |
| ERBB2 | I767M | Different Mutation | Neratinib (ERBB2 inhibitor) | Resistant | BRCA | Case report |
| ERBB2 | I767M | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Pre-clinical |
| ERBB2 | I767M | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Case report |
| ERBB2 | I767M | Different Mutation | Lapatinib (ERBB2 inhibitor) | Resistant | BRCA | Pre-clinical |
| ERBB2 | I767M | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | CANCER | Pre-clinical |
| ERBB2 | I767M | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Complete Match | Dacomitinib (Pan ERBB inhibitor) | Responsive | NSCLC | Early trials |
| ERBB2 | I767M | Complete Match | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Mutation | ERBB2 inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Mutation | ERBB2 mAb inhibitor | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Mutation | Neratinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Mutation | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | LUAD | Early trials |
| ERBB2 | I767M | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | I767M | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | COREAD | Late trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | OV | Early trials |
| ERBB2 | I767M | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | BLCA | Case report |
| ERBB2 | I767M | Different Alteration | Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) | Responsive | COREAD | Case report |
| ERBB2 | I767M | Different Alteration | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | I767M | Different Alteration | Osimertinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BT | Early trials |
| ERBB2 | I767M | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Early trials |
| ERBB2 | I767M | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | BT | Early trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) | Responsive | BRCA | Early trials |
| ERBB2 | I767M | Different Alteration | HER2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | Pertuzumab (ERBB2 mAb inhibitor) | Responsive | ST | Early trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | ST, GEJA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | ERBB2 inhibitor;CDK4/6 inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB2 | I767M | Different Alteration | Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) | Responsive | BRCA | FDA guidelines |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | Responsive | HNC | Case report |
| ERBB2 | I767M | Different Alteration | Neratinib (ERBB2 inhibitor) | Responsive | BRCA | Late trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab (ERBB2 mAb inhibitor) | No Responsive | ED | Early trials |
| ERBB2 | I767M | Different Alteration | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Responsive | ED | Pre-clinical |
| ERBB2 | I767M | Different Alteration | Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) | Responsive | ST | Early trials |
| ERBB2 | I767M | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | ST | Case report |
| ERBB2 | I767M | Different Alteration | EGFR inhibitor | Resistant | LUAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | H1047R), PIK3CA MUT (R108H | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | H168P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H168P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H168P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H168P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H168P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H168P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H168P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H168P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H168P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H168P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H168P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H168P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H168P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H168P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H168P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q136* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q136* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q136* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q136* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q136* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q136* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q136* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q136* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q136* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q136* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q136* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q136* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | S1002C | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | S1002C | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | S1002C | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | S1002C | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | S1002C | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | S1002C | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| ARID1A | Q528* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q528* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q528* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q528* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| ESR1 | Y246* | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| TP53 | R280* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R280* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R280* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R280* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R280* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R280* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R280* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R280* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R280* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R280* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R280* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FLCN | S333* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | R | Case report |
| FLCN | S333* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | TH | Case report |
| TP53 | I232S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I232S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | I232S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | I232S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | I232S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | I232S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I232S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I232S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I232S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | I232S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | I232S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | I232S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I232S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | I232S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I232S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ESR1 | G274G | Different Alteration | ESR1 inhibitor | Resistant | BRCA | Pre-clinical |
| NTRK1 | R583H | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | R583H | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | R583H | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | R583H | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| NOTCH2 | E1780K | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | E317E | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| PTEN | C124G | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | C124G | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | C124G | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | C124G | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | C124G | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | C124G | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | C124G | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | C124G | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | C124G | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | C124G | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | C124G | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | C124G | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | C124G | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | C124G | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | C124G | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | C124G | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | C124G | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | C124G | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | C124G | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | C124G | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | C124G | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | C124G | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | C124G | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | C124G | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | C124G | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| RET | L846I | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | L846I | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | L846I | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | L846I | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | L846I | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | L846I | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L846I | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L846I | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | L846I | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| KMT2A | T1842A | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | T1842A | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | T1842A | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | T1842A | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | T1842A | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | T1842A | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| JAK2 | splice_acceptor_variant | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | S932T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | S932T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | S932T | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | S932T | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | S932T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | Y1022C | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| TP53 | P278A | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | P278A | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | P278A | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | P278A | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | P278A | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | P278A | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | P278A | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278A | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | P278A | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | P278A | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | P278A | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | P278A | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278A | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | P278A | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | P278A | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | V344M | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | V344M | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | V344M | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | V344M | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | V344M | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | V344M | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | V344M | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | V344M | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NOTCH2 | V2469I | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | intron_variant | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | intron_variant | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| DNMT3A | G890D | Complete Match | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| RB1 | splice_acceptor_variant | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | splice_acceptor_variant | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | splice_acceptor_variant | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | splice_acceptor_variant | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | splice_acceptor_variant | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | splice_acceptor_variant | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | splice_acceptor_variant | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| ROS1 | W1694* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | W1694* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | W1694* | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | W1694* | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | W1694* | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| PDGFRA | D1075N | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| NTRK3 | A573V | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | A573V | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | A573V | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| STK11 | Q123* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | PA | Case report |
| STK11 | Q123* | Complete Match | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | Q123* | Complete Match | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | Q123* | Complete Match | BET inhibitor | Resistant | L | Pre-clinical |
| STK11 | Q123* | Complete Match | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | Q123* | Complete Match | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | Q123* | Complete Match | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | Q123* | Different Alteration | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | Q123* | Different Alteration | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | Q123* | Different Alteration | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | Q123* | Different Alteration | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | Q123* | Different Alteration | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| JAK2 | C75F | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| FGFR2 | E367Q | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | E367Q | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| RET | I625M | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | I625M | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | I625M | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | I625M | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | I625M | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | I625M | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | I625M | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | I625M | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | I625M | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PML | P410A | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | P410A | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | P410A | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| SETD2 | S618* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | S618* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R306* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R306* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R306* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R306* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R306* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R306* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R306* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R306* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R306* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R306* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R306* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R306* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R306* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R306* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R306* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | A276P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | A276P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | A276P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | A276P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | A276P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | A276P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | A276P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A276P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | A276P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | A276P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | A276P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | A276P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A276P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | A276P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | A276P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NF1 | Q347* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | Q347* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | Q347* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q347* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q347* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q347* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | Q347* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | Q347* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | Q347* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q347* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q347* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | Q347* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q347* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q347* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q347* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | Q347* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q347* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q347* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q347* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q347* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q347* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q347* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q347* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q347* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q347* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | Q347* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q347* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | Q347* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q347* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | Q347* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | Q347* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q347* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | Q347* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q347* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | Q347* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | Q347* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | Q347* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q347* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | Q347* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | Q347* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | Q347* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | Q347* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | Q347* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | Q347* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | Q347* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | Q347* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| EPHA3 | splice_donor_variant | Different Alteration | EPHA3 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R282G | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R282G | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R282G | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R282G | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R282G | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R282G | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R282G | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R282G | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R282G | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R282G | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R282G | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R282G | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R282G | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R282G | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R282G | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | K111N | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | K111N | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | K111N | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | K111N | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | K111N | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | K111N | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | K111N | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | K111N | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | M1004I | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | M1004I | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | M1004I | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | M1004I | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | M1004I | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | M1004I | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | M1004I | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | M1004I | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | R958R | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | R958R | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | Q167* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q167* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q167* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q167* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q167* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q167* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q167* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q167* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q167* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q167* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q167* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q167* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q167* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q167* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q167* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| CDH1 | T379T | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ROS1 | T1735T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | T1735T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | T1735T | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | T1735T | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | T1735T | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH1 | A2036V | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | A2036V | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | Y126N | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Y126N | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Y126N | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Y126N | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Y126N | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Y126N | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Y126N | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y126N | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Y126N | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Y126N | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Y126N | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Y126N | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y126N | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Y126N | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Y126N | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V157F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V157F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V157F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V157F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V157F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V157F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V157F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V157F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V157F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V157F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V157F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V157F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V157F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V157F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V157F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ROS1 | P1743Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | P1743Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | P1743Q | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | P1743Q | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | P1743Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NRG1 | 5-UTRSNV | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | 5-UTRSNV | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| BRAF | E433K | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | E433K | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | E433K | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | E433K | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| NTRK3 | R306P | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R306P | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R306P | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| NOTCH2 | H151Y | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| KMT2A | I3288I | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | I3288I | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | I3288I | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | I3288I | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | I3288I | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | I3288I | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PDGFRA | E556K | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| PTPRD | Q193* | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| ALK | E576Q | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E576Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | E576Q | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | E576Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | E576Q | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | E576Q | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | E576Q | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | E576Q | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | E576Q | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | E576Q | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | E576Q | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | E576Q | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | E576Q | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E576Q | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E576Q | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | E576Q | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | E576Q | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | E576Q | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | E576Q | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| SETD2 | S815* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | S815* | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | splice_acceptor_variant | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | splice_acceptor_variant | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| MSH2 | R621* | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| MSH2 | R621* | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| KMT2A | K1185K | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | K1185K | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | K1185K | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | K1185K | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | K1185K | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | K1185K | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PIK3CA | N1044Y | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | N1044Y | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | N1044Y | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N1044Y | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | N1044Y | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N1044Y | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | N1044Y | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | N1044Y | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| KRAS | G12D | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12D | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| KRAS | G12D | Different Mutation | Cetuximab (EGFR mAb inhibitor) | No Responsive | COREAD | Late trials |
| KRAS | G12D | Complete Match | MEK inhibitor | Responsive | ALL | Pre-clinical |
| KRAS | G12D | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Resistant | GIST | Case report |
| KRAS | G12D | Complete Match | MEK inhibitor | Responsive | OV, CER, AML | Pre-clinical |
| KRAS | G12D | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | MEK inhibitor;PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12D | Complete Match | Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) | Responsive | HC | Early trials |
| KRAS | G12D | Complete Match | EGFR inhibitor | Resistant | L | NCCN guidelines |
| KRAS | G12D | Complete Match | CDK4 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | Selumetinib (MEK inhibitor) | Responsive | NSCLC | Early trials |
| KRAS | G12D | Complete Match | BET inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) | Responsive | OV | Pre-clinical |
| KRAS | G12D | Complete Match | FAK inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | EGFR inhibitor | Resistant | NSCLC | Pre-clinical |
| KRAS | G12D | Complete Match | EZH2 inhibitor | Resistant | CANCER | Pre-clinical |
| KRAS | G12D | Complete Match | MEK inhibitor | Responsive | BT, L | Early trials |
| KRAS | G12D | Complete Match | MEK inhibitor;IGF1R inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | MTOR inhibitor;BH3 mimetics | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | EGFR mAb inhibitor;MEK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | pan-RAF inhibitor | Responsive | ED | Case report |
| KRAS | G12D | Complete Match | EGFR mAb inhibitor | Resistant | ST | Pre-clinical |
| KRAS | G12D | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | Selumetinib (MEK inhibitor) | No Responsive | L | Early trials |
| KRAS | G12D | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | LUAD | Pre-clinical |
| KRAS | G12D | Complete Match | Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) | Resistant | COREAD | Late trials |
| KRAS | G12D | Complete Match | pan-RAF inhibitor | Responsive | L | Early trials |
| KRAS | G12D | Complete Match | JAK/TBK1/IKKε inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | FAS inhibitor | Responsive | L | Case report |
| KRAS | G12D | Complete Match | HSP90 inhibitor | Responsive | L | Pre-clinical |
| KRAS | G12D | Complete Match | ERK inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | PI3K pathway inhibitor;MEK inhibitor | No Responsive | PA | Early trials |
| KRAS | G12D | Complete Match | MEK inhibitor;BCL-XL inhibitor | Responsive | COREAD | Pre-clinical |
| KRAS | G12D | Complete Match | Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) | Responsive | PA | Early trials |
| KRAS | G12D | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | NCCN guidelines |
| KRAS | G12D | Complete Match | PI3K pathway inhibitor | Resistant | ED | Pre-clinical |
| KRAS | G12D | Complete Match | CDK4/6 inhibitor;MEK inhibitor | Responsive | CESC | Pre-clinical |
| KRAS | G12D | Different Alteration | BRAF inhibitor;MEK inhibitor | Resistant | COREAD | Case report |
| KRAS | G12D | Different Alteration | BRAF inhibitor;EGFR mAb inhibitor | Resistant | COREAD | Case report |
| SMARCA1 | splice_acceptor_variant | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| BRAF | R347L | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | R347L | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | R347L | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | R347L | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| ALK | G843R | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G843R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | G843R | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | G843R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | G843R | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | G843R | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | G843R | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | G843R | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | G843R | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | G843R | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | G843R | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | G843R | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | G843R | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G843R | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | G843R | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | G843R | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | G843R | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | G843R | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | G843R | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| MAP2K1 | E203K | Different Mutation | MEK inhibitor | Resistant | CANCER | Pre-clinical |
| MAP2K1 | E203K | Different Mutation | novel MEK inhibitor | Responsive | CM | Pre-clinical |
| MAP2K1 | E203K | Different Mutation | MEK inhibitor | Resistant | CM | Case report |
| MAP2K1 | E203K | Different Mutation | ERK inhibitor | Responsive | CANCER | Pre-clinical |
| MAP2K1 | E203K | Complete Match | Vemurafenib (BRAF inhibitor) | Resistant | CM | Case report |
| MAP2K1 | E203K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| MAP2K1 | E203K | Different Mutation | Trametinib (MEK inhibitor) | Responsive | CANCER | Pre-clinical |
| MAP2K1 | E203K | Different Mutation | Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) | Responsive | COREAD | Case report |
| MAP2K1 | E203K | Different Mutation | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| MAP2K1 | E203K | Different Mutation | BRAF inhibitor | Resistant | CM | Early trials |
| MAP2K1 | E203K | Different Mutation | ERK inhibitor | Responsive | CM | Pre-clinical |
| MAP2K1 | E203K | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Case report |
| PTPRD | E661* | Complete Match | IGF1R inhibitor | Responsive | S | Case report |
| AKT3 | S474F | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R582W | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R582W | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | R582W | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| FGFR2 | E471D), FGFR2 MUT* (D472Y | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | E471D), FGFR2 MUT* (D472Y | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| TP53 | Q136E | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q136E | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q136E | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q136E | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q136E | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q136E | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q136E | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136E | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136E | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q136E | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q136E | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136E | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q136E | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q136E | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q136E | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C176* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C176* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C176* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C176* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C176* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C176* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C176* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C176* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C176* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C176* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C176* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C176* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C176* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C176* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C176* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ERBB4 | G500E | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| BRAF | L537S | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | L537S | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | L537S | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | L537S | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| MTOR | I1973F | Different Mutation | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Pre-clinical |
| MTOR | I1973F | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | R | Case report |
| MTOR | I1973F | Complete Match | Everolimus (MTOR inhibitor) | Responsive | AS, R, ST, AG | Case report |
| MTOR | I1973F | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | BLCA | Case report |
| MTOR | I1973F | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | ST | Case report |
| MTOR | I1973F | Different Mutation | Everolimus (MTOR inhibitor) | Resistant | THCA | Case report |
| MTOR | I1973F | Different Mutation | MTOR kinase inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L130V | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L130V | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L130V | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L130V | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L130V | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L130V | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L130V | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L130V | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L130V | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L130V | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L130V | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L130V | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L130V | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L130V | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L130V | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ABL1 | I347I | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | I347I | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | I347I | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | I347I | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | I347I | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | I347I | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | E286K | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E286K | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E286K | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E286K | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E286K | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E286K | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E286K | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E286K | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E286K | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E286K | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E286K | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E286K | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E286K | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E286K | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E286K | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| FGFR2 | V633I | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | V633I | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| ATR | E1922* | Complete Match | Temozolomide (Chemotherapy) | Responsive | G | Pre-clinical |
| ATR | E1922* | Complete Match | Olaparib (PARP inhibitor) | Responsive | CANCER, OV | Pre-clinical |
| ATR | E1922* | Different Alteration | Olaparib (PARP inhibitor) | Responsive | OV, CANCER | Pre-clinical |
| TP53 | I255F | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | I255F | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | I255F | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | I255F | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | I255F | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | I255F | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | I255F | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255F | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | I255F | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | I255F | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | I255F | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | I255F | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255F | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | I255F | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | I255F | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | W91* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | W91* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | W91* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | W91* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | W91* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | W91* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | W91* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | W91* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | W91* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | W91* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | W91* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | W91* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | W91* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | W91* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | W91* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ABL1 | D71N | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | D71N | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | D71N | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | D71N | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | D71N | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | D71N | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| PIK3CA | G106R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | G106R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | G106R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G106R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | G106R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | G106R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | G106R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | G106R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PDGFRA | S1042S | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| TP53 | K132T | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | K132T | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | K132T | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | K132T | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | K132T | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | K132T | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | K132T | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132T | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | K132T | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | K132T | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | K132T | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | K132T | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132T | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | K132T | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | K132T | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BAP1 | T93A | Complete Match | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | T93A | Complete Match | PARP inhibitor | Responsive | R, CANCER | Pre-clinical |
| BAP1 | T93A | Complete Match | HDAC inhibitor | Responsive | CM | Pre-clinical |
| BAP1 | T93A | Different Alteration | PARP inhibitor | Responsive | CANCER, R | Pre-clinical |
| BAP1 | T93A | Different Alteration | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | T93A | Different Alteration | HDAC inhibitor | Responsive | CM | Pre-clinical |
| KMT2A | K255E | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | K255E | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | K255E | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | K255E | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | K255E | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | K255E | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | V157G | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V157G | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V157G | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V157G | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V157G | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V157G | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V157G | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V157G | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V157G | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V157G | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V157G | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V157G | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V157G | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V157G | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V157G | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | Q139* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | Q139* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | Q139* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | Q139* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | Q139* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | Q139* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | Q139* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | Q139* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | Q139* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | Q139* | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | Q139* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | Q139* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| FBXW7 | R465C | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | R465C | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | R465C | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | R465C | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| KMT2A | R442Q | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | R442Q | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | R442Q | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | R442Q | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | R442Q | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | R442Q | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| GATA3 | W329* | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| RB1 | R455* | Different Alteration | Palbociclib (CDK4/6 inhibitor) | Responsive | PRAD | Pre-clinical |
| RB1 | R455* | Complete Match | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | R455* | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | R455* | Complete Match | HDAC inhibitor | Responsive | RB | Pre-clinical |
| RB1 | R455* | Different Alteration | MDM2/MDMX inhibitor | Responsive | RB | Pre-clinical |
| RB1 | R455* | Different Alteration | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| RB1 | R455* | Different Alteration | HDAC inhibitor | Responsive | RB | Pre-clinical |
| AKT3 | E84K | Different Alteration | ATP competitive AKT inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | W91*), TP53 MUT (Y220S | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | W91*), TP53 MUT (Y220S | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| KMT2A | E1464* | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | E1464* | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | E1464* | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | E1464* | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | E1464* | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | E1464* | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| PDGFB | R216C | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| PLCG2 | S225* | Different Mutation | Ibrutinib (BTK inhibitor) | Resistant | CLL | Early trials |
| FAT1 | S3029* | Complete Match | BET inhibitor | Responsive | HNSC | Pre-clinical |
| FBXW7 | G391D | Complete Match | Steroid | Responsive | ALL | Late trials |
| FBXW7 | G391D | Complete Match | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| FBXW7 | G391D | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | COREAD | Pre-clinical |
| FBXW7 | G391D | Different Alteration | Tubulin inhibitor | Resistant | CANCER | Pre-clinical |
| RET | D547D | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | D547D | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | D547D | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | D547D | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | D547D | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | D547D | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | D547D | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | D547D | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | D547D | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| SF3B1 | N626D | Different Mutation | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| JAK2 | P429P | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| NOTCH1 | G1376S | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | G1376S | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | splice_acceptor_variant | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_acceptor_variant | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | splice_acceptor_variant | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | splice_acceptor_variant | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | splice_acceptor_variant | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | E286Q | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E286Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E286Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E286Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E286Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E286Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E286Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E286Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E286Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E286Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E286Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E286Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E286Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E286Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E286Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH1 | E1903D | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | E1903D | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | P104L | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | P104L | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | P104L | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | P104L | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | P104L | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | P104L | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | P104L | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | P104L | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR2 | H545Q | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | H545Q | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| ROS1 | V2068V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | V2068V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | V2068V | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | V2068V | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | V2068V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| NOTCH2 | S1110F | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ARID1A | Q1631* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q1631* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | Q1631* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | Q1631* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH2 | R2400* | Complete Match | Mk-0752 (Gamma secretase inhibitor) | Responsive | ALL, AML, BRCA | Early trials |
| NOTCH2 | R2400* | Complete Match | OMP-59R5 (NOTCH2 inhibitor) | Responsive | SOLID | Early trials |
| NOTCH2 | R2400* | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| CDH1 | K668* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| PIK3CA | E81K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E81K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E81K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E81K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E81K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E81K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E81K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E81K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| BRD4 | M1073I | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| HIF1A | Q730* | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | R | Pre-clinical |
| TP53 | E258* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | E258* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | E258* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | E258* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | E258* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | E258* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | E258* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E258* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | E258* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | E258* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | E258* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | E258* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E258* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | E258* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | E258* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| MET | D414N | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| PDGFRA | 3-UTRSNV | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| CDK12 | E488* | Complete Match | PARP inhibitor | Responsive | OV | Pre-clinical |
| CDK12 | E488* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| NTRK1 | L96V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | L96V | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | L96V | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | L96V | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| ARID1A | R1335* | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | R1335* | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | R1335* | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | R1335* | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q192* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q192* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q192* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q192* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q192* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q192* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q192* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q192* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q192* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q192* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q192* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q192* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q192* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q192* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q192* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | V597G | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | V597G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | V597G | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | V597G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | V597G | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | V597G | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | V597G | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | V597G | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | V597G | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | V597G | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | V597G | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | V597G | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | V597G | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | V597G | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | V597G | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | V597G | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | V597G | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | V597G | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | V597G | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (E726K | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E542K), PIK3CA MUT (E726K | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E542K), PIK3CA MUT (E726K | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NF1 | S2601* | Different Mutation | Vemurafenib (BRAF inhibitor) | Resistant | CM | Pre-clinical |
| NF1 | S2601* | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | HNC | Case report |
| NF1 | S2601* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | S2601* | Complete Match | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | S2601* | Complete Match | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Complete Match | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | S2601* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | NF | Late trials |
| NF1 | S2601* | Complete Match | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Complete Match | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Nilotinib (BCR-ABL inhibitor) | Responsive | MPN, PLEN | Pre-clinical |
| NF1 | S2601* | Complete Match | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | HNC, SG | Case report |
| NF1 | S2601* | Complete Match | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | S2601* | Complete Match | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | S2601* | Complete Match | MEK inhibitor | Responsive | LK, G | Pre-clinical |
| NF1 | S2601* | Complete Match | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | S2601* | Complete Match | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | S2601* | Complete Match | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | MTOR inhibitor | Responsive | LK, G, MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | S2601* | Complete Match | Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) | Responsive | HC | Case report |
| NF1 | S2601* | Complete Match | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | S2601* | Complete Match | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | S2601* | Complete Match | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | S2601* | Complete Match | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Complete Match | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Complete Match | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | S2601* | Complete Match | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | S2601* | Complete Match | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | S2601* | Complete Match | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Complete Match | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | S2601* | Complete Match | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | S2601* | Complete Match | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | S2601* | Different Alteration | MTOR inhibitor | Responsive | MPN, G, LK | Pre-clinical |
| NF1 | S2601* | Different Alteration | PLX3397 (Pan-TK inhibitor) | Responsive | PLEN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Erlotinib (EGFR inhibitor) | Resistant | L | Pre-clinical |
| NF1 | S2601* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Different Alteration | BRD4 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Trametinib (MEK inhibitor) | No Responsive | OS | Case report |
| NF1 | S2601* | Different Alteration | Cediranib (ALK inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | S2601* | Different Alteration | Bevacizumab (VEGFR mAb inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Different Alteration | MEK inhibitor | Responsive | G, LK | Pre-clinical |
| NF1 | S2601* | Different Alteration | Vinblastine (Chemotherapy) | Responsive | G | Early trials |
| NF1 | S2601* | Different Alteration | Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) | No Responsive | MPN | Early trials |
| NF1 | S2601* | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Resistant | L | Pre-clinical |
| NF1 | S2601* | Different Alteration | MTOR inhibitor;HSP90 inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | PLEN | Early trials |
| NF1 | S2601* | Different Alteration | Tamoxifen (Hormonal therapy) | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | SG, HNC | Case report |
| NF1 | S2601* | Different Alteration | Pan-RAF inhibitor;MEK inhibitor | Responsive | CM | Pre-clinical |
| NF1 | S2601* | Different Alteration | Tipifarnib (Farnesyltransferase inhibitor) | No Responsive | PLEN | Early trials |
| NF1 | S2601* | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | PLEN | Early trials |
| NF1 | S2601* | Different Alteration | Retinoic Acid | Resistant | NB | Pre-clinical |
| NF1 | S2601* | Different Alteration | Everolimus (MTOR inhibitor) | No Responsive | MPN | Early trials |
| NF1 | S2601* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | PLEN | Early trials |
| NF1 | S2601* | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | PLEN, MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) | Responsive | G | Case report |
| NF1 | S2601* | Different Alteration | Trametinib (MEK inhibitor) | Responsive | CM | Pre-clinical |
| NF1 | S2601* | Different Alteration | AURK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) | No Responsive | G | Case report |
| NF1 | S2601* | Different Alteration | PD1 Ab inhibitor | Responsive | CM | Early trials |
| NF1 | S2601* | Different Alteration | MEK inhibitor | Responsive | MPN | Pre-clinical |
| NF1 | S2601* | Different Alteration | KIT inhibitor;MTOR inhibitor | Responsive | MPN | Pre-clinical |
| TP53 | L257R | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | L257R | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | L257R | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | L257R | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | L257R | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | L257R | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | L257R | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L257R | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | L257R | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | L257R | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | L257R | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | L257R | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L257R | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | L257R | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | L257R | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NRG1 | A547T | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | A547T | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| TP53 | D281E | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | D281E | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | D281E | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | D281E | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | D281E | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | D281E | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | D281E | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | D281E | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | D281E | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | D281E | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | D281E | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | D281E | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | D281E | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | D281E | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | D281E | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | F258L), PTEN MUT (F258Y | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| RAF1 | E607Q | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | E607Q | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | E607Q | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| BRD4 | intron_variant | Different Alteration | BET inhibitor | Responsive | NMC | Case report |
| TP53 | R280K | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | R280K | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | R280K | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | R280K | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | R280K | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | R280K | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | R280K | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280K | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | R280K | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | R280K | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | R280K | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | R280K | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280K | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | R280K | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | R280K | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SF3B1 | K666N | Complete Match | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (C420R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | E545K), PIK3CA MUT (C420R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | E545K), PIK3CA MUT (C420R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| NTRK3 | L827F | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | L827F | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | L827F | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| SMARCA4 | splice_acceptor_variant | Complete Match | EZH2 inhibitor | Responsive | OVRT | Case report |
| SMARCA4 | splice_acceptor_variant | Complete Match | AURKA inhibitor | Responsive | NSCLC | Pre-clinical |
| SMARCA4 | splice_acceptor_variant | Complete Match | EZH2 inhibitor | Responsive | OV | Case report |
| SMARCA4 | splice_acceptor_variant | Different Alteration | EZH2 inhibitor | Responsive | OVRT | Case report |
| SMARCA4 | splice_acceptor_variant | Different Alteration | EZH2 inhibitor | Responsive | OV | Case report |
| ERBB4 | 5-UTRSNV | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| BCR | D904N | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | D904N | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | D904N | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | D904N | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | D904N | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | D904N | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| PTEN | L140* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | L140* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | L140* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | L140* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | L140* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | L140* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | L140* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | L140* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | L140* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | L140* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | L140* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | L140* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | L140* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | L140* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | L140* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | L140* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | L140* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | L140* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | L140* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | L140* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | L140* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | L140* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | L140* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | L140* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | L140* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| CDK12 | Y246* | Complete Match | PARP inhibitor | Responsive | OV | Pre-clinical |
| CDK12 | Y246* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | T253S), TP53 MUT (Q331* | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | T253S), TP53 MUT (Q331* | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BCR | I57I | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | I57I | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | I57I | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | I57I | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | I57I | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | I57I | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| PTEN | D92E | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | D92E | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | D92E | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | D92E | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | D92E | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | D92E | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | D92E | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | D92E | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | D92E | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | D92E | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | D92E | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | D92E | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | D92E | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | D92E | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | D92E | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | D92E | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | D92E | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | D92E | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | D92E | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | D92E | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | D92E | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | D92E | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | D92E | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | D92E | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | D92E | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PIK3CA | N345H | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | N345H | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | N345H | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N345H | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | N345H | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | N345H | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | N345H | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | N345H | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| FGFR3 | 3-UTRSNV | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | 3-UTRSNV | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | 3-UTRSNV | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| PTEN | A126G | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | A126G | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | A126G | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | A126G | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | A126G | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | A126G | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | A126G | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | A126G | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | A126G | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | A126G | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | A126G | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | A126G | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | A126G | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | A126G | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | A126G | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | A126G | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | A126G | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | A126G | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | A126G | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | A126G | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | A126G | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | A126G | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | A126G | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | A126G | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | A126G | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | intron_variant | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| EGFR | E928V | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | E928V | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| TP53 | V157D | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | V157D | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | V157D | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | V157D | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | V157D | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | V157D | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | V157D | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V157D | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | V157D | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | V157D | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | V157D | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | V157D | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V157D | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | V157D | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | V157D | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| RAF1 | R354W | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | R354W | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | R354W | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| NOTCH2 | C1342C | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| GATA3 | K347* | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | P366R | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | P366R | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | P366R | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | P366R | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | P366R | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | P366R | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | P366R | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | P366R | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| EGFR | A289V | Different Alteration | Cetuximab (EGFR mAb inhibitor) | Responsive | COREAD | FDA guidelines |
| EGFR | A289V | Different Alteration | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | FDA guidelines |
| EGFR | A289V | Different Mutation | Rindopepimut (Vaccine) | Responsive | GB | Late trials |
| EGFR | A289V | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | A289V | Different Mutation | Gefitinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | A289V | Different Mutation | HSP90 inhibitor | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | MEK inhibitor | Responsive | L | Pre-clinical |
| EGFR | A289V | Different Mutation | EGFR TK inhibitor | Responsive | L | Late trials |
| EGFR | A289V | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | NCCN guidelines |
| EGFR | A289V | Different Mutation | Osimertinib (EGFR inhibitor) | Resistant | L | Early trials |
| EGFR | A289V | Different Mutation | EGFR-TKI's (EGFR inhibitor) | Resistant | L | Late trials |
| EGFR | A289V | Different Mutation | HSP90 inhibitor | Responsive | L | Case report |
| EGFR | A289V | Different Mutation | EGFR inhibitor | Resistant | L | Late trials |
| EGFR | A289V | Different Mutation | Poziotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Pre-clinical |
| EGFR | A289V | Different Mutation | HSP90 inhibitor (HSP90 inhibitor) | Responsive | L | Early trials |
| EGFR | A289V | Complete Match | Erlotinib (EGFR inhibitor) | Responsive | G | Pre-clinical |
| EGFR | A289V | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | A289V | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | Rociletinib (EGFR inhibitor) | Resistant | LUAD | Case report |
| EGFR | A289V | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Responsive | COREAD | Case report |
| EGFR | A289V | Different Mutation | novel EGFR mAb inhibitor | Responsive | COREAD | Early trials |
| EGFR | A289V | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | A289V | Different Mutation | Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) | Responsive | HNC | Case report |
| EGFR | A289V | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | A289V | Different Mutation | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Case report |
| EGFR | A289V | Different Mutation | EGFR inhibitor | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | Erlotinib (EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | A289V | Different Mutation | Osimertinib (EGFR inhibitor) | Responsive | NSCLC | FDA guidelines |
| EGFR | A289V | Different Mutation | EGFR inhibitor | Responsive | NSCLC | Late trials |
| EGFR | A289V | Different Mutation | Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Resistant | L | NCCN/CAP guidelines |
| EGFR | A289V | Different Mutation | Erlotinib (EGFR inhibitor) | Responsive | L | Early trials |
| EGFR | A289V | Different Mutation | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | L | Late trials |
| EGFR | A289V | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Pre-clinical |
| EGFR | A289V | Different Mutation | Erlotinib (EGFR inhibitor) | No Responsive | L | Case report |
| EGFR | A289V | Different Mutation | Lapatinib (ERBB2 inhibitor) | Responsive | ED | Case report |
| EGFR | A289V | Different Mutation | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | A289V | Different Mutation | EGFR inhibitor | Resistant | NSCLC | Case report |
| EGFR | A289V | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| EGFR | A289V | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant;Resistant | COREAD | Pre-clinical;Case report |
| EGFR | A289V | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Responsive | HNC | Case report |
| EGFR | A289V | Different Alteration | Gefitinib (EGFR inhibitor) | Responsive | ED | Late trials |
| EGFR | A289V | Different Alteration | Gefitinib (EGFR inhibitor) | No Responsive | HNC | Early trials |
| EGFR | A289V | Different Alteration | EGFR inhibitor | Responsive | HNSC | Case report |
| EGFR | A289V | Different Alteration | EGFR inhibitor | No Responsive | G | Early trials |
| EGFR | A289V | Different Alteration | Erlotinib (EGFR inhibitor) | No Responsive | L | Early trials |
| EGFR | A289V | Different Alteration | EGFR mAb inhibitor | Responsive | COREAD | Late trials |
| EGFR | A289V | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | A289V | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| CDH1 | R335* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | H179Q | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | H179Q | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | H179Q | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | H179Q | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | H179Q | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | H179Q | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | H179Q | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179Q | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | H179Q | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | H179Q | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | H179Q | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | H179Q | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179Q | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | H179Q | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | H179Q | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| BRCA1 | Q1408* | Complete Match | Chemotherapy (PARP inhibitor;Chemotherapy) | Responsive | OV | Early trials |
| BRCA1 | Q1408* | Complete Match | PARP inhibitor | Responsive | BRCA | Early trials |
| BRCA1 | Q1408* | Complete Match | PARP inhibitor;Chemotherapy | Responsive | OV | Early trials |
| BRCA1 | Q1408* | Complete Match | Rucaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | Q1408* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | Q1408* | Complete Match | WEE1 inhibitor | Responsive | CANCER | Case report |
| BRCA1 | Q1408* | Complete Match | Platinum Agent (Chemotherapy) | Responsive | OV | Late trials |
| BRCA1 | Q1408* | Complete Match | Olaparib (PARP inhibitor) | Responsive | PRAD | Early trials |
| BRCA1 | Q1408* | Complete Match | Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) | Responsive | BRCA | Early trials |
| BRCA1 | Q1408* | Complete Match | PARP inhibitor | Responsive | PA | Case report |
| BRCA1 | Q1408* | Complete Match | Olaparib (PARP inhibitor) | Responsive | OV | FDA guidelines |
| BRCA1 | Q1408* | Different Alteration | PARP inhibitor | Responsive | OV | Pre-clinical |
| CDH1 | E512* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| HRAS | G12D | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CER | Pre-clinical |
| HRAS | G12D | Complete Match | MEK inhibitor +/- MTOR inhibitor | Responsive | AML | Pre-clinical |
| HRAS | G12D | Complete Match | MTOR inhibitor | Responsive | CESC | Pre-clinical |
| HRAS | G12D | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | Responsive | CANCER | Early trials |
| ERCC2 | splice_donor_variant | Complete Match | Cisplatin (Chemotherapy) | Responsive | BLCA | Early trials |
| ERCC2 | splice_donor_variant | Complete Match | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| ERCC2 | splice_donor_variant | Different Alteration | PD1/PDL1 inhibitor | Responsive | UTH | Early trials |
| NTRK1 | D209H | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | D209H | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | D209H | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | D209H | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| TP53 | C242G | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C242G | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C242G | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C242G | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C242G | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C242G | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C242G | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C242G | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C242G | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C242G | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C242G | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C242G | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C242G | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C242G | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C242G | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| EGFR | E97Q | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | E97Q | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ROS1 | L1872V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | L1872V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | L1872V | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | L1872V | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | L1872V | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| TP53 | M169I | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | M169I | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | M169I | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | M169I | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | M169I | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | M169I | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | M169I | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M169I | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | M169I | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | M169I | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | M169I | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | M169I | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M169I | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | M169I | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | M169I | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | D1306N), NOTCH2 MUT* (3-UTRSNV | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| NRG1 | R18Q | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | R18Q | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| ABL1 | 3-UTRSNV | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | 3-UTRSNV | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | 3-UTRSNV | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | 3-UTRSNV | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | 3-UTRSNV | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | 3-UTRSNV | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| FGFR2 | H254Y | Different Alteration | FGFR inhibitor | Responsive | COREAD | Early trials |
| FGFR2 | H254Y | Different Alteration | FGFR inhibitor | Responsive | BT | Early trials |
| CDKN1B | Q141*), CDKN1B MUT (Q20* | Complete Match | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| CDKN1B | Q141*), CDKN1B MUT (Q20* | Different Alteration | CDK2/4 inhibitor | Responsive | CANCER | Pre-clinical |
| NOTCH2 | L1690L | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | S127Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | S127Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | S127Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | S127Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | S127Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | S127Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | S127Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S127Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | S127Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | S127Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | S127Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | S127Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S127Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | S127Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | S127Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C275Y | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | C275Y | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | C275Y | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | C275Y | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | C275Y | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | C275Y | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | C275Y | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C275Y | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | C275Y | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | C275Y | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | C275Y | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | C275Y | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C275Y | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | C275Y | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | C275Y | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PTEN | Q149* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Q149* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Q149* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | Q149* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | Q149* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | Q149* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Q149* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Q149* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Q149* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | Q149* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Q149* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Q149* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | Q149* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Q149* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Q149* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Q149* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | Q149* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Q149* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Q149* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Q149* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Q149* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Q149* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Q149* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Q149* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Q149* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | Y76* | Different Mutation | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Y76* | Different Mutation | Panitumumab (EGFR mAb inhibitor) | Resistant | COREAD | Case report |
| PTEN | Y76* | Different Mutation | BYL719 (PIK3CA inhibitor) | Resistant | BRCA | Case report |
| PTEN | Y76* | Complete Match | ATM inhibitor | Responsive | BRCA | Pre-clinical |
| PTEN | Y76* | Complete Match | PI3K pathway inhibitor | Responsive | BRCA, ED, TH, CANCER, L, G, OV | Pre-clinical |
| PTEN | Y76* | Complete Match | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Y76* | Complete Match | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Y76* | Complete Match | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Y76* | Complete Match | PD1 Ab inhibitor | Resistant | CM | Early trials |
| PTEN | Y76* | Complete Match | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Y76* | Complete Match | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Y76* | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| PTEN | Y76* | Complete Match | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Y76* | Complete Match | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Y76* | Complete Match | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Y76* | Different Alteration | PI3K pathway inhibitor | Responsive | L, BRCA, CANCER, G, ED, TH, OV | Pre-clinical |
| PTEN | Y76* | Different Alteration | Everolimus (MTOR inhibitor) | Responsive | PRAD | Early trials |
| PTEN | Y76* | Different Alteration | Sirolimus (MTOR inhibitor) | Responsive | CANCER | Early trials |
| PTEN | Y76* | Different Alteration | PARP inhibitor | Responsive | ED | Case report |
| PTEN | Y76* | Different Alteration | PIK3CB inhibitor | Responsive | PRAD | Case report |
| PTEN | Y76* | Different Alteration | EGFR mAb inhibitor | Resistant | COREAD | Late trials |
| PTEN | Y76* | Different Alteration | MTOR inhibitor | No Responsive | ED | Early trials |
| PTEN | Y76* | Different Alteration | AKT inhibitor | Responsive | PA | Case report |
| PTEN | Y76* | Different Alteration | PI3K pathway inhibitor;AR antagonist | Responsive | PRAD | Pre-clinical |
| PTEN | Y76* | Different Alteration | PI3K pathway inhibitor;MEK inhibitor | Responsive | OV | Pre-clinical |
| IDH1 | R132H | Complete Match | Venetoclax (BCL2 inhibitor) | Responsive | AML | Early trials |
| IDH1 | R132H | Complete Match | IDH1 inhibitor | Responsive | AML | Early trials |
| IDH1 | R132H | Complete Match | AG-120 (IDH1 inhibitor) | Responsive | G | Early trials |
| IDH1 | R132H | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | CH | Early trials |
| IDH1 | R132H | Complete Match | Ivosidenib (IDH1 inhibitor) | Responsive | AML | Early trials |
| IDH1 | R132H | Complete Match | BCL2 inhibitor | Responsive | AML | Pre-clinical |
| IDH1 | R132H | Complete Match | BCL2 inhibitor (BCL2 inhibitor) | Responsive | AML | Pre-clinical |
| IDH1 | R132H | Complete Match | Dasatinib (BCR-ABL inhibitor) | Responsive | BT | Pre-clinical |
| IDH1 | R132H | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| BRAF | A569D | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | CM, LUAD, PRAD | Pre-clinical |
| BRAF | A569D | Different Alteration | MEK inhibitor | Responsive | LUAD, CM, PRAD | Pre-clinical |
| BRAF | A569D | Different Alteration | Selumetinib (MEK inhibitor) | Responsive | OV | Case report |
| BRAF | A569D | Different Alteration | BRAF inhibitor;MEK inhibitor | Responsive | LUAD | Case report |
| HRAS | G12C | Complete Match | PI3K pathway inhibitor;MEK inhibitor | Responsive | CER | Pre-clinical |
| HRAS | G12C | Complete Match | MEK inhibitor +/- MTOR inhibitor | Responsive | AML | Pre-clinical |
| HRAS | G12C | Complete Match | MTOR inhibitor | Responsive | CESC | Pre-clinical |
| HRAS | G12C | Complete Match | Tipifarnib (Farnesyltransferase inhibitor) | Responsive | CANCER | Early trials |
| CDH1 | Q673* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| KMT2A | I1401F | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | I1401F | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | I1401F | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | I1401F | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | I1401F | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | I1401F | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| BAP1 | Y627* | Complete Match | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | Y627* | Complete Match | PARP inhibitor | Responsive | R, CANCER | Pre-clinical |
| BAP1 | Y627* | Complete Match | HDAC inhibitor | Responsive | CM | Pre-clinical |
| BAP1 | Y627* | Different Alteration | PARP inhibitor | Responsive | CANCER, R | Pre-clinical |
| BAP1 | Y627* | Different Alteration | EZH2 inhibitor | Responsive | MESO | Pre-clinical |
| BAP1 | Y627* | Different Alteration | HDAC inhibitor | Responsive | CM | Pre-clinical |
| BCR | 3-UTRSNV | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | 3-UTRSNV | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | 3-UTRSNV | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | 3-UTRSNV | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | 3-UTRSNV | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | 3-UTRSNV | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| KMT2A | 3-UTRSNV | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | 3-UTRSNV | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | 3-UTRSNV | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | 3-UTRSNV | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | 3-UTRSNV | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | 3-UTRSNV | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| TP53 | Q136P | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | Q136P | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | Q136P | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | Q136P | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | Q136P | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | Q136P | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | Q136P | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136P | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136P | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | Q136P | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | Q136P | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | Q136P | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q136P | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | Q136P | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | Q136P | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| ALK | E296K | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E296K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | E296K | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | E296K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | E296K | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | E296K | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | E296K | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | E296K | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | E296K | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | E296K | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | E296K | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | E296K | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | E296K | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E296K | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | E296K | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | E296K | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | E296K | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | E296K | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | E296K | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| ROS1 | splice_acceptor_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | splice_acceptor_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | splice_acceptor_variant | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | splice_acceptor_variant | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | splice_acceptor_variant | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| ERBB4 | H190Y | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| SMARCA1 | S324* | Complete Match | EZH2 inhibitor | Responsive | CANCER | Pre-clinical |
| CDH1 | Q129* | Complete Match | Bicalutamide (AR inhibitor) | Responsive | BRCA | Pre-clinical |
| ARID1A | splice_acceptor_variant | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | splice_acceptor_variant | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | splice_acceptor_variant | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | splice_acceptor_variant | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Loading...
Drug-Gene Interactions help
Druggable categories in the cohort
No meaningful categories found
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|---|---|---|---|---|
| TP53 | CKB | CTX-1 | |||
| TP53 | CKB | Gemcitabine | GEMCITABINE | CHEMBL888 | |
| TP53 | ClearityFoundationClinicalTrial | GRANISETRON | GRANISETRON | CHEMBL289469 | |
| TP53 | CKB | epirubicin | EPIRUBICIN | CHEMBL417 | |
| TP53 | NCI | TOPICAL CORTICOSTEROIDS | |||
| TP53 | CKB | Trametinib | TRAMETINIB | CHEMBL2103875 | |
| TP53 | TALC | vaccine | AD.P53-DC | ||
| TP53 | CKB | Cisplatin | |||
| TP53 | NCI | YONDELIS | YONDELIS | CHEMBL297812 | |
| TP53 | CKB | Doxorubicin | DOXORUBICIN | CHEMBL53463 | |
| TP53 | CGI | MK-1775 | AZD-1775 | CHEMBL1976040 | |
| TP53 | CKB | Paclitaxel | PACLITAXEL | CHEMBL428647 | |
| TP53 | NCI | ZINC CHLORIDE | ZINC CHLORIDE | CHEMBL1200679 | |
| TP53 | CKB | PD-0325901 | PD-0325901 | CHEMBL507361 | |
| TP53 | CKB | PK11007 | |||
| TP53 | CKB | Temozolomide | TEMOZOLOMIDE | CHEMBL810 | |
| TP53 | CKB | TC-A2317 | |||
| TP53 | CKB | NU6027 | CHEMBL303958 | CHEMBL303958 | |
| TP53 | NCI | DAB | |||
| TP53 | CKB | IGF-1R antibody | |||
| TP53 | CKB | PT2399 | |||
| TP53 | CKB | Ifosfamide | IFOSFAMIDE | CHEMBL1024 | |
| TP53 | CIViC | SELUMETINIB (AZD6244) | SELUMETINIB | CHEMBL1614701 | |
| TP53 | CKB | EGFR antibody | |||
| TP53 | NCI | IL-12 | PROXYPHYLLINE | CHEMBL37390 | |
| TP53 | NCI | METHIMAZOLE | METHIMAZOLE | CHEMBL1515 | |
| TP53 | CKB | Cytarabine | CYTARABINE | CHEMBL803 | |
| TP53 | TTD | activator | CURAXIN CBLC102 | ||
| TP53 | CGI | Pramlintide | PRAMLINTIDE | CHEMBL2103758 | |
| TP53 | CIViC | CAPECITABINE | CAPECITABINE | CHEMBL1773 | |
| TP53 | CKB | Docetaxel | DOCETAXEL | CHEMBL92 | |
| TP53 | NCI | PROPYLTHIOURACIL | PROPYLTHIOURACIL | CHEMBL1518 | |
| TP53 | CKB | Ibrutinib | IBRUTINIB | CHEMBL1873475 | |
| TP53 | CKB | INC280 | CAPMATINIB | CHEMBL3188267 | |
| TP53 | CKB | Prodigiosin | PRODIGIOSIN | CHEMBL275787 | |
| TP53 | CKB | CGM097 | |||
| TP53 | CKB | SRA737 | |||
| TP53 | NCI | PUROMYCIN | PUROMYCIN | CHEMBL469912 | |
| TP53 | CKB | ABT-737 | CHEMBL376408 | CHEMBL376408 | |
| TP53 | CKB | Crizotinib | CRIZOTINIB | CHEMBL601719 | |
| TP53 | NCI | RAPAMYCIN | SIROLIMUS | CHEMBL413 | |
| TP53 | CKB | AZD6738 | AZD-6738 | CHEMBL3545178 | |
| TP53 | CKB | p53-SLP vaccine | |||
| TP53 | CKB | Irinotecan | IRINOTECAN | CHEMBL481 | |
| TP53 | NCI | TRIETHYLENETHIOPHOSPHORAMIDE | THIOTEPA | CHEMBL671 | |
| TP53 | NCI | GARLIC | GARLIC | CHEMBL2108463 | |
| TP53 | CKB | MK-8745 | |||
| TP53 | CIViC | AMGMDS3 | |||
| TP53 | CKB | Erlotinib | ERLOTINIB | CHEMBL553 | |
| TP53 | CKB | Pembrolizumab | PEMBROLIZUMAB | CHEMBL3137343 | |
| TP53 | NCI | VEGF | BEVACIZUMAB | CHEMBL1201583 | |
| TP53 | CKB | AMG 232 | |||
| TP53 | CKB | BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| TP53 | CKB | Vemurafenib | VEMURAFENIB | CHEMBL1229517 | |
| TP53 | CKB | YW3-56 | |||
| TP53 | CKB | SAR405838 | |||
| TP53 | CGI | Cisplatin | |||
| TP53 | CGI | Abemaciclib | ABEMACICLIB | CHEMBL3301610 | |
| TP53 | CKB | PF-00477736 | PF-00477736 | CHEMBL3545137 | |
| TP53 | CKB | AMG 900 | AMG-900 | CHEMBL2140408 | |
| TP53 | CKB | GSK2830371 | |||
| TP53 | CKB | unspecified IGF-1R antibody | |||
| TP53 | NCI | DNA VACCINE | |||
| TP53 | CKB | Doxil | |||
| TP53 | CKB | AMG 337 | AMG-337 | CHEMBL3545212 | |
| TP53 | CKB | AZD6482 | AZD-6482 | CHEMBL2165191 | |
| TP53 | CGI | Decitabine | DECITABINE | CHEMBL1201129 | |
| TP53 | CIViC | NUTLIN-3A | |||
| TP53 | CKB | Bevacizumab | BEVACIZUMAB | CHEMBL1201583 | |
| TP53 | NCI | TRIFLUOPERAZINE | TRIFLUOPERAZINE | CHEMBL422 | |
| TP53 | CIViC | TAMOXIFEN | TAMOXIFEN | CHEMBL83 | |
| TP53 | CIViC | DOCETAXEL | DOCETAXEL | CHEMBL92 | |
| TP53 | CKB | ERBB3 antibody | |||
| TP53 | CKB | Tanespimycin | TANESPIMYCIN | CHEMBL109480 | |
| TP53 | CKB | JQ1 | |||
| TP53 | CKB | R547 | RG-547 | CHEMBL384304 | |
| TP53 | CKB | Selumetinib | SELUMETINIB | CHEMBL1614701 | |
| TP53 | CGI | AZD6738 | AZD-6738 | CHEMBL3545178 | |
| TP53 | CKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| TP53 | NCI | TIRAPAZAMINE | TIRAPAZAMINE | CHEMBL50882 | |
| TP53 | CIViC | CISPLATIN | |||
| TP53 | CKB | Trifluridine | TRIFLURIDINE | CHEMBL1129 | |
| TP53 | CIViC | DOXORUBICIN | DOXORUBICIN | CHEMBL53463 | |
| TP53 | CKB | Epirubicin | EPIRUBICIN | CHEMBL417 | |
| TP53 | CKB | Radiotherapy | |||
| TP53 | CKB | NSC59984 | |||
| TP53 | CKB | Duvelisib | DUVELISIB | CHEMBL3039502 | |
| TP53 | CIViC | CETUXIMAB | CETUXIMAB | CHEMBL1201577 | |
| TP53 | NCI | MPA | MYCOPHENOLIC ACID | CHEMBL866 | |
| TP53 | CKB | Vorinostat | VORINOSTAT | CHEMBL98 | |
| TP53 | CKB | Alvespimycin | ALVESPIMYCIN | CHEMBL383824 | |
| TP53 | CKB | Daunoxome | |||
| TP53 | CKB | APR-246 | |||
| TP53 | CKB | Cyclophosphamide | CYCLOPHOSPHAMIDE | CHEMBL88 | |
| TP53 | CKB | APG-115 | |||
| TP53 | CKB | AZD2461 | |||
| TP53 | CKB | unspecified ERBB3 antibody | |||
| TP53 | CKB | MI-63 | |||
| TP53 | CIViC | CHEMOTHERAPY | |||
| TP53 | CKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| TP53 | CKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| TP53 | CKB | Nutlin-3a | |||
| TP53 | CKB | Dasatinib | DASATINIB | CHEMBL1421 | |
| TP53 | CKB | Carboplatin | CARBOPLATIN | CHEMBL1351 | |
| TP53 | NCI | CISPLATIN | |||
| TP53 | CKB | Sapanisertib | INK-128 | CHEMBL3545056 | |
| TP53 | CKB | NSC319726 | |||
| TP53 | CKB | p28 | |||
| TP53 | CKB | Dabrafenib | DABRAFENIB | CHEMBL2028663 | |
| TP53 | NCI | CAROTENOID | |||
| TP53 | CKB | DS-7423 | DS-7423 | CHEMBL3545248 | |
| TP53 | CKB | ONC201 | |||
| TP53 | CKB | Camptosar | |||
| TP53 | CKB | Ganetespib | GANETESPIB | CHEMBL2103879 | |
| TP53 | CKB | RO6839921 | |||
| TP53 | CKB | LY3009120 | LY-3009120 | CHEMBL3545195 | |
| TP53 | CKB | Ad.p53-DC vaccine | |||
| TP53 | CKB | Flourouracil | |||
| TP53 | NCI | RITUXIMAB | RITUXIMAB | CHEMBL1201576 | |
| TP53 | NCI | SAPONIN | |||
| TP53 | NCI | MCP-1 | |||
| TP53 | NCI | DES | DIETHYLSTILBESTROL | CHEMBL411 | |
| TP53 | NCI | R-FLURBIPROFEN | TARENFLURBIL | CHEMBL190083 | |
| TP53 | NCI | HALOPERIDOL | HALOPERIDOL | CHEMBL54 | |
| TP53 | CKB | PF-04217903 | PF-04217903 | CHEMBL2001019 | |
| TP53 | CKB | Oxaliplatin | OXALIPLATIN | CHEMBL414804 | |
| TP53 | CKB | Serdemetan | |||
| TP53 | TALC | inhibitor | BORTEZOMIB | BORTEZOMIB | CHEMBL325041 |
| TP53 | CKB | CPUY201112 | |||
| TP53 | CKB | MVAp53 | |||
| TP53 | CKB | Pazopanib | PAZOPANIB | CHEMBL477772 | |
| TP53 | CGI | Mitomycin C | MITOMYCIN | CHEMBL105 | |
| TP53 | NCI | FAS LIGAND | RIZATRIPTAN | CHEMBL905 | |
| TP53 | CKB | thioureidobutyronitrile | |||
| TP53 | CKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| TP53 | CKB | Nutlin-3 | NUTLIN-3 | CHEMBL191334 | |
| TP53 | CKB | Abemaciclib | ABEMACICLIB | CHEMBL3301610 | |
| TP53 | CKB | Navitoclax | NAVITOCLAX | CHEMBL443684 | |
| TP53 | CKB | PF-06463922 | LORLATINIB | CHEMBL3286830 | |
| TP53 | CIViC | ADJUVANT CHEMOTHERAPY | |||
| TP53 | CKB | ALRN-6924 | |||
| TP53 | CKB | GDC-0425 | RG-7602 | CHEMBL3545007 | |
| TP53 | CKB | SP600125 | SP-600125 | CHEMBL1725279 | |
| TP53 | CKB | MPI-0479605 | HEMICHOLINIUM-3 | CHEMBL268697 | |
| TP53 | CKB | Avastin | BEVACIZUMAB | CHEMBL1201583 | |
| TP53 | NCI | VESNARINONE | VESNARINONE | CHEMBL17423 | |
| TP53 | CKB | EMD 1214063 | Tepotinib | CHEMBL3402762 | |
| TP53 | CKB | Pimasertib | PIMASERTIB | CHEMBL2107832 | |
| TP53 | CKB | RG7112 | |||
| TP53 | CKB | LB-100 | |||
| TP53 | CKB | ||||
| TP53 | CKB | AZD7762 | AZD-7762 | CHEMBL2041933 | |
| TP53 | CKB | HDM201 | |||
| TP53 | NCI | L-744,832 | CHEMBL1221512 | CHEMBL1221512 | |
| TP53 | CKB | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| TP53 | CKB | Etoposide | ETOPOSIDE | CHEMBL44657 | |
| TP53 | CKB | ReACp53 | |||
| TP53 | NCI | ENALAPRIL | ENALAPRIL | CHEMBL578 | |
| TP53 | NCI | SELECTIVE ESTROGEN RECEPTOR MODULATORS | |||
| TP53 | CKB | unspecified EGFR antibody | |||
| TP53 | CKB | MK-1775 | AZD-1775 | CHEMBL1976040 | |
| TP53 | CGI | Doxorubicin | DOXORUBICIN | CHEMBL53463 | |
| TP53 | CKB | LY411575 | CHEMBL392068 | CHEMBL392068 | |
| TP53 | CKB | PI-3065 | |||
| TP53 | CGI | Gemcitabine | GEMCITABINE | CHEMBL888 | |
| TP53 | NCI | METHYLPREDNISOLONE | METHYLPREDNISOLONE | CHEMBL650 | |
| TP53 | CIViC | CARBOPLATIN | CARBOPLATIN | CHEMBL1351 | |
| TP53 | CKB | Demcizumab | DEMCIZUMAB | CHEMBL2109384 | |
| TP53 | CIViC | RG7112 | |||
| TP53 | CKB | Sirolimus | SIROLIMUS | CHEMBL413 | |
| TP53 | NCI | INTERFERON ALPHA-2B | INTERFERON ALFA-2B | CHEMBL1201558 | |
| TP53 | CKB | Daunorubicin | DAUNORUBICIN | CHEMBL178 | |
| TP53 | NCI | GOSSYPOL | GOSSYPOL | CHEMBL51483 | |
| TP53 | CKB | BLZ945 | |||
| TP53 | CKB | PHA-680632 | PHA-680632 | CHEMBL363160 | |
| TP53 | CKB | Topotecan | TOPOTECAN | CHEMBL84 | |
| TP53 | CKB | 7RH | |||
| TP53 | CKB | LGX818 | ENCORAFENIB | CHEMBL3301612 | |
| TP53 | NCI | INOSITOL | INOSITOL | CHEMBL1222251 | |
| TP53 | TALC | vaccine | EP-2101 | ||
| TP53 | CIViC | OXALIPLATIN | OXALIPLATIN | CHEMBL414804 | |
| TP53 | CKB | ABT-263 | NAVITOCLAX | CHEMBL443684 | |
| TP53 | CKB | MK-8242 | |||
| TP53 | CKB | VX-970 | VX-970 | CHEMBL3545202 | |
| TP53 | CKB | CP-31398 | |||
| TP53 | NCI | URSODEOXYCHOLIC ACID | URSODIOL | CHEMBL1551 | |
| TP53 | CKB | Ad5CMV-p53 gene | |||
| TP53 | NCI | PACLITAXEL | PACLITAXEL | CHEMBL428647 | |
| TP53 | CKB | CEP-8983 | |||
| TP53 | CKB | Panitumumab | PANITUMUMAB | CHEMBL1201827 | |
| TP53 | NCI | STREPTONIGRIN | STREPTONIGRIN | CHEMBL11417 | |
| TP53 | CKB | Seliciclib | SELICICLIB | CHEMBL14762 | |
| TP53 | CKB | PD0166285 |
Phenotype
Protein
Drug
Loading...
There are patients available from the BCN Biobank that match the selected/a subset of the criteria. Explore the data available for these patients using our Cohort Browser.
Researchers can request samples from BCNB website to support their research activities.
*Based on your filtering criteria you can view the number of available patients and associated samples in BCNBIn order to apply for samples, please use the BCNB Request System to submit an Expression of interest (EOI) form.
If you require further details please contact us at tissue.bank@breastcancernow.org
| Patient ID | Age at Diagnosis | Sex | Race | Definition | Menopausal Status | Cancer Type | ER | PR | HER2 | Event | Event Site | Survival Status | Survival Time (years) | Subtype | Genetic Ancestry | hidden |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCGA-A7-A13G | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | new primary | skin | alive | 1.97 | LumA | European | TCGA.A7.A13G.01A.11R.A13Q.07 |
| TCGA-A7-A13G | 79 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | new primary | skin | alive | 1.97 | LumA | European | TCGA.A7.A13G.11A.51R.A13Q.07 |
| TCGA-E2-A10B | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | new primary | lung | alive | 2.05 | LumA | European | TCGA.E2.A10B.01A.11R.A10J.07 |
| TCGA-E2-A14R | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | new primary | endometrial | alive | 2.31 | Basal | European | TCGA.E2.A14R.01A.11R.A115.07 |
| TCGA-A7-A13H | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | new primary | skin | alive | 2.46 | NA | European | TCGA.A7.A13H.01A.11R.A22K.07 |
| TCGA-AR-A5QM | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | new primary | melanoma | alive | 6.11 | LumA | European | TCGA.AR.A5QM.01A.11R.A27Q.07 |
| TCGA-B6-A2IU | 62 | female | White | Primary solid Tumor | indeterminate | ILC | positive | positive | not evaluated | new primary | lung | alive | 14.17 | LumA | European | TCGA.B6.A2IU.01A.32R.A18M.07 |
| TCGA-B6-A0WZ | 50 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | new primary | bone | alive | 17.23 | LumA | African_admix | TCGA.B6.A0WZ.01A.11R.A109.07 |
| TCGA-BH-A18V | 48 | female | White | Primary solid Tumor | not available | IDC | negative | negative | negative | metastasis | intramammary node | dead | 4.26 | Basal | European | TCGA.BH.A18V.01A.11R.A12D.07 |
| TCGA-BH-A18V | 48 | female | White | Solid Tissue Normal | not available | IDC | negative | negative | negative | metastasis | intramammary node | dead | 4.26 | Basal | European | TCGA.BH.A18V.11A.52R.A12D.07 |
| TCGA-E9-A1NI | 51 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | NA | NA | European | TCGA.E9.A1NI.01A.11R.A14D.07 |
| TCGA-PL-A8LV | 54 | female | Black or African American | Primary solid Tumor | unknown | medullary carcinoma | not evaluated | not evaluated | not evaluated | NA | NA | alive | NA | Basal | African | TCGA.PL.A8LV.01A.21R.A41B.07 |
| TCGA-A2-A25D | 90 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | NA | LumA | European | TCGA.A2.A25D.01A.12R.A16F.07 |
| TCGA-A8-A06N | 66 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | NA | LumB | European | TCGA.A8.A06N.01A.11R.A00Z.07 |
| TCGA-A8-A081 | 80 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | NA | LumB | European | TCGA.A8.A081.01A.11R.A00Z.07 |
| TCGA-A8-A083 | 67 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | NA | LumA | European | TCGA.A8.A083.01A.21R.A00Z.07 |
| TCGA-A8-A08H | 66 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | NA | Normal | European | TCGA.A8.A08H.01A.21R.A00Z.07 |
| TCGA-A8-A090 | 74 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | NA | LumA | European | TCGA.A8.A090.01A.11R.A00Z.07 |
| TCGA-A8-A094 | 75 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | NA | Her2 | European | TCGA.A8.A094.01A.11R.A00Z.07 |
| TCGA-A8-A096 | 73 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | NA | LumB | European | TCGA.A8.A096.01A.11R.A00Z.07 |
| TCGA-A8-A09G | 79 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | NA | Her2 | European | TCGA.A8.A09G.01A.21R.A00Z.07 |
| TCGA-A8-A09Z | 83 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | NA | LumB | European | TCGA.A8.A09Z.01A.11R.A00Z.07 |
| TCGA-AC-A3W6 | 90 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | NA | NA | European | TCGA.AC.A3W6.01A.12R.A22K.07 |
| TCGA-C8-A12K | 80 | female | Asian | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | NA | Basal | East Asian | TCGA.C8.A12K.01A.21R.A115.07 |
| TCGA-C8-A12T | 43 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | NA | Her2 | East Asian | TCGA.C8.A12T.01A.11R.A115.07 |
| TCGA-C8-A133 | 65 | female | White | Primary solid Tumor | postmenopausal | ductal/mucinous | positive | positive | not evaluated | NA | NA | alive | NA | NA | South Asian_admix | TCGA.C8.A133.01A.32R.A12D.07 |
| TCGA-C8-A26Y | 90 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | NA | Her2 | East Asian | TCGA.C8.A26Y.01A.11R.A16F.07 |
| TCGA-D8-A1JK | 90 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | NA | Basal | European | TCGA.D8.A1JK.01A.11R.A13Q.07 |
| TCGA-LL-A6FP | 90 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | NA | LumA | European | TCGA.LL.A6FP.01A.11R.A31O.07 |
| TCGA-AC-A7VC | 56 | female | White | Primary solid Tumor | postmenopausal | metaplastic carcinoma | negative | negative | negative | NA | NA | alive | NA | Basal | European | TCGA.AC.A7VC.01A.11R.A352.07 |
| TCGA-C8-A275 | 56 | female | Asian | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | NA | Her2 | East Asian | TCGA.C8.A275.01A.21R.A16F.07 |
| TCGA-AN-A0AM | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.01 | LumB | European | TCGA.AN.A0AM.01A.11R.A034.07 |
| TCGA-C8-A1HJ | 53 | female | Asian | Primary solid Tumor | perimenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.01 | Basal | East Asian | TCGA.C8.A1HJ.01A.11R.A13Q.07 |
| TCGA-E9-A1N4 | 41 | female | White | Primary solid Tumor | premenopausal | IDC/ILC | positive | positive | positive | NA | NA | alive | 0.01 | NA | European | TCGA.E9.A1N4.01A.11R.A14M.07 |
| TCGA-E9-A1N4 | 41 | female | White | Solid Tissue Normal | premenopausal | IDC/ILC | positive | positive | positive | NA | NA | alive | 0.01 | NA | European | TCGA.E9.A1N4.11A.33R.A14M.07 |
| TCGA-PL-A8LX | 35 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | metastasis | bone|liver | alive | 0.01 | LumA | African | TCGA.PL.A8LX.01A.11R.A41B.07 |
| TCGA-C8-A273 | 29 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.02 | LumA | East Asian | TCGA.C8.A273.01A.11R.A16F.07 |
| TCGA-AN-A041 | 29 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | positive | NA | NA | alive | 0.02 | LumA | European_admix | TCGA.AN.A041.01A.11R.A034.07 |
| TCGA-C8-A12W | 49 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.02 | LumB | East Asian | TCGA.C8.A12W.01A.11R.A115.07 |
| TCGA-C8-A138 | 54 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 0.02 | Her2 | East Asian | TCGA.C8.A138.01A.11R.A115.07 |
| TCGA-C8-A1HK | 53 | female | Asian | Primary solid Tumor | perimenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.02 | Her2 | East Asian | TCGA.C8.A1HK.01A.21R.A13Q.07 |
| TCGA-C8-A26W | 58 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.02 | LumB | East Asian | TCGA.C8.A26W.01A.11R.A16F.07 |
| TCGA-C8-A3M8 | 68 | female | Asian | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 0.02 | LumB | East Asian | TCGA.C8.A3M8.01A.11R.A213.07 |
| TCGA-AR-A0U0 | 73 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 0.02 | Basal | European | TCGA.AR.A0U0.01A.11R.A109.07 |
| TCGA-C8-A8HP | 59 | female | Asian | Primary solid Tumor | postmenopausal | metaplastic carcinoma | negative | negative | positive | NA | NA | alive | 0.02 | Her2 | East Asian | TCGA.C8.A8HP.01A.11R.A36F.07 |
| TCGA-E9-A5FL | 65 | female | White | Primary solid Tumor | postmenopausal | metaplastic carcinoma | negative | negative | negative | NA | NA | alive | 0.02 | Basal | European | TCGA.E9.A5FL.01A.11R.A27Q.07 |
| TCGA-PL-A8LY | 30 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.02 | Normal | African | TCGA.PL.A8LY.01A.11R.A41B.07 |
| TCGA-AC-A5XU | 74 | female | Black or African American | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 0.02 | LumA | African | TCGA.AC.A5XU.01A.11R.A28M.07 |
| TCGA-AN-A0XP | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.02 | LumA | European | TCGA.AN.A0XP.01A.11R.A109.07 |
| TCGA-C8-A26V | 47 | female | Asian | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.02 | LumB | East Asian | TCGA.C8.A26V.01A.11R.A16F.07 |
| TCGA-C8-A278 | 61 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.02 | Her2 | East Asian | TCGA.C8.A278.01A.11R.A169.07 |
| TCGA-C8-A8HQ | 53 | female | Asian | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 0.02 | NA | East Asian | TCGA.C8.A8HQ.01A.11R.A36F.07 |
| TCGA-AN-A03X | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A03X.01A.21R.A00Z.07 |
| TCGA-AN-A03Y | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.03 | LumB | European | TCGA.AN.A03Y.01A.21R.A00Z.07 |
| TCGA-AN-A046 | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A046.01A.21R.A034.07 |
| TCGA-AN-A0AR | 55 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.03 | Basal | European | TCGA.AN.A0AR.01A.11R.A00Z.07 |
| TCGA-AN-A0AS | 70 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A0AS.01A.11R.A00Z.07 |
| TCGA-AN-A0AT | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.03 | Basal | European | TCGA.AN.A0AT.01A.11R.A034.07 |
| TCGA-AN-A0FV | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.03 | Her2 | European | TCGA.AN.A0FV.01A.11R.A00Z.07 |
| TCGA-AN-A0FX | 52 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.03 | Basal | European | TCGA.AN.A0FX.01A.11R.A034.07 |
| TCGA-AN-A0FY | 55 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.03 | LumB | European | TCGA.AN.A0FY.01A.11R.A034.07 |
| TCGA-AN-A0FZ | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | positive | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A0FZ.01A.11R.A034.07 |
| TCGA-AN-A0XN | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A0XN.01A.21R.A109.07 |
| TCGA-AN-A0XR | 55 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.03 | LumB | European | TCGA.AN.A0XR.01A.11R.A109.07 |
| TCGA-AN-A0XS | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A0XS.01A.22R.A109.07 |
| TCGA-AN-A0XT | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A0XT.01A.11R.A109.07 |
| TCGA-AN-A0XU | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.03 | Basal | European | TCGA.AN.A0XU.01A.11R.A109.07 |
| TCGA-AN-A0FW | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | Indeterminate | negative | NA | NA | alive | 0.03 | LumA | European | TCGA.AN.A0FW.01A.11R.A034.07 |
| TCGA-E2-A1IL | 78 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.04 | LumA | European | TCGA.E2.A1IL.01A.11R.A14D.07 |
| TCGA-AN-A0G0 | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.04 | NA | European | TCGA.AN.A0G0.01A.11R.A034.07 |
| TCGA-AN-A049 | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.05 | LumA | European | TCGA.AN.A049.01A.21R.A00Z.07 |
| TCGA-E9-A1R2 | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 0.05 | LumA | European | TCGA.E9.A1R2.01A.11R.A14D.07 |
| TCGA-E9-A1RD | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.05 | LumA | European | TCGA.E9.A1RD.01A.11R.A157.07 |
| TCGA-E9-A1RD | 67 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.05 | LumA | European | TCGA.E9.A1RD.11A.33R.A157.07 |
| TCGA-E9-A244 | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.06 | Basal | European | TCGA.E9.A244.01A.11R.A169.07 |
| TCGA-E9-A227 | 42 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.07 | LumA | European | TCGA.E9.A227.01A.11R.A157.07 |
| TCGA-D8-A27R | 41 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.08 | LumB | European | TCGA.D8.A27R.01A.11R.A16F.07 |
| TCGA-E9-A1R4 | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.08 | LumB | European | TCGA.E9.A1R4.01A.21R.A14D.07 |
| TCGA-E9-A249 | 45 | female | White | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.08 | LumB | European | TCGA.E9.A249.01A.11R.A169.07 |
| TCGA-A8-A08A | 89 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.08 | LumA | European | TCGA.A8.A08A.01A.11R.A32Y.07 |
| TCGA-A8-A09W | 70 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.08 | LumB | European | TCGA.A8.A09W.01A.11R.A00Z.07 |
| TCGA-A8-A0A7 | 57 | female | not available | Primary solid Tumor | postmenopausal | ILC | negative | negative | positive | NA | NA | alive | 0.08 | Her2 | European | TCGA.A8.A0A7.01A.11R.A00Z.07 |
| TCGA-A8-A06Q | 63 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.08 | LumB | European | TCGA.A8.A06Q.01A.11R.A034.07 |
| TCGA-A8-A06Z | 84 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.08 | LumB | European | TCGA.A8.A06Z.01A.11R.A00Z.07 |
| TCGA-A8-A09C | 69 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.08 | LumB | European | TCGA.A8.A09C.01A.11R.A00Z.07 |
| TCGA-A8-A09N | 57 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.08 | LumB | European | TCGA.A8.A09N.01A.11R.A00Z.07 |
| TCGA-AC-A2QH | 58 | female | White | Primary solid Tumor | postmenopausal | metaplastic carcinoma | negative | negative | negative | NA | NA | alive | 0.08 | Basal | European | TCGA.AC.A2QH.01A.11R.A18M.07 |
| TCGA-AC-A8OQ | 72 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | Indeterminate | NA | NA | alive | 0.09 | Basal | African_admix | TCGA.AC.A8OQ.01A.11R.A41B.07 |
| TCGA-E2-A15K | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.09 | LumB | European | TCGA.E2.A15K.01A.11R.A12P.07 |
| TCGA-E2-A15K | 58 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.09 | LumB | European | TCGA.E2.A15K.11A.13R.A12P.07 |
| TCGA-E9-A1RF | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.1 | LumA | European | TCGA.E9.A1RF.01A.11R.A157.07 |
| TCGA-E9-A1RF | 68 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.1 | LumA | European | TCGA.E9.A1RF.11A.32R.A157.07 |
| TCGA-AC-A8OR | 75 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 0.11 | NA | European | TCGA.AC.A8OR.01A.21R.A41B.07 |
| TCGA-E2-A15H | 38 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.11 | LumA | European | TCGA.E2.A15H.01A.11R.A12D.07 |
| TCGA-E9-A1R5 | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.11 | LumA | European | TCGA.E9.A1R5.01A.11R.A14M.07 |
| TCGA-E9-A243 | 52 | female | White | Primary solid Tumor | perimenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.12 | Basal | European | TCGA.E9.A243.01A.21R.A169.07 |
| TCGA-AC-A2FB | 65 | female | White | Primary solid Tumor | not available | ILC | positive | positive | positive | NA | NA | alive | 0.12 | LumA | European | TCGA.AC.A2FB.01A.11R.A17B.07 |
| TCGA-AC-A2FB | 65 | female | White | Solid Tissue Normal | not available | ILC | positive | positive | positive | NA | NA | alive | 0.12 | LumA | European | TCGA.AC.A2FB.11A.13R.A17B.07 |
| TCGA-E9-A1RI | 43 | female | White | Primary solid Tumor | premenopausal | IDC/ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.13 | NA | European | TCGA.E9.A1RI.01A.11R.A169.07 |
| TCGA-E9-A1RI | 43 | female | White | Solid Tissue Normal | premenopausal | IDC/ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.13 | NA | European | TCGA.E9.A1RI.11A.41R.A169.07 |
| TCGA-D8-A145 | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.13 | LumA | European | TCGA.D8.A145.01A.11R.A115.07 |
| TCGA-D8-A27P | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.13 | LumA | European | TCGA.D8.A27P.01A.11R.A16F.07 |
| TCGA-D8-A1XS | 48 | male | White | Primary solid Tumor | not applicable | ductal/micropapillary | positive | positive | positive | NA | NA | alive | 0.14 | NA | European | TCGA.D8.A1XS.01A.11R.A14M.07 |
| TCGA-AC-A6NO | 43 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | positive | negative | NA | NA | alive | 0.14 | LumA | African_admix | TCGA.AC.A6NO.01A.12R.A33J.07 |
| TCGA-AN-A04D | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.14 | Basal | European | TCGA.AN.A04D.01A.21R.A034.07 |
| TCGA-A7-A3RF | 79 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | metastasis | bone>liver | alive | 0.15 | NA | European | TCGA.A7.A3RF.01A.11R.A22K.07 |
| TCGA-AN-A04C | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.15 | Her2 | European | TCGA.AN.A04C.01A.21R.A034.07 |
| TCGA-AC-A3W5 | 65 | female | Black or African American | Primary solid Tumor | not evaluated | ILC | positive | positive | not evaluated | NA | NA | alive | 0.15 | Her2 | African | TCGA.AC.A3W5.01A.11R.A22K.07 |
| TCGA-AC-A62Y | 79 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.15 | LumA | European | TCGA.AC.A62Y.01A.11R.A29R.07 |
| TCGA-C8-A132 | 56 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 0.16 | LumA | East Asian | TCGA.C8.A132.01A.31R.A115.07 |
| TCGA-OL-A66P | 75 | female | Black or African American | Primary solid Tumor | not available | IDC | negative | negative | not evaluated | NA | NA | alive | 0.16 | Her2 | African | TCGA.OL.A66P.01A.11R.A31O.07 |
| TCGA-E9-A248 | 51 | female | White | Primary solid Tumor | perimenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.16 | Her2 | European | TCGA.E9.A248.01A.11R.A169.07 |
| TCGA-BH-A18G | 81 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.17 | Basal | European | TCGA.BH.A18G.01A.11R.A12D.07 |
| TCGA-D8-A142 | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 0.17 | Basal | European | TCGA.D8.A142.01A.11R.A115.07 |
| TCGA-AC-A5EH | 76 | female | Black or African American | Primary solid Tumor | not available | IDC | positive | negative | negative | NA | NA | alive | 0.17 | Her2 | African_admix | TCGA.AC.A5EH.01A.11R.A28M.07 |
| TCGA-E9-A1R3 | 70 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.18 | LumA | European | TCGA.E9.A1R3.01A.31R.A14M.07 |
| TCGA-OK-A5Q2 | 59 | female | not available | Primary solid Tumor | unknown | ILC | positive | positive | negative | NA | NA | alive | 0.18 | LumA | African | TCGA.OK.A5Q2.01A.11R.A27Q.07 |
| TCGA-A7-A26J | 49 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.19 | LumA | European | TCGA.A7.A26J.01A.11R.A169.07 |
| TCGA-C8-A131 | 82 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.19 | Basal | East Asian | TCGA.C8.A131.01A.11R.A115.07 |
| TCGA-AC-A8OS | 71 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 0.19 | LumA | European | TCGA.AC.A8OS.01A.12R.A41B.07 |
| TCGA-C8-A1HM | 74 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.19 | LumB | East Asian | TCGA.C8.A1HM.01A.12R.A137.07 |
| TCGA-AC-A23E | 50 | female | White | Primary solid Tumor | not available | IDC | positive | positive | not evaluated | NA | NA | alive | 0.2 | LumA | European | TCGA.AC.A23E.01A.11R.A157.07 |
| TCGA-BH-A0HL | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.2 | NA | European | TCGA.BH.A0HL.01A.11R.A10U.07 |
| TCGA-D8-A1Y2 | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 0.2 | LumB | European | TCGA.D8.A1Y2.01A.11R.A157.07 |
| TCGA-D8-A27V | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.2 | LumA | European | TCGA.D8.A27V.01A.12R.A17B.07 |
| TCGA-AC-A7VB | 51 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | negative | not evaluated | NA | NA | alive | 0.2 | LumB | African_admix | TCGA.AC.A7VB.01A.11R.A352.07 |
| TCGA-A7-A3J1 | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.21 | NA | European | TCGA.A7.A3J1.01A.11R.A213.07 |
| TCGA-D8-A1XG | 86 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.21 | LumA | European | TCGA.D8.A1XG.01A.11R.A14D.07 |
| TCGA-A7-A3J0 | 62 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 0.21 | NA | European | TCGA.A7.A3J0.01A.11R.A213.07 |
| TCGA-BH-A0HO | 48 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.21 | LumA | European | TCGA.BH.A0HO.01A.11R.A034.07 |
| TCGA-AQ-A54N | 51 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 0.21 | NA | African | TCGA.AQ.A54N.01A.11R.A266.07 |
| TCGA-BH-A0DS | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.21 | LumA | European | TCGA.BH.A0DS.01A.11R.A056.07 |
| TCGA-HN-A2NL | 56 | female | not available | Primary solid Tumor | postmenopausal | ILC | negative | negative | negative | NA | NA | alive | 0.22 | Basal | European | TCGA.HN.A2NL.01A.11R.A18M.07 |
| TCGA-LL-A6FQ | 77 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.22 | LumA | African | TCGA.LL.A6FQ.01A.11R.A31O.07 |
| TCGA-D8-A1XY | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.22 | LumA | European | TCGA.D8.A1XY.01A.11R.A14M.07 |
| TCGA-AR-A24P | 47 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.23 | LumA | European | TCGA.AR.A24P.01A.11R.A169.07 |
| TCGA-E9-A1R6 | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.23 | LumA | European | TCGA.E9.A1R6.01A.11R.A14D.07 |
| TCGA-D8-A1X7 | 40 | female | White | Primary solid Tumor | premenopausal | ductal partially papillary | positive | positive | negative | NA | NA | alive | 0.23 | NA | European | TCGA.D8.A1X7.01A.11R.A14M.07 |
| TCGA-MS-A51U | 44 | female | White | Primary solid Tumor | not available | ILC | positive | positive | negative | NA | NA | alive | 0.23 | NA | European | TCGA.MS.A51U.01A.31R.A266.07 |
| TCGA-AN-A04A | 36 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.25 | LumA | European | TCGA.AN.A04A.01A.21R.A034.07 |
| TCGA-E9-A6HE | 45 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.25 | LumA | European | TCGA.E9.A6HE.01A.11R.A31O.07 |
| TCGA-AC-A3TM | 50 | female | White | Primary solid Tumor | perimenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 0.25 | NA | European | TCGA.AC.A3TM.01A.11R.A22K.07 |
| TCGA-C8-A130 | 52 | female | Asian | Primary solid Tumor | perimenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.26 | LumB | East Asian | TCGA.C8.A130.01A.31R.A115.07 |
| TCGA-D8-A1JF | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.26 | Her2 | European | TCGA.D8.A1JF.01A.11R.A13Q.07 |
| TCGA-D8-A1XF | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.27 | LumB | European | TCGA.D8.A1XF.01A.11R.A14D.07 |
| TCGA-LL-A5YO | 50 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.27 | Her2 | African | TCGA.LL.A5YO.01A.21R.A28M.07 |
| TCGA-BH-A0DQ | 42 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.27 | LumA | European | TCGA.BH.A0DQ.01A.11R.A084.07 |
| TCGA-BH-A0DQ | 42 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.27 | LumA | European | TCGA.BH.A0DQ.11A.12R.A089.07 |
| TCGA-BH-A5IZ | 51 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.27 | Basal | African | TCGA.BH.A5IZ.01A.11R.A27Q.07 |
| TCGA-LL-A7T0 | 70 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.27 | LumB | African | TCGA.LL.A7T0.01A.31R.A352.07 |
| TCGA-C8-A1HN | 56 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.27 | LumB | East Asian | TCGA.C8.A1HN.01A.11R.A137.07 |
| TCGA-LL-A5YP | 49 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.27 | Basal | African | TCGA.LL.A5YP.01A.21R.A28M.07 |
| TCGA-BH-A0E0 | 38 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.37 | Basal | European | TCGA.BH.A0E0.01A.11R.A056.07 |
| TCGA-BH-A0E0 | 38 | female | White | Solid Tissue Normal | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.37 | Basal | European | TCGA.BH.A0E0.11A.13R.A089.07 |
| TCGA-BH-A6R9 | 61 | female | White | Primary solid Tumor | postmenopausal | metaplastic carcinoma | negative | positive | negative | NA | NA | alive | 0.44 | Normal | European | TCGA.BH.A6R9.01A.21R.A32P.07 |
| TCGA-AN-A0XV | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.44 | LumA | European | TCGA.AN.A0XV.01A.11R.A109.07 |
| TCGA-AN-A0XL | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.45 | LumA | European | TCGA.AN.A0XL.01A.11R.A10J.07 |
| TCGA-E2-A2P6 | 77 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 0.46 | LumA | American | TCGA.E2.A2P6.01A.11R.A19W.07 |
| TCGA-AN-A0XW | 36 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.47 | LumA | European | TCGA.AN.A0XW.01A.11R.A109.07 |
| TCGA-BH-A0RX | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.47 | Basal | European | TCGA.BH.A0RX.01A.21R.A084.07 |
| TCGA-AN-A0FF | 32 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.47 | LumB | European | TCGA.AN.A0FF.01A.11R.A034.07 |
| TCGA-BH-A0HK | 81 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.49 | LumA | European | TCGA.BH.A0HK.01A.11R.A056.07 |
| TCGA-BH-A0HK | 81 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.49 | LumA | European | TCGA.BH.A0HK.11A.11R.A089.07 |
| TCGA-EW-A1PC | 66 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.51 | NA | African | TCGA.EW.A1PC.01B.11R.A21T.07 |
| TCGA-AN-A0FD | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.54 | LumA | European | TCGA.AN.A0FD.01A.11R.A034.07 |
| TCGA-BH-A28Q | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.54 | LumA | European | TCGA.BH.A28Q.01A.11R.A16F.07 |
| TCGA-AN-A0FS | 55 | female | White | Primary solid Tumor | perimenopausal | ILC | positive | negative | positive | NA | NA | alive | 0.57 | LumA | European | TCGA.AN.A0FS.01A.11R.A034.07 |
| TCGA-AN-A0FK | 88 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.58 | LumA | European | TCGA.AN.A0FK.01A.11R.A034.07 |
| TCGA-AN-A0FT | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.59 | LumA | European | TCGA.AN.A0FT.01A.11R.A034.07 |
| TCGA-B6-A400 | 43 | female | Black or African American | Primary solid Tumor | unknown | IDC | negative | negative | negative | NA | NA | alive | 0.59 | NA | African | TCGA.B6.A400.01A.11R.A239.07 |
| TCGA-LD-A7W5 | 52 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.59 | LumA | African | TCGA.LD.A7W5.01A.22R.A352.07 |
| TCGA-AN-A0FN | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 0.6 | LumA | European | TCGA.AN.A0FN.01A.11R.A034.07 |
| TCGA-BH-A18I | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.6 | LumA | European | TCGA.BH.A18I.01A.11R.A12D.07 |
| TCGA-A2-A4RW | 49 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.61 | NA | European | TCGA.A2.A4RW.01A.21R.A266.07 |
| TCGA-AN-A0AK | 76 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 0.61 | LumB | European | TCGA.AN.A0AK.01A.21R.A00Z.07 |
| TCGA-AR-A2LL | 70 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 0.61 | NA | European | TCGA.AR.A2LL.01A.11R.A180.07 |
| TCGA-GI-A2C8 | 63 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 0.62 | LumA | European | TCGA.GI.A2C8.01A.11R.A16F.07 |
| TCGA-GI-A2C8 | 63 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | NA | NA | alive | 0.62 | LumA | European | TCGA.GI.A2C8.11A.22R.A16F.07 |
| TCGA-AN-A0AL | 41 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.62 | Basal | European | TCGA.AN.A0AL.01A.11R.A00Z.07 |
| TCGA-A7-A0CG | 78 | female | White | Primary solid Tumor | postmenopausal | ILC/IDC (grade 1) | positive | negative | negative | NA | NA | alive | 0.63 | NA | European | TCGA.A7.A0CG.01A.12R.A056.07 |
| TCGA-AN-A0FL | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.63 | Basal | European | TCGA.AN.A0FL.01A.11R.A034.07 |
| TCGA-A7-A0CH | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.64 | LumA | European | TCGA.A7.A0CH.01A.21R.A00Z.07 |
| TCGA-A7-A0CH | 79 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.64 | LumA | European | TCGA.A7.A0CH.11A.32R.A089.07 |
| TCGA-A1-A0SM | 77 | male | White | Primary solid Tumor | not applicable | IDC | positive | negative | positive | NA | NA | alive | 0.66 | NA | European | TCGA.A1.A0SM.01A.11R.A084.07 |
| TCGA-AN-A0FJ | 59 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | negative | positive | NA | NA | alive | 0.66 | Basal | European | TCGA.AN.A0FJ.01A.11R.A00Z.07 |
| TCGA-E2-A56Z | 69 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.69 | LumB | African_admix | TCGA.E2.A56Z.01A.12R.A29R.07 |
| TCGA-EW-A1IY | 38 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.71 | LumB | East Asian | TCGA.EW.A1IY.01A.11R.A13Q.07 |
| TCGA-A1-A0SB | 70 | female | White | Primary solid Tumor | postmenopausal | adenoid cystic carcinoma | positive | negative | negative | NA | NA | alive | 0.71 | NA | European | TCGA.A1.A0SB.01A.11R.A144.07 |
| TCGA-A7-A6VY | 48 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.73 | Basal | African_admix | TCGA.A7.A6VY.01A.12R.A33J.07 |
| TCGA-A7-A0DB | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.73 | LumA | European | TCGA.A7.A0DB.01A.11R.A00Z.07 |
| TCGA-A7-A0DB | 56 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.73 | LumA | European | TCGA.A7.A0DB.11A.33R.A089.07 |
| TCGA-BH-A18F | 50 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.73 | LumA | European | TCGA.BH.A18F.01A.11R.A12D.07 |
| TCGA-OL-A97C | 67 | female | Black or African American | Primary solid Tumor | postmenopausal | malignant phyllodes | negative | negative | not evaluated | metastasis | lung | alive | 0.74 | NA | African | TCGA.OL.A97C.01A.32R.A41B.07 |
| TCGA-A7-A0D9 | 37 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.75 | LumA | European | TCGA.A7.A0D9.01A.31R.A056.07 |
| TCGA-A7-A0D9 | 37 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.75 | LumA | European | TCGA.A7.A0D9.11A.53R.A089.07 |
| TCGA-A8-A07R | 80 | female | not available | Primary solid Tumor | not available | IDC | negative | negative | positive | NA | NA | alive | 0.75 | NA | European | TCGA.A8.A07R.01A.21R.A034.07 |
| TCGA-A8-A09R | 82 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.75 | LumB | European | TCGA.A8.A09R.01A.11R.A00Z.07 |
| TCGA-A8-A079 | 69 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.75 | LumB | European | TCGA.A8.A079.01A.21R.A00Z.07 |
| TCGA-A7-A6VW | 48 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.78 | Basal | African_admix | TCGA.A7.A6VW.01A.21R.A33J.07 |
| TCGA-BH-AB28 | 53 | female | White | Primary solid Tumor | unknown | ILC | positive | positive | negative | NA | NA | alive | 0.79 | LumA | European | TCGA.BH.AB28.01A.31R.A41B.07 |
| TCGA-D8-A27K | 47 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.79 | LumA | European | TCGA.D8.A27K.01A.11R.A16F.07 |
| TCGA-E9-A2JT | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.79 | LumA | European | TCGA.E9.A2JT.01A.22R.A18M.07 |
| TCGA-E2-A15O | 89 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | locoregional recurrence | not available | alive | 0.79 | LumA | African | TCGA.E2.A15O.01A.11R.A115.07 |
| TCGA-BH-A0E6 | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 0.8 | Basal | European | TCGA.BH.A0E6.01A.11R.A034.07 |
| TCGA-BH-A6R8 | 46 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | positive | not evaluated | NA | NA | alive | 0.8 | LumA | African | TCGA.BH.A6R8.01A.21R.A33J.07 |
| TCGA-AO-A0J4 | 41 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.8 | Basal | African | TCGA.AO.A0J4.01A.11R.A034.07 |
| TCGA-PL-A8LZ | 29 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 0.83 | Basal | African | TCGA.PL.A8LZ.01A.31R.A36F.07 |
| TCGA-5T-A9QA | 52 | female | Black or African American | Primary solid Tumor | unknown | IDC/mucinous | positive | negative | equivocal | NA | NA | alive | 0.83 | NA | African | TCGA.5T.A9QA.01A.11R.A41B.07 |
| TCGA-AN-A0AJ | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.83 | LumB | European | TCGA.AN.A0AJ.01A.11R.A00Z.07 |
| TCGA-A8-A07O | 51 | female | not available | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.83 | Basal | European | TCGA.A8.A07O.01A.11R.A00Z.07 |
| TCGA-A8-A07W | 76 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.83 | LumB | European | TCGA.A8.A07W.01A.11R.A00Z.07 |
| TCGA-A8-A099 | 76 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.83 | LumA | European | TCGA.A8.A099.01A.11R.A00Z.07 |
| TCGA-A8-A09A | 40 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.83 | LumA | European | TCGA.A8.A09A.01A.11R.A00Z.07 |
| TCGA-A7-A0CE | 57 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | equivocal | NA | NA | alive | 0.85 | Basal | European | TCGA.A7.A0CE.01A.11R.A00Z.07 |
| TCGA-A7-A0CE | 57 | female | White | Solid Tissue Normal | indeterminate | IDC | negative | negative | equivocal | NA | NA | alive | 0.85 | Basal | European | TCGA.A7.A0CE.11A.21R.A089.07 |
| TCGA-A7-A6VV | 51 | female | Black or African American | Primary solid Tumor | perimenopausal | IDC | negative | negative | negative | NA | NA | alive | 0.86 | Basal | African | TCGA.A7.A6VV.01A.22R.A33J.07 |
| TCGA-A7-A6VX | 68 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.87 | LumB | African | TCGA.A7.A6VX.01A.12R.A33J.07 |
| TCGA-C8-A1HL | 38 | female | Asian | Primary solid Tumor | premenopausal | Infiltrating mucinous-papillary ductal carcinoma | positive | negative | equivocal | NA | NA | alive | 0.87 | NA | East Asian | TCGA.C8.A1HL.01A.11R.A137.07 |
| TCGA-A2-A25F | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | 0.88 | Basal | European | TCGA.A2.A25F.01A.11R.A169.07 |
| TCGA-A7-A3IZ | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | equivocal | NA | NA | alive | 0.88 | NA | European | TCGA.A7.A3IZ.01A.11R.A213.07 |
| TCGA-LD-A9QF | 73 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.88 | Normal | African_admix | TCGA.LD.A9QF.01A.32R.A41B.07 |
| TCGA-BH-A28O | 50 | female | White | Primary solid Tumor | not available | ILC | positive | positive | negative | NA | NA | alive | 0.89 | NA | European | TCGA.BH.A28O.01A.11R.A22K.07 |
| TCGA-A7-A5ZW | 47 | female | Black or African American | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.89 | LumA | African_admix | TCGA.A7.A5ZW.01A.12R.A29R.07 |
| TCGA-BH-A0GZ | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 0.9 | LumA | European | TCGA.BH.A0GZ.01A.11R.A056.07 |
| TCGA-AC-A23G | 76 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 0.9 | NA | European | TCGA.AC.A23G.01A.11R.A213.07 |
| TCGA-C8-A1HF | 48 | female | Asian | Primary solid Tumor | premenopausal | IDC | negative | positive | positive | NA | NA | alive | 0.91 | Her2 | East Asian | TCGA.C8.A1HF.01A.11R.A137.07 |
| TCGA-A8-A07P | 68 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 0.91 | LumA | European | TCGA.A8.A07P.01A.11R.A00Z.07 |
| TCGA-A7-A5ZX | 48 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.92 | LumA | European | TCGA.A7.A5ZX.01A.12R.A29R.07 |
| TCGA-E2-A1IU | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.92 | LumA | European | TCGA.E2.A1IU.01A.11R.A14D.07 |
| TCGA-C8-A1HI | 40 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.94 | LumA | East Asian | TCGA.C8.A1HI.01A.11R.A137.07 |
| TCGA-A7-A3IY | 71 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 0.94 | NA | European | TCGA.A7.A3IY.01A.21R.A21T.07 |
| TCGA-C8-A1HG | 50 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.94 | LumB | East Asian | TCGA.C8.A1HG.01A.11R.A137.07 |
| TCGA-W8-A86G | 66 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 0.95 | LumA | European | TCGA.W8.A86G.01A.21R.A36F.07 |
| TCGA-4H-AAAK | 50 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 0.95 | LumA | European | TCGA.4H.AAAK.01A.12R.A41B.07 |
| TCGA-AO-A1KS | 69 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 0.96 | LumB | European | TCGA.AO.A1KS.01A.11R.A13Q.07 |
| TCGA-JL-A3YX | 46 | female | Asian | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 0.96 | LumA | South Asian_admix | TCGA.JL.A3YX.01A.11R.A22U.07 |
| TCGA-BH-A0BW | 71 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not available | NA | NA | alive | 0.97 | Basal | African_admix | TCGA.BH.A0BW.01A.11R.A115.07 |
| TCGA-BH-A0BW | 71 | female | Black or African American | Solid Tissue Normal | postmenopausal | IDC | negative | negative | not available | NA | NA | alive | 0.97 | Basal | African_admix | TCGA.BH.A0BW.11A.12R.A115.07 |
| TCGA-C8-A12M | 70 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 0.98 | LumB | East Asian | TCGA.C8.A12M.01A.11R.A115.07 |
| TCGA-C8-A12N | 58 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.98 | LumA | East Asian | TCGA.C8.A12N.01A.11R.A115.07 |
| TCGA-C8-A12P | 55 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 0.98 | Her2 | East Asian | TCGA.C8.A12P.01A.11R.A115.07 |
| TCGA-JL-A3YW | 49 | female | Asian | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 0.99 | NA | South Asian | TCGA.JL.A3YW.01A.12R.A239.07 |
| TCGA-D8-A13Y | 52 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 0.99 | LumB | European | TCGA.D8.A13Y.01A.11R.A115.07 |
| TCGA-C8-A12L | 67 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 0.99 | Her2 | East Asian | TCGA.C8.A12L.01A.11R.A115.07 |
| TCGA-A7-A426 | 50 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.0 | NA | European | TCGA.A7.A426.01A.22R.A24H.07 |
| TCGA-A8-A07J | 35 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.0 | LumA | European | TCGA.A8.A07J.01A.11R.A00Z.07 |
| TCGA-A8-A08I | 53 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.0 | LumB | European | TCGA.A8.A08I.01A.11R.A00Z.07 |
| TCGA-A8-A097 | 65 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.0 | LumA | European | TCGA.A8.A097.01A.11R.A034.07 |
| TCGA-A8-A09B | 58 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.0 | LumA | European | TCGA.A8.A09B.01A.11R.A00Z.07 |
| TCGA-A8-A0A1 | 84 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.0 | LumA | European | TCGA.A8.A0A1.01A.11R.A00Z.07 |
| TCGA-E9-A1N8 | 48 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | not evaluated | negative | NA | NA | alive | 1.0 | Basal | European | TCGA.E9.A1N8.01A.11R.A144.07 |
| TCGA-D8-A1JG | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.0 | Her2 | European | TCGA.D8.A1JG.01B.11R.A13Q.07 |
| TCGA-A7-A5ZV | 62 | female | Black or African American | Primary solid Tumor | postmenopausal | infiltrating carcinoma NOS | negative | negative | equivocal | NA | NA | alive | 1.01 | NA | African | TCGA.A7.A5ZV.01A.11R.A28M.07 |
| TCGA-D8-A1JS | 77 | female | White | Primary solid Tumor | postmenopausal | papillary | positive | positive | negative | NA | NA | alive | 1.02 | NA | European | TCGA.D8.A1JS.01A.11R.A13Q.07 |
| TCGA-EW-A1IW | 80 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.02 | LumA | European | TCGA.EW.A1IW.01A.11R.A13Q.07 |
| TCGA-A7-A0CD | 66 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | equivocal | NA | NA | alive | 1.02 | LumA | European | TCGA.A7.A0CD.01A.11R.A00Z.07 |
| TCGA-A7-A0DA | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.02 | Basal | European | TCGA.A7.A0DA.01A.31R.A115.07 |
| TCGA-AC-A6IX | 49 | female | White | Primary solid Tumor | perimenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 1.02 | LumA | European | TCGA.AC.A6IX.01A.12R.A32P.07 |
| TCGA-D8-A27W | 55 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | equivocal | NA | NA | alive | 1.02 | NA | European | TCGA.D8.A27W.01A.11R.A16F.07 |
| TCGA-AN-A0XO | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.03 | LumA | European | TCGA.AN.A0XO.01A.11R.A109.07 |
| TCGA-C8-A1HE | 59 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.03 | LumA | East Asian | TCGA.C8.A1HE.01A.11R.A13Q.07 |
| TCGA-C8-A1HO | 34 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.03 | LumA | East Asian | TCGA.C8.A1HO.01A.11R.A13Q.07 |
| TCGA-E9-A295 | 71 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.03 | LumA | European | TCGA.E9.A295.01A.11R.A16F.07 |
| TCGA-C8-A26X | 58 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.03 | Her2 | East Asian | TCGA.C8.A26X.01A.31R.A16F.07 |
| TCGA-C8-A137 | 34 | female | Asian | Primary solid Tumor | premenopausal | IDC | negative | negative | positive | locoregional recurrence | not available | alive | 1.04 | Her2 | East Asian | TCGA.C8.A137.01A.11R.A115.07 |
| TCGA-E9-A228 | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.04 | LumB | European | TCGA.E9.A228.01A.31R.A157.07 |
| TCGA-C8-A12Z | 45 | female | Asian | Primary solid Tumor | perimenopausal | IDC | negative | negative | positive | NA | NA | alive | 1.05 | Her2 | East Asian | TCGA.C8.A12Z.01A.11R.A115.07 |
| TCGA-C8-A134 | 52 | female | Asian | Primary solid Tumor | perimenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.05 | Basal | East Asian | TCGA.C8.A134.01A.11R.A115.07 |
| TCGA-C8-A12O | 50 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.05 | LumA | East Asian | TCGA.C8.A12O.01A.11R.A115.07 |
| TCGA-C8-A12U | 46 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.05 | LumB | East Asian | TCGA.C8.A12U.01A.11R.A115.07 |
| TCGA-C8-A12V | 55 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.05 | Basal | East Asian | TCGA.C8.A12V.01A.11R.A115.07 |
| TCGA-C8-A12X | 62 | female | Asian | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 1.05 | NA | East Asian | TCGA.C8.A12X.01A.11R.A115.07 |
| TCGA-D8-A1XW | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | 1.05 | Normal | European | TCGA.D8.A1XW.01A.11R.A14M.07 |
| TCGA-BH-A0HU | 52 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.07 | LumB | European | TCGA.BH.A0HU.01A.11R.A034.07 |
| TCGA-C8-A135 | 64 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 1.08 | Her2 | East Asian | TCGA.C8.A135.01A.11R.A115.07 |
| TCGA-LL-A5YM | 88 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | locoregional recurrence | skin chest wall | alive | 1.08 | LumB | African | TCGA.LL.A5YM.01A.11R.A28M.07 |
| TCGA-D8-A1XU | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.08 | LumA | European | TCGA.D8.A1XU.01A.11R.A14M.07 |
| TCGA-A8-A06O | 60 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.08 | LumB | European | TCGA.A8.A06O.01A.11R.A00Z.07 |
| TCGA-A8-A06P | 63 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.08 | LumA | European | TCGA.A8.A06P.01A.11R.A00Z.07 |
| TCGA-A8-A086 | 59 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.08 | LumA | European | TCGA.A8.A086.01A.11R.A00Z.07 |
| TCGA-A8-A09D | 47 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.08 | LumA | European | TCGA.A8.A09D.01A.11R.A00Z.07 |
| TCGA-A8-A0A4 | 73 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.08 | LumA | European | TCGA.A8.A0A4.01A.11R.A00Z.07 |
| TCGA-D8-A27H | 72 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.09 | Basal | European | TCGA.D8.A27H.01A.11R.A16F.07 |
| TCGA-D8-A27T | 53 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.09 | LumA | European | TCGA.D8.A27T.01A.11R.A16F.07 |
| TCGA-E9-A1N9 | 58 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | negative | positive | positive | NA | NA | alive | 1.09 | NA | European | TCGA.E9.A1N9.01A.11R.A14D.07 |
| TCGA-E9-A1N9 | 58 | female | White | Solid Tissue Normal | postmenopausal | IDC/ILC | negative | positive | positive | NA | NA | alive | 1.09 | NA | European | TCGA.E9.A1N9.11A.71R.A14D.07 |
| TCGA-E9-A22D | 38 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.1 | LumB | European | TCGA.E9.A22D.01A.11R.A157.07 |
| TCGA-LD-A74U | 79 | female | White | Primary solid Tumor | not available | \ILC, classical type, focal pleomorphic type\"" | positive | negative | negative | NA | NA | alive | 1.1 | NA | European | TCGA.LD.A74U.01A.13R.A33J.07 |
| TCGA-D8-A140 | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.1 | LumA | European | TCGA.D8.A140.01A.11R.A115.07 |
| TCGA-EW-A1J2 | 50 | female | Black or African American | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.1 | LumA | South Asian | TCGA.EW.A1J2.01A.21R.A13Q.07 |
| TCGA-LD-A7W6 | 54 | female | White | Primary solid Tumor | postmenopausal | \ILC, mixed classical (70%) and pleomorphic/solid (30%) types\"" | positive | positive | negative | NA | NA | alive | 1.11 | NA | European | TCGA.LD.A7W6.01A.81R.A352.07 |
| TCGA-D8-A1JT | 70 | female | White | Primary solid Tumor | postmenopausal | ductal and papillary | positive | positive | equivocal | NA | NA | alive | 1.11 | NA | European | TCGA.D8.A1JT.01A.31R.A13Q.07 |
| TCGA-E9-A229 | 37 | female | White | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.11 | LumA | European | TCGA.E9.A229.01A.31R.A157.07 |
| TCGA-C8-A8HR | 49 | female | Asian | Primary solid Tumor | perimenopausal | ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.12 | Normal | East Asian | TCGA.C8.A8HR.01A.11R.A36F.07 |
| TCGA-D8-A27G | 75 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.12 | LumA | European | TCGA.D8.A27G.01A.11R.A16F.07 |
| TCGA-D8-A27M | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.12 | Basal | European | TCGA.D8.A27M.01A.11R.A16F.07 |
| TCGA-GM-A5PV | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 1.13 | LumA | European | TCGA.GM.A5PV.01A.11R.A28M.07 |
| TCGA-AC-A6IW | 73 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.13 | Basal | African | TCGA.AC.A6IW.01A.12R.A33J.07 |
| TCGA-BH-A0HP | 65 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | 1.13 | LumA | European | TCGA.BH.A0HP.01A.12R.A084.07 |
| TCGA-A1-A0SJ | 39 | female | Black or African American | Primary solid Tumor | not available | IDC | positive | positive | equivocal | NA | NA | alive | 1.14 | LumA | African_admix | TCGA.A1.A0SJ.01A.11R.A084.07 |
| TCGA-AC-A62X | 72 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | not evaluated | NA | NA | alive | 1.14 | Basal | African | TCGA.AC.A62X.01A.11R.A29R.07 |
| TCGA-A7-A4SB | 56 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.14 | NA | European | TCGA.A7.A4SB.01A.21R.A266.07 |
| TCGA-E9-A1NE | 28 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.15 | LumA | European | TCGA.E9.A1NE.01A.21R.A14M.07 |
| TCGA-S3-AA11 | 67 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.15 | LumA | African | TCGA.S3.AA11.01A.31R.A41B.07 |
| TCGA-BH-A0DK | 49 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.16 | LumA | European | TCGA.BH.A0DK.01A.21R.A056.07 |
| TCGA-BH-A0DK | 49 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.16 | LumA | European | TCGA.BH.A0DK.11A.13R.A089.07 |
| TCGA-EW-A1PD | 61 | male | White | Primary solid Tumor | not applicable | IDC | positive | positive | equivocal | NA | NA | alive | 1.16 | NA | European | TCGA.EW.A1PD.01A.11R.A144.07 |
| TCGA-S3-AA17 | 64 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.16 | LumB | African_admix | TCGA.S3.AA17.01A.11R.A41B.07 |
| TCGA-A8-A07I | 69 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.17 | Her2 | European | TCGA.A8.A07I.01A.11R.A00Z.07 |
| TCGA-D8-A1JH | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.17 | LumA | European | TCGA.D8.A1JH.01A.11R.A13Q.07 |
| TCGA-E2-A15S | 34 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 1.17 | LumB | European | TCGA.E2.A15S.01A.11R.A115.07 |
| TCGA-D8-A1Y3 | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 1.18 | LumB | European | TCGA.D8.A1Y3.01A.11R.A157.07 |
| TCGA-D8-A143 | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.18 | Basal | European | TCGA.D8.A143.01A.11R.A115.07 |
| TCGA-D8-A1J8 | 77 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.18 | LumB | European | TCGA.D8.A1J8.01A.11R.A13Q.07 |
| TCGA-A1-A0SG | 61 | female | White | Primary solid Tumor | postmenopausal | micropapillary carcinoma invasive | positive | positive | negative | NA | NA | alive | 1.19 | NA | European | TCGA.A1.A0SG.01A.11R.A144.07 |
| TCGA-BH-A0E2 | 49 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.19 | LumA | African | TCGA.BH.A0E2.01A.11R.A056.07 |
| TCGA-A1-A0SD | 59 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 1.2 | LumA | European | TCGA.A1.A0SD.01A.11R.A115.07 |
| TCGA-C8-A27B | 48 | female | Asian | Primary solid Tumor | perimenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.2 | Basal | East Asian | TCGA.C8.A27B.01A.11R.A169.07 |
| TCGA-D8-A27I | 58 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.2 | LumA | European | TCGA.D8.A27I.01A.11R.A16F.07 |
| TCGA-A2-A0YI | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.21 | LumA | European | TCGA.A2.A0YI.01A.31R.A10J.07 |
| TCGA-A7-A4SD | 52 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.21 | Basal | African | TCGA.A7.A4SD.01A.11R.A266.07 |
| TCGA-D8-A1XK | 55 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.21 | Basal | European | TCGA.D8.A1XK.01A.21R.A14M.07 |
| TCGA-D8-A3Z5 | 54 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.21 | NA | European | TCGA.D8.A3Z5.01A.41R.A24H.07 |
| TCGA-LL-A740 | 61 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.21 | LumA | African | TCGA.LL.A740.01A.21R.A32P.07 |
| TCGA-A2-A0YL | 48 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.22 | LumA | European | TCGA.A2.A0YL.01A.21R.A109.07 |
| TCGA-A7-A4SC | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | equivocal | NA | NA | alive | 1.22 | NA | European | TCGA.A7.A4SC.01A.12R.A266.07 |
| TCGA-A7-A425 | 70 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | Indeterminate | locoregional recurrence | breast>bone | alive | 1.22 | LumA | European | TCGA.A7.A425.01A.11R.A24H.07 |
| TCGA-D8-A1JU | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.22 | LumA | European | TCGA.D8.A1JU.01A.11R.A13Q.07 |
| TCGA-LL-A5YN | 46 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.22 | LumA | African | TCGA.LL.A5YN.01A.11R.A28M.07 |
| TCGA-A7-A56D | 84 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.23 | LumA | African | TCGA.A7.A56D.01A.11R.A27Q.07 |
| TCGA-E2-A158 | 43 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.23 | Basal | European | TCGA.E2.A158.01A.11R.A12D.07 |
| TCGA-E2-A158 | 43 | female | White | Solid Tissue Normal | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.23 | Basal | European | TCGA.E2.A158.11A.22R.A12D.07 |
| TCGA-AC-A3OD | 68 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.23 | LumA | European | TCGA.AC.A3OD.01A.11R.A21T.07 |
| TCGA-A7-A4SA | 40 | female | White | Primary solid Tumor | premenopausal | ILC | positive | negative | negative | NA | NA | alive | 1.24 | NA | European | TCGA.A7.A4SA.01A.11R.A266.07 |
| TCGA-AC-A3TN | 75 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.25 | NA | European | TCGA.AC.A3TN.01A.11R.A22K.07 |
| TCGA-E2-A15T | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.25 | LumB | European | TCGA.E2.A15T.01A.11R.A115.07 |
| TCGA-A8-A09M | 75 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.25 | LumB | European | TCGA.A8.A09M.01A.11R.A00Z.07 |
| TCGA-A8-A09V | 51 | female | not available | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.25 | LumA | European | TCGA.A8.A09V.01A.11R.A034.07 |
| TCGA-A8-A084 | 81 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.25 | NA | European | TCGA.A8.A084.01A.21R.A00Z.07 |
| TCGA-BH-A0H0 | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.26 | LumB | European | TCGA.BH.A0H0.01A.11R.A056.07 |
| TCGA-D8-A1XV | 84 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | equivocal | NA | NA | alive | 1.26 | NA | European | TCGA.D8.A1XV.01A.11R.A14M.07 |
| TCGA-EW-A6S9 | 34 | female | Black or African American | Primary solid Tumor | not available | IDC | positive | positive | positive | NA | NA | alive | 1.27 | LumA | African_admix | TCGA.EW.A6S9.01A.22R.A33J.07 |
| TCGA-D8-A1XZ | 81 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.28 | LumB | European | TCGA.D8.A1XZ.01A.11R.A14M.07 |
| TCGA-XX-A899 | 46 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.28 | LumA | European | TCGA.XX.A899.01A.11R.A36F.07 |
| TCGA-A2-A0YF | 67 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.28 | LumA | African_admix | TCGA.A2.A0YF.01A.21R.A109.07 |
| TCGA-C8-A26Z | 59 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.29 | LumA | East Asian | TCGA.C8.A26Z.01A.11R.A16F.07 |
| TCGA-E2-A1LS | 46 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.29 | NA | European | TCGA.E2.A1LS.01A.12R.A157.07 |
| TCGA-E2-A1LS | 46 | female | White | Solid Tissue Normal | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.29 | NA | European | TCGA.E2.A1LS.11A.32R.A157.07 |
| TCGA-AC-A3W7 | 66 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | 1.29 | NA | European | TCGA.AC.A3W7.01A.11R.A22K.07 |
| TCGA-D8-A1Y0 | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.29 | LumA | European | TCGA.D8.A1Y0.01A.11R.A14M.07 |
| TCGA-D8-A1XO | 56 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.3 | LumA | European | TCGA.D8.A1XO.01A.11R.A14M.07 |
| TCGA-AQ-A1H2 | 84 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 1.3 | LumA | European | TCGA.AQ.A1H2.01A.11R.A13Q.07 |
| TCGA-BH-A0DP | 60 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.3 | LumA | European | TCGA.BH.A0DP.01A.21R.A056.07 |
| TCGA-BH-A0DP | 60 | female | White | Solid Tissue Normal | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.3 | LumA | European | TCGA.BH.A0DP.11A.12R.A089.07 |
| TCGA-BH-A0E1 | 52 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.31 | LumA | European | TCGA.BH.A0E1.01A.11R.A056.07 |
| TCGA-BH-A0E1 | 52 | female | White | Solid Tissue Normal | perimenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.31 | LumA | European | TCGA.BH.A0E1.11A.13R.A089.07 |
| TCGA-EW-A1J5 | 59 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.31 | LumA | European | TCGA.EW.A1J5.01A.11R.A13Q.07 |
| TCGA-LL-A73Y | 67 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.31 | Basal | African | TCGA.LL.A73Y.01A.11R.A33J.07 |
| TCGA-E2-A3DX | 43 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 1.31 | NA | European | TCGA.E2.A3DX.01A.21R.A213.07 |
| TCGA-D8-A1JC | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.31 | LumB | European | TCGA.D8.A1JC.01A.11R.A13Q.07 |
| TCGA-D8-A1XR | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.32 | LumB | European | TCGA.D8.A1XR.01A.11R.A14M.07 |
| TCGA-A2-A0EY | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.33 | LumB | European | TCGA.A2.A0EY.01A.11R.A034.07 |
| TCGA-E2-A14P | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 1.33 | Her2 | European | TCGA.E2.A14P.01A.31R.A12D.07 |
| TCGA-AR-A5QN | 68 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.34 | LumA | European | TCGA.AR.A5QN.01A.12R.A28M.07 |
| TCGA-D8-A27F | 40 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.34 | Basal | European | TCGA.D8.A27F.01A.11R.A16F.07 |
| TCGA-XX-A89A | 68 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.34 | LumA | European | TCGA.XX.A89A.01A.11R.A36F.07 |
| TCGA-LL-A6FR | 50 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | positive | equivocal | NA | NA | alive | 1.34 | Basal | African | TCGA.LL.A6FR.01A.12R.A31O.07 |
| TCGA-D8-A73U | 88 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.35 | LumA | European | TCGA.D8.A73U.01A.11R.A33J.07 |
| TCGA-BH-A0DZ | 43 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.36 | LumA | European | TCGA.BH.A0DZ.01A.11R.A00Z.07 |
| TCGA-BH-A0DZ | 43 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.36 | LumA | European | TCGA.BH.A0DZ.11A.22R.A089.07 |
| TCGA-A2-A25B | 39 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | metastasis | bone | alive | 1.36 | LumB | African | TCGA.A2.A25B.01A.11R.A169.07 |
| TCGA-AC-A3HN | 87 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.36 | LumA | European | TCGA.AC.A3HN.01A.11R.A213.07 |
| TCGA-D8-A1XQ | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.37 | Basal | European | TCGA.D8.A1XQ.01A.11R.A14M.07 |
| TCGA-D8-A27L | 49 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.37 | LumA | European | TCGA.D8.A27L.01A.11R.A16F.07 |
| TCGA-A2-A1G6 | 50 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.37 | Normal | European | TCGA.A2.A1G6.01A.11R.A13Q.07 |
| TCGA-E2-A1BC | 63 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.37 | LumA | European | TCGA.E2.A1BC.01A.11R.A12P.07 |
| TCGA-E2-A1BC | 63 | female | not available | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.37 | LumA | European | TCGA.E2.A1BC.11A.32R.A12P.07 |
| TCGA-D8-A1JA | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | locoregional disease | NA | alive | 1.37 | Her2 | European | TCGA.D8.A1JA.01A.11R.A13Q.07 |
| TCGA-EW-A1J3 | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.38 | LumA | European | TCGA.EW.A1J3.01A.11R.A13Q.07 |
| TCGA-D8-A1XT | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 1.39 | Her2 | European | TCGA.D8.A1XT.01A.11R.A14M.07 |
| TCGA-C8-A274 | 63 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.39 | LumB | East Asian | TCGA.C8.A274.01A.11R.A16F.07 |
| TCGA-E9-A1N5 | 45 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | positive | NA | NA | alive | 1.39 | NA | European | TCGA.E9.A1N5.01A.11R.A14D.07 |
| TCGA-E9-A1N5 | 45 | female | White | Solid Tissue Normal | postmenopausal | IDC/ILC | positive | positive | positive | NA | NA | alive | 1.39 | NA | European | TCGA.E9.A1N5.11A.41R.A14D.07 |
| TCGA-EW-A6SA | 59 | male | Black or African American | Primary solid Tumor | not applicable | IDC | positive | negative | negative | NA | NA | alive | 1.4 | NA | African | TCGA.EW.A6SA.01A.21R.A32P.07 |
| TCGA-BH-A0HN | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.41 | NA | European | TCGA.BH.A0HN.01A.11R.A10U.07 |
| TCGA-A8-A075 | 42 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.42 | LumB | European | TCGA.A8.A075.01A.11R.A084.07 |
| TCGA-A8-A0AB | 54 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.42 | LumA | European | TCGA.A8.A0AB.01A.11R.A034.07 |
| TCGA-UL-AAZ6 | 73 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.42 | LumA | African | TCGA.UL.AAZ6.01A.11R.A41B.07 |
| TCGA-D8-A27N | 36 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.42 | LumB | European | TCGA.D8.A27N.01A.11R.A16F.07 |
| TCGA-E2-A15R | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.42 | LumA | European | TCGA.E2.A15R.01A.11R.A115.07 |
| TCGA-LL-A5YL | 64 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | positive | NA | NA | alive | 1.42 | LumA | European | TCGA.LL.A5YL.01A.12R.A29R.07 |
| TCGA-E2-A1BD | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.42 | LumA | European | TCGA.E2.A1BD.01A.11R.A12P.07 |
| TCGA-D8-A1XD | 36 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.43 | NA | European | TCGA.D8.A1XD.01A.11R.A14D.07 |
| TCGA-A2-A25C | 50 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.43 | LumB | European | TCGA.A2.A25C.01A.11R.A169.07 |
| TCGA-BH-A0DO | 78 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.44 | LumA | European | TCGA.BH.A0DO.01B.11R.A12D.07 |
| TCGA-BH-A0DO | 78 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.44 | LumA | European | TCGA.BH.A0DO.11A.22R.A12D.07 |
| TCGA-S3-AA15 | 51 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.44 | Basal | African | TCGA.S3.AA15.01A.11R.A41B.07 |
| TCGA-E2-A15D | 47 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.44 | LumA | European | TCGA.E2.A15D.01A.11R.A115.07 |
| TCGA-A2-A1FW | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.45 | LumB | European | TCGA.A2.A1FW.01A.11R.A13Q.07 |
| TCGA-OL-A66O | 39 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 1.45 | LumA | African | TCGA.OL.A66O.01A.11R.A31O.07 |
| TCGA-S3-AA14 | 47 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.45 | LumA | African | TCGA.S3.AA14.01A.11R.A41B.07 |
| TCGA-D8-A27E | 66 | female | White | Primary solid Tumor | postmenopausal | IDC/mucinous | positive | positive | negative | NA | NA | alive | 1.45 | NA | European | TCGA.D8.A27E.01A.11R.A16F.07 |
| TCGA-E2-A15I | 44 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.45 | LumA | European | TCGA.E2.A15I.01A.21R.A137.07 |
| TCGA-E2-A15I | 44 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.45 | LumA | European | TCGA.E2.A15I.11A.32R.A137.07 |
| TCGA-A2-A0T5 | 39 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.45 | LumA | European | TCGA.A2.A0T5.01A.21R.A084.07 |
| TCGA-D8-A1J9 | 48 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.46 | LumB | European | TCGA.D8.A1J9.01A.11R.A13Q.07 |
| TCGA-EW-A3U0 | 61 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.46 | NA | African_admix | TCGA.EW.A3U0.01A.11R.A22K.07 |
| TCGA-LL-A9Q3 | 69 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.46 | LumA | European | TCGA.LL.A9Q3.01A.11R.A41B.07 |
| TCGA-A2-A0T0 | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.46 | Basal | European | TCGA.A2.A0T0.01A.22R.A084.07 |
| TCGA-D8-A1XM | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.47 | LumA | European | TCGA.D8.A1XM.01A.21R.A14M.07 |
| TCGA-AO-A1KT | 78 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.48 | LumB | European | TCGA.AO.A1KT.01A.11R.A13Q.07 |
| TCGA-D8-A1X6 | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.48 | LumB | European | TCGA.D8.A1X6.01A.11R.A14M.07 |
| TCGA-E9-A1N3 | 70 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.48 | NA | European | TCGA.E9.A1N3.01A.12R.A157.07 |
| TCGA-BH-A0W5 | 77 | female | White | Primary solid Tumor | not available | IDC | positive | positive | equivocal | NA | NA | alive | 1.49 | LumA | European | TCGA.BH.A0W5.01A.11R.A109.07 |
| TCGA-A7-A4SF | 54 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.49 | NA | African | TCGA.A7.A4SF.01A.11R.A266.07 |
| TCGA-A8-A093 | 61 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.49 | LumA | European | TCGA.A8.A093.01A.11R.A00Z.07 |
| TCGA-A8-A06R | 69 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.5 | LumB | European | TCGA.A8.A06R.01A.11R.A00Z.07 |
| TCGA-A8-A082 | 58 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.5 | LumB | European | TCGA.A8.A082.01A.11R.A00Z.07 |
| TCGA-A8-A08F | 59 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.5 | NA | European | TCGA.A8.A08F.01A.11R.A00Z.07 |
| TCGA-GM-A5PX | 65 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.51 | LumA | European | TCGA.GM.A5PX.01A.12R.A28M.07 |
| TCGA-D8-A1JD | 41 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.51 | LumB | European | TCGA.D8.A1JD.01A.11R.A13Q.07 |
| TCGA-D8-A1XB | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.51 | LumA | European | TCGA.D8.A1XB.01A.11R.A14D.07 |
| TCGA-A1-A0SQ | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.52 | LumA | European | TCGA.A1.A0SQ.01A.21R.A144.07 |
| TCGA-A2-A0YE | 48 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.52 | Basal | European | TCGA.A2.A0YE.01A.11R.A109.07 |
| TCGA-BH-A0BD | 47 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.52 | LumB | European | TCGA.BH.A0BD.01A.11R.A034.07 |
| TCGA-E2-A15G | 76 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 1.52 | NA | European | TCGA.E2.A15G.01A.11R.A12D.07 |
| TCGA-BH-A0W7 | 49 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 1.53 | LumA | European | TCGA.BH.A0W7.01A.11R.A115.07 |
| TCGA-E9-A3Q9 | 78 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | Indeterminate | NA | NA | alive | 1.53 | NA | European | TCGA.E9.A3Q9.01A.11R.A21T.07 |
| TCGA-EW-A1P6 | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.54 | LumA | European | TCGA.EW.A1P6.01A.11R.A144.07 |
| TCGA-S3-A6ZG | 71 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 1.54 | NA | African_admix | TCGA.S3.A6ZG.01A.22R.A32P.07 |
| TCGA-D8-A3Z6 | 56 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.54 | LumA | European | TCGA.D8.A3Z6.01A.11R.A239.07 |
| TCGA-D8-A1X5 | 81 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.55 | LumB | European | TCGA.D8.A1X5.01A.11R.A14D.07 |
| TCGA-A2-A0YJ | 39 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | metastasis | cervical lymph node | alive | 1.55 | Basal | European | TCGA.A2.A0YJ.01A.11R.A109.07 |
| TCGA-AC-A6IV | 47 | female | White | Primary solid Tumor | not available | ILC | positive | positive | equivocal | NA | NA | alive | 1.56 | LumA | European | TCGA.AC.A6IV.01A.12R.A33J.07 |
| TCGA-A2-A0T3 | 37 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.56 | LumB | European | TCGA.A2.A0T3.01A.21R.A115.07 |
| TCGA-D8-A1JB | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.56 | LumA | European | TCGA.D8.A1JB.01A.11R.A13Q.07 |
| TCGA-S3-A6ZF | 64 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.57 | LumB | African | TCGA.S3.A6ZF.01A.32R.A32P.07 |
| TCGA-BH-A8FZ | 58 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.57 | Normal | European | TCGA.BH.A8FZ.01A.11R.A352.07 |
| TCGA-E2-A1LG | 50 | female | Black or African American | Primary solid Tumor | perimenopausal | ILC | negative | negative | equivocal | NA | NA | alive | 1.57 | Basal | African | TCGA.E2.A1LG.01A.21R.A14M.07 |
| TCGA-S3-AA12 | 82 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | metastasis | lung|adrenal gland | alive | 1.57 | LumA | African | TCGA.S3.AA12.01A.11R.A41B.07 |
| TCGA-A2-A0T6 | 50 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.57 | LumA | European | TCGA.A2.A0T6.01A.11R.A084.07 |
| TCGA-D8-A1JE | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.57 | LumB | European | TCGA.D8.A1JE.01A.11R.A13Q.07 |
| TCGA-EW-A1PA | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.57 | LumA | European | TCGA.EW.A1PA.01A.11R.A144.07 |
| TCGA-E9-A1NH | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.58 | LumA | European | TCGA.E9.A1NH.01A.11R.A14D.07 |
| TCGA-A8-A07F | 65 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.58 | LumA | European | TCGA.A8.A07F.01A.11R.A00Z.07 |
| TCGA-A8-A07G | 65 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.58 | LumA | European | TCGA.A8.A07G.01A.11R.A034.07 |
| TCGA-D8-A1JI | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.58 | LumB | European | TCGA.D8.A1JI.01A.11R.A13Q.07 |
| TCGA-E2-A576 | 69 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.58 | LumA | African | TCGA.E2.A576.01A.11R.A31O.07 |
| TCGA-A8-A09T | 68 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.59 | LumA | European | TCGA.A8.A09T.01A.11R.A00Z.07 |
| TCGA-A8-A0A2 | 66 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.59 | LumA | European | TCGA.A8.A0A2.01A.11R.A034.07 |
| TCGA-A8-A07C | 57 | female | not available | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.59 | NA | European | TCGA.A8.A07C.01A.11R.A034.07 |
| TCGA-A8-A08S | 71 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.59 | NA | European | TCGA.A8.A08S.01A.11R.A034.07 |
| TCGA-A8-A091 | 61 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | not available | NA | alive | 1.59 | LumA | European | TCGA.A8.A091.01A.11R.A00Z.07 |
| TCGA-A1-A0SP | 40 | female | not available | Primary solid Tumor | not available | IDC | negative | negative | negative | NA | NA | alive | 1.6 | Basal | European | TCGA.A1.A0SP.01A.11R.A084.07 |
| TCGA-A2-A1G1 | 85 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.6 | Basal | European | TCGA.A2.A1G1.01A.21R.A13Q.07 |
| TCGA-D8-A147 | 45 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | negative | NA | NA | alive | 1.6 | Basal | European | TCGA.D8.A147.01A.11R.A115.07 |
| TCGA-AC-A23C | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.6 | LumA | European | TCGA.AC.A23C.01A.12R.A169.07 |
| TCGA-S3-AA10 | 65 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.6 | Basal | African | TCGA.S3.AA10.01A.21R.A41B.07 |
| TCGA-A2-A0YK | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | 1.61 | Normal | European | TCGA.A2.A0YK.01A.22R.A109.07 |
| TCGA-AC-A2QI | 76 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | 1.61 | NA | European | TCGA.AC.A2QI.01A.12R.A19W.07 |
| TCGA-AC-A5XS | 74 | female | White | Primary solid Tumor | not available | ILC | positive | positive | negative | NA | NA | alive | 1.61 | LumA | European | TCGA.AC.A5XS.01A.11R.A29R.07 |
| TCGA-D8-A1JM | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.62 | Basal | European | TCGA.D8.A1JM.01A.11R.A13Q.07 |
| TCGA-E2-A15J | 51 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.62 | LumA | European | TCGA.E2.A15J.01A.11R.A12P.07 |
| TCGA-E2-A154 | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.62 | LumA | European | TCGA.E2.A154.01A.11R.A115.07 |
| TCGA-LL-A7SZ | 49 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.63 | LumA | African | TCGA.LL.A7SZ.01A.32R.A352.07 |
| TCGA-A2-A1G4 | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.63 | LumB | European | TCGA.A2.A1G4.01A.11R.A13Q.07 |
| TCGA-E2-A15P | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.63 | LumA | European | TCGA.E2.A15P.01A.11R.A115.07 |
| TCGA-LL-A8F5 | 61 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.63 | Basal | African | TCGA.LL.A8F5.01A.11R.A36F.07 |
| TCGA-E2-A1L9 | 40 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.64 | LumA | European | TCGA.E2.A1L9.01A.11R.A13Q.07 |
| TCGA-D8-A1XL | 34 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.66 | LumB | European | TCGA.D8.A1XL.01A.11R.A14M.07 |
| TCGA-A8-A08G | 41 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.66 | LumB | European | TCGA.A8.A08G.01A.11R.A00Z.07 |
| TCGA-EW-A1PH | 52 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.66 | Basal | European | TCGA.EW.A1PH.01A.11R.A14M.07 |
| TCGA-A8-A07E | 81 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.66 | LumA | European | TCGA.A8.A07E.01A.11R.A034.07 |
| TCGA-EW-A1PB | 70 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.66 | Basal | African | TCGA.EW.A1PB.01A.11R.A144.07 |
| TCGA-D8-A1JJ | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.67 | LumB | European | TCGA.D8.A1JJ.01A.31R.A14M.07 |
| TCGA-D8-A1JL | 72 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.67 | Basal | European | TCGA.D8.A1JL.01A.11R.A13Q.07 |
| TCGA-BH-A2L8 | 45 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.68 | LumA | European | TCGA.BH.A2L8.01A.11R.A18M.07 |
| TCGA-AC-A8OP | 72 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 1.68 | LumA | African | TCGA.AC.A8OP.01A.11R.A36F.07 |
| TCGA-AR-A1AY | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.68 | Basal | European | TCGA.AR.A1AY.01A.21R.A12P.07 |
| TCGA-A2-A1G0 | 49 | female | White | Primary solid Tumor | premenopausal | Infiltrating Tubulolobular Carcinoma | positive | positive | equivocal | NA | NA | alive | 1.69 | NA | European | TCGA.A2.A1G0.01A.11R.A13Q.07 |
| TCGA-AO-A0J7 | 71 | female | White | Primary solid Tumor | postmenopausal | ductal/mucinous | positive | positive | negative | NA | NA | alive | 1.69 | NA | European | TCGA.AO.A0J7.01A.11R.A034.07 |
| TCGA-BH-A0HI | 78 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.7 | LumA | European | TCGA.BH.A0HI.01A.11R.A084.07 |
| TCGA-D8-A1JN | 80 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | Indeterminate | NA | NA | alive | 1.7 | LumA | European | TCGA.D8.A1JN.01A.11R.A13Q.07 |
| TCGA-OL-A5S0 | 66 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | not evaluated | NA | NA | alive | 1.7 | Basal | African_admix | TCGA.OL.A5S0.01A.11R.A28M.07 |
| TCGA-AO-A1KO | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.7 | Normal | European | TCGA.AO.A1KO.01A.31R.A13Q.07 |
| TCGA-AR-A5QP | 54 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.7 | LumA | European | TCGA.AR.A5QP.01A.11R.A28M.07 |
| TCGA-BH-A0AW | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.7 | Her2 | European | TCGA.BH.A0AW.01A.11R.A056.07 |
| TCGA-A2-A0T4 | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.71 | LumA | European | TCGA.A2.A0T4.01A.31R.A084.07 |
| TCGA-D8-A141 | 40 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | negative | NA | NA | alive | 1.71 | LumA | European | TCGA.D8.A141.01A.11R.A115.07 |
| TCGA-E2-A15L | 65 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.71 | LumA | African | TCGA.E2.A15L.01A.11R.A12D.07 |
| TCGA-E9-A1RH | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.71 | Her2 | European | TCGA.E9.A1RH.01A.21R.A169.07 |
| TCGA-E9-A1RH | 63 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.71 | Her2 | European | TCGA.E9.A1RH.11A.34R.A169.07 |
| TCGA-S3-AA0Z | 63 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.72 | Basal | African | TCGA.S3.AA0Z.01A.11R.A41B.07 |
| TCGA-E2-A15E | 40 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 1.72 | LumA | European | TCGA.E2.A15E.01A.11R.A12D.07 |
| TCGA-E9-A22H | 42 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.72 | LumB | European_admix | TCGA.E9.A22H.01A.11R.A157.07 |
| TCGA-A2-A0T7 | 51 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.73 | LumA | European | TCGA.A2.A0T7.01A.21R.A084.07 |
| TCGA-A1-A0SI | 52 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 1.74 | LumB | European | TCGA.A1.A0SI.01A.11R.A144.07 |
| TCGA-A2-A3KC | 55 | female | Black or African American | Primary solid Tumor | premenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.74 | NA | African_admix | TCGA.A2.A3KC.01A.11R.A213.07 |
| TCGA-BH-A42V | 41 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.74 | LumA | African | TCGA.BH.A42V.01A.11R.A24H.07 |
| TCGA-D8-A13Z | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.74 | Her2 | European | TCGA.D8.A13Z.01A.11R.A115.07 |
| TCGA-D8-A1JP | 73 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.75 | LumA | European | TCGA.D8.A1JP.01A.11R.A13Q.07 |
| TCGA-A8-A0A6 | 64 | female | not available | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.75 | LumA | European | TCGA.A8.A0A6.01A.12R.A056.07 |
| TCGA-E2-A155 | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.75 | LumB | European | TCGA.E2.A155.01A.11R.A12D.07 |
| TCGA-S3-A6ZH | 29 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | positive | equivocal | NA | NA | alive | 1.75 | LumA | African | TCGA.S3.A6ZH.01A.22R.A32P.07 |
| TCGA-A2-A0D0 | 60 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.76 | Basal | African | TCGA.A2.A0D0.01A.11R.A00Z.07 |
| TCGA-A2-A4S2 | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.76 | LumA | European | TCGA.A2.A4S2.01A.12R.A266.07 |
| TCGA-D8-A146 | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.76 | NA | European | TCGA.D8.A146.01A.31R.A115.07 |
| TCGA-A7-A4SE | 54 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.76 | Basal | African | TCGA.A7.A4SE.01A.11R.A266.07 |
| TCGA-E9-A1R7 | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.77 | LumB | European | TCGA.E9.A1R7.01A.11R.A14M.07 |
| TCGA-E9-A1R7 | 64 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.77 | LumB | European | TCGA.E9.A1R7.11A.42R.A14M.07 |
| TCGA-LD-A66U | 44 | female | White | Primary solid Tumor | not evaluated | ILC | positive | positive | negative | NA | NA | alive | 1.77 | LumA | European | TCGA.LD.A66U.01A.11R.A31O.07 |
| TCGA-E9-A1RG | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.77 | LumB | European | TCGA.E9.A1RG.01A.11R.A14D.07 |
| TCGA-EW-A3E8 | 60 | female | White | Primary solid Tumor | not evaluated | ILC | positive | negative | negative | NA | NA | alive | 1.77 | NA | European | TCGA.EW.A3E8.01B.11R.A24H.07 |
| TCGA-A2-A4RY | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.77 | NA | European | TCGA.A2.A4RY.01A.31R.A266.07 |
| TCGA-AO-A0JF | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.78 | LumA | European | TCGA.AO.A0JF.01A.11R.A056.07 |
| TCGA-AO-A0J3 | 67 | female | White | Primary solid Tumor | postmenopausal | neuroendocrine and ductal | positive | positive | equivocal | NA | NA | alive | 1.78 | NA | European | TCGA.AO.A0J3.01A.11R.A034.07 |
| TCGA-BH-A18H | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.79 | LumA | European | TCGA.BH.A18H.01A.11R.A12D.07 |
| TCGA-E9-A1NA | 58 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | positive | NA | NA | alive | 1.79 | NA | European | TCGA.E9.A1NA.01A.11R.A144.07 |
| TCGA-E9-A1NA | 58 | female | White | Solid Tissue Normal | postmenopausal | IDC/ILC | positive | positive | positive | NA | NA | alive | 1.79 | NA | European | TCGA.E9.A1NA.11A.33R.A144.07 |
| TCGA-AO-A0JA | 36 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | metastasis | bone | alive | 1.79 | LumA | African_admix | TCGA.AO.A0JA.01A.11R.A056.07 |
| TCGA-E2-A15F | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.8 | LumA | European | TCGA.E2.A15F.01A.11R.A115.07 |
| TCGA-E2-A1IH | 80 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.8 | LumA | European | TCGA.E2.A1IH.01A.11R.A13Q.07 |
| TCGA-A2-A0YH | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.8 | LumB | European | TCGA.A2.A0YH.01A.11R.A109.07 |
| TCGA-D8-A4Z1 | 68 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.8 | LumA | European | TCGA.D8.A4Z1.01A.21R.A266.07 |
| TCGA-E9-A1RE | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 1.8 | LumB | European | TCGA.E9.A1RE.01A.11R.A157.07 |
| TCGA-BH-A0BJ | 41 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.81 | LumA | European | TCGA.BH.A0BJ.01A.11R.A056.07 |
| TCGA-BH-A0BJ | 41 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.81 | LumA | European | TCGA.BH.A0BJ.11A.23R.A089.07 |
| TCGA-A7-A26I | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.81 | Basal | European | TCGA.A7.A26I.01A.11R.A169.07 |
| TCGA-BH-A8G0 | 54 | female | White | Primary solid Tumor | perimenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.81 | LumA | European | TCGA.BH.A8G0.01A.11R.A352.07 |
| TCGA-D8-A1XJ | 76 | female | White | Primary solid Tumor | postmenopausal | ductal/mucinous | positive | positive | positive | NA | NA | alive | 1.82 | NA | European | TCGA.D8.A1XJ.01A.11R.A14M.07 |
| TCGA-AQ-A54O | 51 | male | Black or African American | Primary solid Tumor | not applicable | IDC | positive | positive | negative | NA | NA | alive | 1.82 | NA | African | TCGA.AQ.A54O.01A.11R.A266.07 |
| TCGA-A2-A0YG | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.82 | LumB | European | TCGA.A2.A0YG.01A.21R.A109.07 |
| TCGA-A2-A4S3 | 59 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.82 | LumB | African_admix | TCGA.A2.A4S3.01A.21R.A266.07 |
| TCGA-A2-A04U | 47 | female | White | Primary solid Tumor | perimenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.84 | Basal | European | TCGA.A2.A04U.01A.11R.A115.07 |
| TCGA-AC-A3QP | 79 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 1.85 | LumA | European | TCGA.AC.A3QP.01A.11R.A22U.07 |
| TCGA-E2-A1IN | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.85 | LumA | European | TCGA.E2.A1IN.01A.11R.A13Q.07 |
| TCGA-AC-A2B8 | 84 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | new primary | rectum | alive | 1.85 | LumA | European | TCGA.AC.A2B8.01A.11R.A17B.07 |
| TCGA-E2-A573 | 48 | female | Black or African American | Primary solid Tumor | perimenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 1.85 | Basal | African | TCGA.E2.A573.01A.11R.A29R.07 |
| TCGA-A7-A2KD | 53 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 1.86 | LumB | African | TCGA.A7.A2KD.01A.31R.A21T.07 |
| TCGA-OL-A5RZ | 57 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | not evaluated | NA | NA | alive | 1.86 | Her2 | African | TCGA.OL.A5RZ.01A.11R.A28M.07 |
| TCGA-AO-A0J8 | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.86 | LumA | European | TCGA.AO.A0J8.01A.21R.A034.07 |
| TCGA-A2-A1FZ | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.87 | LumA | European | TCGA.A2.A1FZ.01A.51R.A14D.07 |
| TCGA-E2-A1IO | 37 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.88 | LumA | European | TCGA.E2.A1IO.01A.11R.A144.07 |
| TCGA-E2-A1IK | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.89 | LumA | European | TCGA.E2.A1IK.01A.11R.A144.07 |
| TCGA-E9-A22B | 71 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | negative | negative | NA | NA | alive | 1.89 | NA | European | TCGA.E9.A22B.01A.11R.A157.07 |
| TCGA-E2-A15C | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 1.9 | LumA | European | TCGA.E2.A15C.01A.31R.A12D.07 |
| TCGA-EW-A1OW | 58 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.9 | NA | African | TCGA.EW.A1OW.01A.21R.A144.07 |
| TCGA-BH-A0WA | 82 | female | White | Primary solid Tumor | not available | not available | negative | negative | negative | NA | NA | alive | 1.92 | NA | European | TCGA.BH.A0WA.01A.11R.A109.07 |
| TCGA-A8-A08B | 52 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | negative | positive | NA | NA | alive | 1.92 | Her2 | European | TCGA.A8.A08B.01A.11R.A00Z.07 |
| TCGA-BH-A0H7 | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.92 | LumA | European | TCGA.BH.A0H7.01A.13R.A056.07 |
| TCGA-BH-A0H7 | 65 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.92 | LumA | European | TCGA.BH.A0H7.11A.13R.A089.07 |
| TCGA-EW-A1P5 | 77 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.92 | LumA | European | TCGA.EW.A1P5.01A.11R.A144.07 |
| TCGA-A2-A4S0 | 77 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 1.93 | NA | European | TCGA.A2.A4S0.01A.21R.A266.07 |
| TCGA-AC-A3YI | 74 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 1.94 | Normal | European | TCGA.AC.A3YI.01A.21R.A239.07 |
| TCGA-E2-A153 | 51 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.94 | LumA | European | TCGA.E2.A153.01A.12R.A12D.07 |
| TCGA-E2-A153 | 51 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.94 | LumA | European | TCGA.E2.A153.11A.31R.A12D.07 |
| TCGA-E9-A1NC | 61 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | negative | positive | positive | NA | NA | alive | 1.94 | NA | European | TCGA.E9.A1NC.01A.21R.A26B.07 |
| TCGA-AR-A0TU | 35 | female | not available | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.94 | NA | European | TCGA.AR.A0TU.01A.31R.A109.07 |
| TCGA-E2-A15A | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.94 | LumB | European | TCGA.E2.A15A.01A.11R.A12D.07 |
| TCGA-GI-A2C9 | 58 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.95 | NA | African | TCGA.GI.A2C9.01A.11R.A21T.07 |
| TCGA-GI-A2C9 | 58 | female | Black or African American | Solid Tissue Normal | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 1.95 | NA | African | TCGA.GI.A2C9.11A.22R.A21T.07 |
| TCGA-BH-A0DG | 30 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.95 | LumA | African | TCGA.BH.A0DG.01A.21R.A12P.07 |
| TCGA-BH-A0DG | 30 | female | Black or African American | Solid Tissue Normal | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.95 | LumA | African | TCGA.BH.A0DG.11A.43R.A12P.07 |
| TCGA-E9-A22A | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 1.95 | LumB | European | TCGA.E9.A22A.01A.11R.A157.07 |
| TCGA-A2-A1FV | 74 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.95 | LumA | European | TCGA.A2.A1FV.01A.11R.A13Q.07 |
| TCGA-OL-A66I | 36 | female | Black or African American | Primary solid Tumor | not evaluated | IDC | negative | negative | not evaluated | NA | NA | alive | 1.95 | Basal | African | TCGA.OL.A66I.01A.21R.A29R.07 |
| TCGA-BH-A5J0 | 63 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.96 | LumA | African | TCGA.BH.A5J0.01A.11R.A27Q.07 |
| TCGA-E9-A22G | 47 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 1.96 | Basal | European | TCGA.E9.A22G.01A.11R.A157.07 |
| TCGA-A7-A26G | 50 | female | Black or African American | Primary solid Tumor | premenopausal | IDC with Metaplastic features (area of sarcomatoid carcinoma) | negative | negative | negative | NA | NA | alive | 1.98 | NA | African | TCGA.A7.A26G.01A.21R.A169.07 |
| TCGA-A7-A26H | 72 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | not available | NA | alive | 1.98 | LumA | European | TCGA.A7.A26H.01A.11R.A169.07 |
| TCGA-E9-A54Y | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 1.98 | LumB | European | TCGA.E9.A54Y.01A.11R.A466.07 |
| TCGA-E2-A156 | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.99 | LumA | European | TCGA.E2.A156.01A.11R.A12D.07 |
| TCGA-BH-A0HF | 77 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 1.99 | NA | European | TCGA.BH.A0HF.01A.11R.A056.07 |
| TCGA-D8-A1X9 | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 1.99 | LumA | European | TCGA.D8.A1X9.01A.12R.A157.07 |
| TCGA-E9-A54X | 85 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 1.99 | NA | European | TCGA.E9.A54X.01A.11R.A266.07 |
| TCGA-BH-A0W3 | 58 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | equivocal | NA | NA | alive | 1.99 | LumB | European | TCGA.BH.A0W3.01A.11R.A109.07 |
| TCGA-A2-A0EU | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.01 | LumA | European | TCGA.A2.A0EU.01A.22R.A056.07 |
| TCGA-OL-A5RV | 43 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 2.01 | LumA | African | TCGA.OL.A5RV.01A.12R.A28M.07 |
| TCGA-AC-A3QQ | 54 | female | White | Primary solid Tumor | perimenopausal | ILC | positive | positive | positive | NA | NA | alive | 2.01 | LumA | European | TCGA.AC.A3QQ.01A.11R.A22K.07 |
| TCGA-A7-A26F | 55 | female | White | Primary solid Tumor | postmenopausal | \adenocarcinoma with squamous differentiation, metaplastic\"" | negative | negative | equivocal | NA | NA | alive | 2.02 | NA | European | TCGA.A7.A26F.01A.21R.A169.07 |
| TCGA-AR-A0TW | 50 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.02 | LumA | European | TCGA.AR.A0TW.01A.11R.A084.07 |
| TCGA-A2-A4RX | 67 | female | Black or African American | Primary solid Tumor | postmenopausal | metaplastic carcinoma | positive | positive | negative | NA | NA | alive | 2.03 | NA | African | TCGA.A2.A4RX.01A.11R.A266.07 |
| TCGA-BH-A0EI | 51 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.03 | LumA | European | TCGA.BH.A0EI.01A.11R.A115.07 |
| TCGA-GM-A3NY | 72 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.03 | NA | European | TCGA.GM.A3NY.01A.11R.A21T.07 |
| TCGA-BH-A0EB | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.04 | LumA | European | TCGA.BH.A0EB.01A.11R.A034.07 |
| TCGA-BH-A0AU | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.04 | LumB | European | TCGA.BH.A0AU.01A.11R.A12P.07 |
| TCGA-BH-A0AU | 45 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.04 | LumB | European | TCGA.BH.A0AU.11A.11R.A12P.07 |
| TCGA-BH-A0H6 | 82 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.05 | LumA | European | TCGA.BH.A0H6.01A.21R.A056.07 |
| TCGA-C8-A27A | 48 | female | Asian | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.05 | LumB | East Asian | TCGA.C8.A27A.01A.11R.A169.07 |
| TCGA-E9-A24A | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.05 | LumA | European | TCGA.E9.A24A.01A.11R.A169.07 |
| TCGA-E2-A14V | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.05 | Her2 | European | TCGA.E2.A14V.01A.11R.A12D.07 |
| TCGA-A2-A0EX | 46 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.06 | LumA | European | TCGA.A2.A0EX.01A.21R.A034.07 |
| TCGA-OL-A5RY | 52 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | not evaluated | NA | NA | alive | 2.06 | Normal | African | TCGA.OL.A5RY.01A.21R.A28M.07 |
| TCGA-AC-A3YJ | 66 | female | White | Primary solid Tumor | postmenopausal | invasive papillary carcinoma | positive | positive | not available | NA | NA | alive | 2.06 | NA | European | TCGA.AC.A3YJ.01A.11R.A22U.07 |
| TCGA-AQ-A04H | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 2.06 | LumB | European | TCGA.AQ.A04H.01B.11R.A10J.07 |
| TCGA-E9-A1QZ | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.07 | LumA | European | TCGA.E9.A1QZ.01A.21R.A169.07 |
| TCGA-BH-A0BG | 73 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.07 | Basal | European | TCGA.BH.A0BG.01A.11R.A115.07 |
| TCGA-BH-A0W4 | 46 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 2.08 | LumA | European | TCGA.BH.A0W4.01A.11R.A109.07 |
| TCGA-LL-A440 | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.08 | LumA | European | TCGA.LL.A440.01A.11R.A24H.07 |
| TCGA-A8-A07U | 66 | female | not available | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | 2.08 | Basal | European | TCGA.A8.A07U.01A.11R.A034.07 |
| TCGA-EW-A6SB | 62 | female | Black or African American | Primary solid Tumor | not available | IDC | negative | negative | negative | NA | NA | alive | 2.08 | Basal | African | TCGA.EW.A6SB.01A.12R.A32P.07 |
| TCGA-A2-A0D2 | 45 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.08 | Basal | European | TCGA.A2.A0D2.01A.21R.A034.07 |
| TCGA-A8-A09Q | 83 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.08 | LumB | European | TCGA.A8.A09Q.01A.11R.A00Z.07 |
| TCGA-LL-A50Y | 84 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.09 | LumA | European | TCGA.LL.A50Y.01A.11R.A266.07 |
| TCGA-E2-A107 | 54 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | equivocal | NA | NA | alive | 2.09 | LumA | European | TCGA.E2.A107.01A.11R.A10J.07 |
| TCGA-A2-A04Y | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.09 | LumB | European | TCGA.A2.A04Y.01A.21R.A034.07 |
| TCGA-A7-A13F | 44 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.09 | LumB | European | TCGA.A7.A13F.01A.11R.A12P.07 |
| TCGA-A7-A13F | 44 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.09 | LumB | European | TCGA.A7.A13F.11A.42R.A12P.07 |
| TCGA-A2-A0D4 | 37 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.1 | LumB | African_admix | TCGA.A2.A0D4.01A.11R.A00Z.07 |
| TCGA-D8-A73X | 53 | female | White | Primary solid Tumor | postmenopausal | tubular carcinoma | positive | positive | negative | NA | NA | alive | 2.1 | NA | European | TCGA.D8.A73X.01A.11R.A32P.07 |
| TCGA-A2-A0YD | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 2.11 | LumA | European | TCGA.A2.A0YD.01A.11R.A109.07 |
| TCGA-E2-A150 | 48 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.12 | Basal | European | TCGA.E2.A150.01A.11R.A12D.07 |
| TCGA-AO-A0J6 | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.12 | Basal | European | TCGA.AO.A0J6.01A.11R.A034.07 |
| TCGA-BH-A0AY | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.13 | LumA | European | TCGA.BH.A0AY.01A.21R.A00Z.07 |
| TCGA-BH-A0AY | 62 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.13 | LumA | European | TCGA.BH.A0AY.11A.23R.A089.07 |
| TCGA-D8-A1X8 | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | Indeterminate | negative | NA | NA | alive | 2.14 | LumA | European | TCGA.D8.A1X8.01A.11R.A14M.07 |
| TCGA-E9-A5UO | 41 | female | White | Primary solid Tumor | premenopausal | mucinous carcinoma | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.15 | NA | European | TCGA.E9.A5UO.01A.11R.A28M.07 |
| TCGA-A2-A0D1 | 76 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.15 | Her2 | European | TCGA.A2.A0D1.01A.11R.A034.07 |
| TCGA-EW-A2FV | 39 | female | White | Primary solid Tumor | premenopausal | invasive micropapillary ductal carcinoma | positive | positive | negative | NA | NA | alive | 2.16 | NA | European | TCGA.EW.A2FV.01A.11R.A17B.07 |
| TCGA-EW-A1OV | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.16 | Her2 | European | TCGA.EW.A1OV.01A.11R.A144.07 |
| TCGA-A8-A06Y | 66 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | not available | not available | alive | 2.17 | LumA | European | TCGA.A8.A06Y.01A.21R.A00Z.07 |
| TCGA-OL-A66N | 59 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | not evaluated | NA | NA | alive | 2.17 | LumA | European | TCGA.OL.A66N.01A.12R.A31O.07 |
| TCGA-E9-A3HO | 49 | female | White | Primary solid Tumor | premenopausal | ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.17 | LumB | European | TCGA.E9.A3HO.01A.11R.A213.07 |
| TCGA-BH-A202 | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.18 | LumB | European | TCGA.BH.A202.01A.11R.A14M.07 |
| TCGA-OL-A5RW | 40 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 2.18 | Basal | African | TCGA.OL.A5RW.01A.11R.A28M.07 |
| TCGA-AO-A0JG | 49 | female | White | Primary solid Tumor | postmenopausal | ductal/mucinous | positive | positive | negative | NA | NA | alive | 2.18 | NA | European | TCGA.AO.A0JG.01A.31R.A084.07 |
| TCGA-E9-A5UP | 63 | female | White | Primary solid Tumor | postmenopausal | infiltrating papillary adenocarcinoma | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.2 | NA | European | TCGA.E9.A5UP.01A.11R.A28M.07 |
| TCGA-A2-A3KD | 47 | female | White | Primary solid Tumor | premenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 2.2 | NA | European | TCGA.A2.A3KD.01A.12R.A213.07 |
| TCGA-BH-A0HB | 55 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.21 | LumA | European | TCGA.BH.A0HB.01A.11R.A056.07 |
| TCGA-A2-A0ET | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.21 | LumA | European | TCGA.A2.A0ET.01A.31R.A034.07 |
| TCGA-E2-A574 | 44 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 2.21 | Basal | African_admix | TCGA.E2.A574.01A.11R.A29R.07 |
| TCGA-E9-A5FK | 60 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.22 | LumA | European | TCGA.E9.A5FK.01A.11R.A27Q.07 |
| TCGA-OL-A66H | 74 | female | Black or African American | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | not evaluated | NA | NA | alive | 2.22 | NA | African_admix | TCGA.OL.A66H.01A.11R.A29R.07 |
| TCGA-AQ-A04J | 45 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.24 | Basal | European | TCGA.AQ.A04J.01A.02R.A034.07 |
| TCGA-A2-A4S1 | 66 | female | White | Primary solid Tumor | postmenopausal | metaplastic carcinoma | positive | negative | negative | NA | NA | alive | 2.25 | Basal | European | TCGA.A2.A4S1.01A.21R.A266.07 |
| TCGA-A8-A0A9 | 80 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.25 | LumA | European | TCGA.A8.A0A9.01A.11R.A00Z.07 |
| TCGA-E2-A152 | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | metastasis | liver>breast recur | alive | 2.26 | Her2 | European | TCGA.E2.A152.01A.11R.A12D.07 |
| TCGA-BH-A0BQ | 39 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | locoregional recurrence | dermis|epidermis | alive | 2.26 | LumA | European | TCGA.BH.A0BQ.01A.21R.A115.07 |
| TCGA-BH-A0BQ | 39 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | positive | locoregional recurrence | dermis|epidermis | alive | 2.26 | LumA | European | TCGA.BH.A0BQ.11A.33R.A115.07 |
| TCGA-E9-A247 | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.27 | LumA | European | TCGA.E9.A247.01A.11R.A169.07 |
| TCGA-BH-A0HX | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.27 | LumA | European | TCGA.BH.A0HX.01A.21R.A056.07 |
| TCGA-E2-A572 | 72 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.28 | NA | African_admix | TCGA.E2.A572.01A.13R.A31O.07 |
| TCGA-E2-A14S | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.28 | NA | European | TCGA.E2.A14S.01A.11R.A12D.07 |
| TCGA-E2-A1L7 | 40 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | new primary | contralateral | alive | 2.28 | LumB | European | TCGA.E2.A1L7.01A.11R.A144.07 |
| TCGA-E2-A1L7 | 40 | female | White | Solid Tissue Normal | premenopausal | IDC | negative | negative | negative | new primary | contralateral | alive | 2.28 | LumB | European | TCGA.E2.A1L7.11A.33R.A144.07 |
| TCGA-E2-A108 | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.29 | Normal | European | TCGA.E2.A108.01A.13R.A10J.07 |
| TCGA-E2-A14U | 74 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.29 | NA | European_admix | TCGA.E2.A14U.01A.11R.A22K.07 |
| TCGA-E9-A1ND | 75 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.29 | Basal | European | TCGA.E9.A1ND.01A.11R.A144.07 |
| TCGA-E9-A1ND | 75 | female | White | Solid Tissue Normal | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.29 | Basal | European | TCGA.E9.A1ND.11A.43R.A144.07 |
| TCGA-D8-A1XA | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.3 | LumA | European | TCGA.D8.A1XA.01A.11R.A14D.07 |
| TCGA-OL-A5RU | 63 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 2.3 | LumA | African | TCGA.OL.A5RU.01A.11R.A28M.07 |
| TCGA-AR-A2LR | 49 | female | White | Primary solid Tumor | postmenopausal | metaplastic carcinoma | negative | negative | negative | NA | NA | alive | 2.32 | NA | European | TCGA.AR.A2LR.01A.12R.A18M.07 |
| TCGA-OL-A6VR | 48 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | positive | negative | NA | NA | alive | 2.32 | LumA | African_admix | TCGA.OL.A6VR.01A.32R.A33J.07 |
| TCGA-LQ-A4E4 | 73 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | metastasis | bone | alive | 2.32 | NA | European | TCGA.LQ.A4E4.01A.11R.A266.07 |
| TCGA-E2-A1II | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | positive | negative | NA | NA | alive | 2.33 | Basal | European | TCGA.E2.A1II.01A.11R.A144.07 |
| TCGA-A1-A0SO | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 2.33 | Basal | European | TCGA.A1.A0SO.01A.22R.A084.07 |
| TCGA-A8-A07Z | 85 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.34 | LumA | European | TCGA.A8.A07Z.01A.11R.A00Z.07 |
| TCGA-E2-A10C | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.34 | LumB | European | TCGA.E2.A10C.01A.21R.A10J.07 |
| TCGA-BH-A0HA | 31 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | not available | NA | NA | alive | 2.34 | LumA | European | TCGA.BH.A0HA.01A.11R.A12P.07 |
| TCGA-BH-A0HA | 31 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | not available | NA | NA | alive | 2.34 | LumA | European | TCGA.BH.A0HA.11A.31R.A12P.07 |
| TCGA-BH-A201 | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.34 | LumA | European | TCGA.BH.A201.01A.11R.A14M.07 |
| TCGA-OL-A6VO | 43 | female | Black or African American | Primary solid Tumor | unknown | IDC | negative | negative | negative | NA | NA | alive | 2.35 | Basal | African_admix | TCGA.OL.A6VO.01A.12R.A33J.07 |
| TCGA-A2-A3Y0 | 57 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 2.35 | Basal | African | TCGA.A2.A3Y0.01A.11R.A239.07 |
| TCGA-E9-A1R0 | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.35 | LumA | European | TCGA.E9.A1R0.01A.22R.A16F.07 |
| TCGA-AO-A12H | 69 | female | Black or African American | Primary solid Tumor | premenopausal | mucinous/papillary | positive | positive | negative | NA | NA | alive | 2.36 | NA | African | TCGA.AO.A12H.01A.11R.A115.07 |
| TCGA-E2-A10E | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.37 | NA | European | TCGA.E2.A10E.01A.21R.A10J.07 |
| TCGA-E2-A1IJ | 57 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.37 | LumA | European | TCGA.E2.A1IJ.01A.11R.A144.07 |
| TCGA-BH-A0AZ | 47 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.37 | LumA | European | TCGA.BH.A0AZ.01A.21R.A12P.07 |
| TCGA-BH-A0AZ | 47 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.37 | LumA | European | TCGA.BH.A0AZ.11A.22R.A12P.07 |
| TCGA-E2-A1B6 | 44 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 2.37 | Basal | European | TCGA.E2.A1B6.01A.31R.A12P.07 |
| TCGA-BH-A0HY | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | alive | 2.38 | LumB | European | TCGA.BH.A0HY.01A.11R.A056.07 |
| TCGA-E2-A14Y | 35 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.38 | Basal | European | TCGA.E2.A14Y.01A.21R.A12D.07 |
| TCGA-A2-A0D3 | 42 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.4 | LumA | European | TCGA.A2.A0D3.01A.11R.A115.07 |
| TCGA-EW-A1PG | 53 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.4 | Normal | European | TCGA.EW.A1PG.01A.11R.A144.07 |
| TCGA-E2-A10F | 47 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.4 | LumA | European | TCGA.E2.A10F.01A.11R.A10J.07 |
| TCGA-OL-A5RX | 51 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 2.4 | LumA | African | TCGA.OL.A5RX.01A.11R.A28M.07 |
| TCGA-A8-A08C | 65 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.41 | NA | European | TCGA.A8.A08C.01A.11R.A00Z.07 |
| TCGA-WT-AB44 | 77 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.42 | LumA | European | TCGA.WT.AB44.01A.11R.A41B.07 |
| TCGA-AO-A03V | 41 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.43 | LumA | European | TCGA.AO.A03V.01A.11R.A115.07 |
| TCGA-LL-A442 | 56 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.43 | NA | African | TCGA.LL.A442.01A.11R.A24H.07 |
| TCGA-AC-A4ZE | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 2.44 | LumA | European | TCGA.AC.A4ZE.01A.11R.A41B.07 |
| TCGA-E2-A14T | 52 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.44 | LumA | European | TCGA.E2.A14T.01A.11R.A115.07 |
| TCGA-AR-A2LQ | 59 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.45 | Normal | European | TCGA.AR.A2LQ.01A.22R.A18M.07 |
| TCGA-AR-A0TV | 66 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.48 | LumB | European | TCGA.AR.A0TV.01A.21R.A084.07 |
| TCGA-EW-A1OY | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.49 | LumB | European | TCGA.EW.A1OY.01A.11R.A144.07 |
| TCGA-EW-A1OX | 43 | female | White | Primary solid Tumor | premenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | alive | 2.49 | NA | African_admix | TCGA.EW.A1OX.01A.11R.A144.07 |
| TCGA-A8-A09K | 68 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.5 | NA | European | TCGA.A8.A09K.01A.11R.A00Z.07 |
| TCGA-BH-A0DI | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.5 | LumA | European | TCGA.BH.A0DI.01A.21R.A12P.07 |
| TCGA-E9-A22E | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.5 | LumB | European | TCGA.E9.A22E.01A.11R.A157.07 |
| TCGA-E9-A3QA | 33 | female | White | Primary solid Tumor | premenopausal | medullary carcinoma | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.51 | Basal | European | TCGA.E9.A3QA.01A.61R.A22K.07 |
| TCGA-EW-A1P1 | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | metastasis | lung | alive | 2.52 | Normal | European | TCGA.EW.A1P1.01A.31R.A14D.07 |
| TCGA-BH-A0GY | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.53 | LumA | European | TCGA.BH.A0GY.01A.11R.A056.07 |
| TCGA-E9-A3X8 | 48 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | alive | 2.54 | LumA | European | TCGA.E9.A3X8.01A.31R.A22U.07 |
| TCGA-A7-A0CJ | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.55 | LumB | European | TCGA.A7.A0CJ.01A.21R.A00Z.07 |
| TCGA-E2-A570 | 47 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 2.55 | LumA | African | TCGA.E2.A570.01A.11R.A29R.07 |
| TCGA-A2-A1FX | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 2.56 | LumB | European | TCGA.A2.A1FX.01A.11R.A13Q.07 |
| TCGA-AR-A2LO | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 2.56 | LumA | European | TCGA.AR.A2LO.01A.31R.A18M.07 |
| TCGA-EW-A1OZ | 56 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 2.58 | LumB | African | TCGA.EW.A1OZ.01A.11R.A144.07 |
| TCGA-A8-A092 | 48 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.58 | LumB | European | TCGA.A8.A092.01A.11R.A00Z.07 |
| TCGA-A8-A08O | 45 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | not available | not available | alive | 2.58 | LumA | European | TCGA.A8.A08O.01A.21R.A056.07 |
| TCGA-A8-A08P | 70 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.58 | LumB | European | TCGA.A8.A08P.01A.11R.A00Z.07 |
| TCGA-A8-A09E | 73 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 2.58 | NA | European | TCGA.A8.A09E.01A.11R.A00Z.07 |
| TCGA-BH-A0EE | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.58 | Her2 | European | TCGA.BH.A0EE.01A.11R.A034.07 |
| TCGA-OL-A66L | 71 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 2.59 | LumA | African | TCGA.OL.A66L.01A.12R.A31O.07 |
| TCGA-BH-A0DE | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.6 | LumA | European | TCGA.BH.A0DE.01A.11R.A115.07 |
| TCGA-EW-A6SC | 60 | female | Black or African American | Primary solid Tumor | not available | ILC | positive | positive | negative | NA | NA | alive | 2.61 | LumA | African | TCGA.EW.A6SC.01A.12R.A32P.07 |
| TCGA-A7-A26E | 71 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.61 | LumA | European | TCGA.A7.A26E.01A.11R.A169.07 |
| TCGA-E2-A1IF | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.62 | LumA | European | TCGA.E2.A1IF.01A.11R.A144.07 |
| TCGA-A2-A0YM | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 2.64 | Basal | European | TCGA.A2.A0YM.01A.11R.A109.07 |
| TCGA-A7-A13D | 46 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | positive | equivocal | NA | NA | alive | 2.64 | Basal | African | TCGA.A7.A13D.01A.13R.A12P.07 |
| TCGA-A2-A0EV | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.65 | LumA | European | TCGA.A2.A0EV.01A.11R.A034.07 |
| TCGA-E2-A14X | 55 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.66 | Basal | African_admix | TCGA.E2.A14X.01A.11R.A115.07 |
| TCGA-E2-A1LB | 41 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.66 | Her2 | African | TCGA.E2.A1LB.01A.11R.A144.07 |
| TCGA-E2-A1LB | 41 | female | Black or African American | Solid Tissue Normal | premenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.66 | Her2 | African | TCGA.E2.A1LB.11A.22R.A144.07 |
| TCGA-A2-A3XZ | 46 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | positive | NA | NA | alive | 2.66 | Her2 | African | TCGA.A2.A3XZ.01A.42R.A239.07 |
| TCGA-OL-A5D8 | 40 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 2.66 | LumA | African | TCGA.OL.A5D8.01A.11R.A27Q.07 |
| TCGA-BH-A0BC | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.67 | LumA | European | TCGA.BH.A0BC.01A.22R.A084.07 |
| TCGA-BH-A0BC | 60 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.67 | LumA | European | TCGA.BH.A0BC.11A.22R.A089.07 |
| TCGA-E2-A14Q | 50 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.67 | LumA | European | TCGA.E2.A14Q.01A.11R.A12D.07 |
| TCGA-E2-A14W | 78 | male | White | Primary solid Tumor | not applicable | IDC | positive | positive | not evaluated | NA | NA | alive | 2.67 | NA | European | TCGA.E2.A14W.01A.11R.A12D.07 |
| TCGA-A8-A07L | 58 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.67 | LumB | European | TCGA.A8.A07L.01A.11R.A00Z.07 |
| TCGA-E9-A1RA | 48 | female | White | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 2.67 | LumA | European | TCGA.E9.A1RA.01A.11R.A14D.07 |
| TCGA-GM-A3XG | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.69 | NA | European | TCGA.GM.A3XG.01A.31R.A24H.07 |
| TCGA-E2-A1IE | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | metastasis | liver | alive | 2.69 | LumA | European | TCGA.E2.A1IE.01A.11R.A13Q.07 |
| TCGA-E2-A1B5 | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.69 | LumA | European | TCGA.E2.A1B5.01A.21R.A12P.07 |
| TCGA-AC-A3BB | 46 | female | Black or African American | Primary solid Tumor | not available | ILC | positive | positive | negative | NA | NA | alive | 2.7 | NA | African | TCGA.AC.A3BB.01A.21R.A19W.07 |
| TCGA-EW-A1P3 | 48 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.7 | LumA | European | TCGA.EW.A1P3.01A.11R.A144.07 |
| TCGA-AQ-A1H3 | 49 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.71 | LumA | European | TCGA.AQ.A1H3.01A.31R.A13Q.07 |
| TCGA-A2-A0YC | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | metastasis | bone | alive | 2.71 | LumA | European | TCGA.A2.A0YC.01A.11R.A109.07 |
| TCGA-AR-A24W | 55 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.71 | LumA | European | TCGA.AR.A24W.01A.11R.A169.07 |
| TCGA-A2-A3XV | 46 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 2.73 | Her2 | African_admix | TCGA.A2.A3XV.01A.21R.A239.07 |
| TCGA-LL-A441 | 62 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 2.73 | NA | African | TCGA.LL.A441.01A.11R.A24H.07 |
| TCGA-AO-A0J2 | 41 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 2.73 | Her2 | European | TCGA.AO.A0J2.01A.11R.A034.07 |
| TCGA-AR-A2LN | 65 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 2.73 | LumA | European | TCGA.AR.A2LN.01A.21R.A18M.07 |
| TCGA-E2-A1IG | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.73 | LumA | European | TCGA.E2.A1IG.01A.11R.A144.07 |
| TCGA-E2-A1IG | 45 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 2.73 | LumA | European | TCGA.E2.A1IG.11A.22R.A144.07 |
| TCGA-EW-A6SD | 32 | female | Black or African American | Primary solid Tumor | not available | IDC | negative | negative | not evaluated | NA | NA | alive | 2.77 | Her2 | African | TCGA.EW.A6SD.01A.12R.A33J.07 |
| TCGA-BH-A0HQ | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.07 | LumA | European | TCGA.BH.A0HQ.01A.11R.A034.07 |
| TCGA-A8-A085 | 44 | male | not available | Primary solid Tumor | not applicable | IDC | positive | positive | negative | NA | NA | alive | 3.08 | NA | European | TCGA.A8.A085.01A.11R.A00Z.07 |
| TCGA-BH-A0BA | 51 | female | White | Primary solid Tumor | premenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 3.1 | NA | European | TCGA.BH.A0BA.01A.11R.A056.07 |
| TCGA-BH-A0BA | 51 | female | White | Solid Tissue Normal | premenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 3.1 | NA | European | TCGA.BH.A0BA.11A.22R.A19E.07 |
| TCGA-BH-A0B1 | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.14 | NA | European | TCGA.BH.A0B1.01A.12R.A056.07 |
| TCGA-AR-A1AS | 54 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.15 | LumA | South Asian | TCGA.AR.A1AS.01A.11R.A12P.07 |
| TCGA-BH-A0DH | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.16 | LumA | European | TCGA.BH.A0DH.01A.11R.A084.07 |
| TCGA-BH-A0DH | 63 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.16 | LumA | European | TCGA.BH.A0DH.11A.31R.A089.07 |
| TCGA-A8-A0AD | 83 | female | not available | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 3.17 | NA | European | TCGA.A8.A0AD.01A.11R.A056.07 |
| TCGA-BH-A0B4 | 65 | male | White | Primary solid Tumor | not applicable | IDC | positive | positive | equivocal | NA | NA | alive | 3.26 | NA | European | TCGA.BH.A0B4.01A.11R.A00Z.07 |
| TCGA-A1-A0SN | 50 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 3.27 | LumB | European | TCGA.A1.A0SN.01A.11R.A144.07 |
| TCGA-BH-A0B3 | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 3.29 | Basal | European | TCGA.BH.A0B3.01A.11R.A056.07 |
| TCGA-BH-A0B3 | 53 | female | White | Solid Tissue Normal | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 3.29 | Basal | European | TCGA.BH.A0B3.11B.21R.A089.07 |
| TCGA-EW-A1IX | 48 | female | Asian | Primary solid Tumor | perimenopausal | invasive tubulolobular carcinoma | positive | positive | negative | NA | NA | alive | 3.31 | NA | East Asian | TCGA.EW.A1IX.01A.12R.A144.07 |
| TCGA-A8-A08Z | 76 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.33 | LumA | European | TCGA.A8.A08Z.01A.21R.A00Z.07 |
| TCGA-E9-A1RC | 56 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 3.35 | NA | European | TCGA.E9.A1RC.01A.11R.A157.07 |
| TCGA-E9-A1RC | 56 | female | White | Solid Tissue Normal | postmenopausal | IDC/ILC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 3.35 | NA | European | TCGA.E9.A1RC.11A.33R.A157.07 |
| TCGA-BH-A0H9 | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 3.41 | LumA | European | TCGA.BH.A0H9.01A.11R.A056.07 |
| TCGA-BH-A0H9 | 69 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 3.41 | LumA | European | TCGA.BH.A0H9.11A.22R.A466.07 |
| TCGA-EW-A1P0 | 55 | female | White | Primary solid Tumor | postmenopausal | IDC/mucinous | positive | negative | negative | metastasis | mediastinal lymph node | alive | 3.43 | NA | European | TCGA.EW.A1P0.01A.11R.A144.07 |
| TCGA-BH-A0C0 | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 3.48 | LumB | European | TCGA.BH.A0C0.01A.21R.A056.07 |
| TCGA-BH-A0C0 | 62 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 3.48 | LumB | European | TCGA.BH.A0C0.11A.21R.A089.07 |
| TCGA-A8-A095 | 45 | female | not available | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.5 | LumB | European | TCGA.A8.A095.01A.11R.A00Z.07 |
| TCGA-A8-A07B | 69 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 3.58 | LumA | European | TCGA.A8.A07B.01A.11R.A00Z.07 |
| TCGA-A8-A08X | 43 | female | not available | Primary solid Tumor | premenopausal | IDC | negative | negative | positive | not available | not available | alive | 3.58 | Her2 | European | TCGA.A8.A08X.01A.21R.A00Z.07 |
| TCGA-E2-A105 | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 3.58 | LumA | European | TCGA.E2.A105.01A.11R.A10J.07 |
| TCGA-E2-A1LL | 73 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | metastasis | liver | alive | 3.58 | Basal | African_admix | TCGA.E2.A1LL.01A.11R.A144.07 |
| TCGA-A1-A0SE | 56 | female | White | Primary solid Tumor | premenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 3.62 | NA | European | TCGA.A1.A0SE.01A.11R.A084.07 |
| TCGA-B6-A1KC | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 3.63 | LumB | European | TCGA.B6.A1KC.01B.11R.A157.07 |
| TCGA-A2-A0SY | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 3.69 | LumA | European | TCGA.A2.A0SY.01A.31R.A084.07 |
| TCGA-E2-A14O | 76 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 3.72 | LumB | European | TCGA.E2.A14O.01A.31R.A115.07 |
| TCGA-BH-A0E7 | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 3.73 | LumA | European | TCGA.BH.A0E7.01A.11R.A034.07 |
| TCGA-A8-A09I | 84 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 3.75 | LumB | European | TCGA.A8.A09I.01A.22R.A034.07 |
| TCGA-E2-A109 | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 3.88 | LumB | European | TCGA.E2.A109.01A.11R.A10J.07 |
| TCGA-E2-A14N | 37 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 3.93 | Basal | European | TCGA.E2.A14N.01A.31R.A137.07 |
| TCGA-A1-A0SH | 39 | female | White | Primary solid Tumor | premenopausal | IDC | negative | positive | equivocal | NA | NA | alive | 3.93 | LumA | European | TCGA.A1.A0SH.01A.11R.A084.07 |
| TCGA-3C-AALK | 52 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | positive | positive | NA | NA | alive | 3.96 | LumA | African | TCGA.3C.AALK.01A.11R.A41B.07 |
| TCGA-A1-A0SF | 54 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.01 | LumA | European | TCGA.A1.A0SF.01A.11R.A144.07 |
| TCGA-5L-AAT1 | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | metastasis | bone | alive | 4.03 | NA | European | TCGA.5L.AAT1.01A.12R.A41B.07 |
| TCGA-3C-AALJ | 62 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | Indeterminate | NA | NA | alive | 4.04 | LumB | African_admix | TCGA.3C.AALJ.01A.31R.A41B.07 |
| TCGA-C8-A12Y | 44 | female | Asian | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 4.04 | LumA | East Asian | TCGA.C8.A12Y.01A.11R.A12D.07 |
| TCGA-BH-A0BV | 78 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.16 | LumA | European | TCGA.BH.A0BV.01A.11R.A00Z.07 |
| TCGA-BH-A0BV | 78 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.16 | LumA | European | TCGA.BH.A0BV.11A.31R.A089.07 |
| TCGA-AO-A0JI | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 4.18 | LumA | European | TCGA.AO.A0JI.01A.21R.A056.07 |
| TCGA-A2-A0SX | 48 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 4.2 | Basal | European | TCGA.A2.A0SX.01A.12R.A084.07 |
| TCGA-AO-A0JB | 50 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.22 | Normal | European | TCGA.AO.A0JB.01A.11R.A32Y.07 |
| TCGA-AO-A0JC | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.24 | LumA | European | TCGA.AO.A0JC.01A.11R.A056.07 |
| TCGA-AR-A24K | 46 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 4.24 | LumB | European | TCGA.AR.A24K.01A.11R.A169.07 |
| TCGA-BH-A0HW | 62 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 4.27 | LumB | East Asian | TCGA.BH.A0HW.01A.11R.A034.07 |
| TCGA-BH-A0B8 | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 4.3 | NA | European | TCGA.BH.A0B8.01A.21R.A056.07 |
| TCGA-BH-A0B8 | 64 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 4.3 | NA | European | TCGA.BH.A0B8.11A.41R.A089.07 |
| TCGA-BH-A0B9 | 44 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 4.3 | Basal | European | TCGA.BH.A0B9.01A.11R.A056.07 |
| TCGA-A2-A259 | 70 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.37 | LumA | African_admix | TCGA.A2.A259.01A.11R.A16F.07 |
| TCGA-EW-A2FS | 41 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 4.39 | LumA | African | TCGA.EW.A2FS.01A.11R.A17B.07 |
| TCGA-WT-AB41 | 55 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 4.41 | LumA | African | TCGA.WT.AB41.01A.11R.A41B.07 |
| TCGA-AO-A0J9 | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | metastasis | bone | alive | 4.42 | LumA | European | TCGA.AO.A0J9.01A.11R.A034.07 |
| TCGA-A8-A06T | 75 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 4.42 | LumA | European | TCGA.A8.A06T.01A.11R.A00Z.07 |
| TCGA-A2-A0CZ | 46 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.42 | NA | European | TCGA.A2.A0CZ.01A.11R.A034.07 |
| TCGA-BH-A0H5 | 45 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not available | NA | NA | alive | 4.44 | LumA | European | TCGA.BH.A0H5.01A.21R.A115.07 |
| TCGA-BH-A0H5 | 45 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | not available | NA | NA | alive | 4.44 | LumA | European | TCGA.BH.A0H5.11A.62R.A115.07 |
| TCGA-E2-A1B0 | 50 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 4.47 | Her2 | European | TCGA.E2.A1B0.01A.11R.A12P.07 |
| TCGA-AO-A12G | 75 | female | White | Primary solid Tumor | postmenopausal | pleomorphic ILC | positive | positive | positive | NA | NA | alive | 4.49 | NA | European | TCGA.AO.A12G.01A.11R.A10J.07 |
| TCGA-A8-A076 | 66 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 4.5 | LumB | European | TCGA.A8.A076.01A.21R.A00Z.07 |
| TCGA-E2-A1L6 | 44 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.51 | LumA | European | TCGA.E2.A1L6.01A.11R.A13Q.07 |
| TCGA-A2-A0SU | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.55 | LumA | European | TCGA.A2.A0SU.01A.11R.A084.07 |
| TCGA-A2-A0CY | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 4.58 | NA | European | TCGA.A2.A0CY.01A.12R.A034.07 |
| TCGA-EW-A2FR | 59 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 4.58 | Her2 | South Asian | TCGA.EW.A2FR.01A.11R.A21T.07 |
| TCGA-AO-A0JL | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 4.61 | NA | European | TCGA.AO.A0JL.01A.11R.A056.07 |
| TCGA-A2-A04X | 34 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 4.62 | Her2 | European | TCGA.A2.A04X.01A.21R.A034.07 |
| TCGA-A2-A3XW | 42 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 4.69 | Normal | African_admix | TCGA.A2.A3XW.01A.11R.A239.07 |
| TCGA-A2-A0CX | 52 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | positive | NA | NA | alive | 4.73 | Her2 | European | TCGA.A2.A0CX.01A.21R.A00Z.07 |
| TCGA-OL-A5D7 | 70 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 4.87 | Basal | African_admix | TCGA.OL.A5D7.01A.11R.A27Q.07 |
| TCGA-OL-A5DA | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 4.88 | LumA | European | TCGA.OL.A5DA.01A.11R.A27Q.07 |
| TCGA-BH-A0AV | 52 | female | Black or African American | Primary solid Tumor | not available | IDC | negative | negative | not available | NA | NA | alive | 4.98 | Basal | African_admix | TCGA.BH.A0AV.01A.31R.A115.07 |
| TCGA-AO-A12F | 36 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 5.04 | Basal | European | TCGA.AO.A12F.01A.11R.A115.07 |
| TCGA-AC-A2FG | 79 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | not evaluated | NA | NA | alive | 5.07 | LumA | European | TCGA.AC.A2FG.01A.11R.A17B.07 |
| TCGA-AR-A1AV | 68 | male | White | Primary solid Tumor | not applicable | IDC | positive | positive | negative | NA | NA | alive | 5.1 | NA | European | TCGA.AR.A1AV.01A.21R.A12P.07 |
| TCGA-AO-A03M | 29 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 5.11 | LumA | European | TCGA.AO.A03M.01B.11R.A10J.07 |
| TCGA-BH-A0BM | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 5.14 | LumA | European | TCGA.BH.A0BM.01A.11R.A056.07 |
| TCGA-BH-A0BM | 54 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 5.14 | LumA | European | TCGA.BH.A0BM.11A.12R.A089.07 |
| TCGA-AO-A1KQ | 84 | male | White | Primary solid Tumor | not applicable | IDC | positive | positive | negative | NA | NA | alive | 5.15 | NA | European | TCGA.AO.A1KQ.01A.11R.A13Q.07 |
| TCGA-AO-A0JJ | 54 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 5.17 | LumA | European | TCGA.AO.A0JJ.01A.11R.A056.07 |
| TCGA-BH-A0H3 | 46 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | not available | NA | NA | alive | 5.28 | LumA | European | TCGA.BH.A0H3.01A.11R.A12P.07 |
| TCGA-AR-A2LM | 49 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 5.3 | LumA | European | TCGA.AR.A2LM.01A.11R.A180.07 |
| TCGA-PE-A5DD | 64 | female | Asian | Primary solid Tumor | postmenopausal | ILC | positive | negative | positive | NA | NA | alive | 5.35 | LumA | East Asian_admix | TCGA.PE.A5DD.01A.12R.A27Q.07 |
| TCGA-AR-A0TX | 64 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 5.4 | Her2 | European | TCGA.AR.A0TX.01A.11R.A084.07 |
| TCGA-OL-A66J | 80 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 5.46 | LumA | European | TCGA.OL.A66J.01A.11R.A29R.07 |
| TCGA-GM-A3XN | 44 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 5.53 | NA | European | TCGA.GM.A3XN.01A.12R.A22U.07 |
| TCGA-AO-A03N | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | locoregional disease | NA | alive | 5.56 | LumB | European | TCGA.AO.A03N.01B.11R.A10J.07 |
| TCGA-V7-A7HQ | 75 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 5.57 | LumA | African_admix | TCGA.V7.A7HQ.01A.11R.A33J.07 |
| TCGA-BH-A0DV | 54 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 5.65 | LumA | European | TCGA.BH.A0DV.01A.21R.A12P.07 |
| TCGA-BH-A0DV | 54 | female | White | Solid Tissue Normal | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 5.65 | LumA | European | TCGA.BH.A0DV.11A.22R.A12P.07 |
| TCGA-B6-A408 | 55 | female | Black or African American | Primary solid Tumor | unknown | IDC/ILC | positive | positive | equivocal | NA | NA | alive | 5.67 | NA | African | TCGA.B6.A408.01A.12R.A24H.07 |
| TCGA-B6-A0RG | 26 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | NA | NA | alive | 5.7 | LumA | European | TCGA.B6.A0RG.01A.11R.A056.07 |
| TCGA-AO-A03R | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 5.72 | Normal | European | TCGA.AO.A03R.01A.21R.A034.07 |
| TCGA-GM-A3XL | 49 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 5.77 | Basal | African | TCGA.GM.A3XL.01A.11R.A22U.07 |
| TCGA-AO-A03T | 42 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 5.82 | Normal | European | TCGA.AO.A03T.01A.21R.A034.07 |
| TCGA-BH-A0B5 | 40 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 5.85 | LumA | European | TCGA.BH.A0B5.01A.11R.A12P.07 |
| TCGA-BH-A0B5 | 40 | female | White | Solid Tissue Normal | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 5.85 | LumA | European | TCGA.BH.A0B5.11A.23R.A12P.07 |
| TCGA-AO-A12E | 51 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 5.86 | LumA | European | TCGA.AO.A12E.01A.11R.A10J.07 |
| TCGA-GM-A2DF | 53 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 5.9 | Basal | African | TCGA.GM.A2DF.01A.11R.A180.07 |
| TCGA-BH-A0DX | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 5.9 | LumA | European | TCGA.BH.A0DX.01A.11R.A115.07 |
| TCGA-AR-A255 | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 5.92 | LumA | European | TCGA.AR.A255.01A.11R.A169.07 |
| TCGA-B6-A40C | 51 | female | White | Primary solid Tumor | unknown | ILC | positive | positive | negative | NA | NA | alive | 5.92 | LumA | European | TCGA.B6.A40C.01A.11R.A239.07 |
| TCGA-A2-A0ES | 52 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 6.0 | LumA | European | TCGA.A2.A0ES.01A.11R.A115.07 |
| TCGA-AO-A0JD | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.0 | LumB | European | TCGA.AO.A0JD.01A.11R.A056.07 |
| TCGA-GM-A4E0 | 67 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | alive | 6.0 | LumA | European | TCGA.GM.A4E0.01A.12R.A266.07 |
| TCGA-GM-A2DH | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 6.0 | Her2 | European | TCGA.GM.A2DH.01A.11R.A180.07 |
| TCGA-BH-A0BO | 54 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.02 | LumA | European | TCGA.BH.A0BO.01A.23R.A12D.07 |
| TCGA-AC-A2BK | 78 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 6.08 | Basal | African | TCGA.AC.A2BK.01A.11R.A21T.07 |
| TCGA-B6-A1KI | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 6.12 | LumA | European | TCGA.B6.A1KI.01A.11R.A14M.07 |
| TCGA-E2-A1L8 | 52 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 6.13 | LumA | African | TCGA.E2.A1L8.01A.11R.A13Q.07 |
| TCGA-A2-A04T | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 6.15 | Basal | European | TCGA.A2.A04T.01A.21R.A034.07 |
| TCGA-AC-A2FO | 65 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | 6.17 | LumA | European | TCGA.AC.A2FO.01A.11R.A180.07 |
| TCGA-BH-A0BZ | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.17 | LumB | European | TCGA.BH.A0BZ.01A.31R.A12P.07 |
| TCGA-BH-A0BZ | 59 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.17 | LumB | European | TCGA.BH.A0BZ.11A.61R.A12P.07 |
| TCGA-A2-A0ER | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 6.2 | LumA | European | TCGA.A2.A0ER.01A.21R.A034.07 |
| TCGA-BH-A0BL | 35 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 6.24 | Basal | European | TCGA.BH.A0BL.01A.11R.A115.07 |
| TCGA-B6-A402 | 47 | female | Black or African American | Primary solid Tumor | unknown | IDC | negative | negative | negative | locoregional recurrence | breast>lymph node | alive | 6.25 | NA | African | TCGA.B6.A402.01A.11R.A239.07 |
| TCGA-GM-A2DD | 53 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 6.25 | Normal | European | TCGA.GM.A2DD.01A.11R.A180.07 |
| TCGA-A2-A0CT | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 6.27 | LumA | European | TCGA.A2.A0CT.01A.31R.A056.07 |
| TCGA-E2-A1AZ | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | Indeterminate | NA | NA | alive | 6.38 | Basal | American | TCGA.E2.A1AZ.01A.11R.A12P.07 |
| TCGA-BH-A0BR | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.38 | LumA | European | TCGA.BH.A0BR.01A.21R.A115.07 |
| TCGA-AO-A0JE | 53 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 6.39 | Her2 | African | TCGA.AO.A0JE.01A.11R.A056.07 |
| TCGA-BH-A0BT | 56 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | alive | 6.48 | LumA | European | TCGA.BH.A0BT.01A.11R.A12P.07 |
| TCGA-BH-A0BT | 56 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | NA | NA | alive | 6.48 | LumA | European | TCGA.BH.A0BT.11A.21R.A12P.07 |
| TCGA-AO-A12C | 42 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 6.49 | NA | European | TCGA.AO.A12C.01A.11R.A10J.07 |
| TCGA-BH-A0DL | 64 | female | White | Primary solid Tumor | postmenopausal | IDC with metaplastic carcinoma and focal apocrine features | positive | negative | negative | NA | NA | alive | 6.52 | NA | European | TCGA.BH.A0DL.01A.11R.A115.07 |
| TCGA-BH-A0DL | 64 | female | White | Solid Tissue Normal | postmenopausal | IDC with metaplastic carcinoma and focal apocrine features | positive | negative | negative | NA | NA | alive | 6.52 | NA | European | TCGA.BH.A0DL.11A.13R.A115.07 |
| TCGA-AR-A1AJ | 83 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 6.52 | Basal | European | TCGA.AR.A1AJ.01A.21R.A12P.07 |
| TCGA-A2-A04Q | 48 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 6.53 | Basal | European | TCGA.A2.A04Q.01A.21R.A034.07 |
| TCGA-BH-A0DT | 41 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.58 | LumA | European | TCGA.BH.A0DT.01A.21R.A12D.07 |
| TCGA-BH-A0DT | 41 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.58 | LumA | European | TCGA.BH.A0DT.11A.12R.A12D.07 |
| TCGA-GM-A2DB | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 6.59 | Her2 | European | TCGA.GM.A2DB.01A.31R.A18M.07 |
| TCGA-A2-A0EQ | 64 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | alive | 6.64 | Her2 | African | TCGA.A2.A0EQ.01A.11R.A034.07 |
| TCGA-A2-A0EO | 54 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.69 | LumA | European | TCGA.A2.A0EO.01A.11R.A034.07 |
| TCGA-AO-A03L | 34 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 6.69 | LumA | South Asian_admix | TCGA.AO.A03L.01A.41R.A056.07 |
| TCGA-BH-A0B0 | 56 | female | Black or African American | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 6.78 | LumA | African_admix | TCGA.BH.A0B0.01A.21R.A115.07 |
| TCGA-BH-A0B6 | 47 | female | White | Primary solid Tumor | not available | IDC | positive | positive | positive | NA | NA | alive | 6.8 | NA | European | TCGA.BH.A0B6.01A.11R.A19W.07 |
| TCGA-BH-A0DD | 58 | male | White | Primary solid Tumor | not applicable | IDC | positive | positive | positive | NA | NA | alive | 6.81 | NA | European | TCGA.BH.A0DD.01A.31R.A12P.07 |
| TCGA-BH-A0DD | 58 | male | White | Solid Tissue Normal | not applicable | IDC | positive | positive | positive | NA | NA | alive | 6.81 | NA | European | TCGA.BH.A0DD.11A.23R.A12P.07 |
| TCGA-BH-A0E9 | 53 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 6.81 | LumA | European | TCGA.BH.A0E9.01B.11R.A115.07 |
| TCGA-AO-A1KR | 51 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 6.88 | Basal | European | TCGA.AO.A1KR.01A.12R.A144.07 |
| TCGA-AO-A12D | 43 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | positive | NA | NA | alive | 6.89 | Her2 | European | TCGA.AO.A12D.01A.11R.A115.07 |
| TCGA-GM-A2DC | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 6.94 | LumA | European | TCGA.GM.A2DC.01A.11R.A18M.07 |
| TCGA-E2-A106 | 34 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 6.96 | NA | East Asian | TCGA.E2.A106.01A.11R.A10J.07 |
| TCGA-AR-A0TS | 46 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 7.0 | Basal | European | TCGA.AR.A0TS.01A.11R.A115.07 |
| TCGA-BH-A0B7 | 42 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 7.01 | Her2 | European | TCGA.BH.A0B7.01A.12R.A115.07 |
| TCGA-BH-A0B7 | 42 | female | White | Solid Tissue Normal | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 7.01 | Her2 | European | TCGA.BH.A0B7.11A.34R.A115.07 |
| TCGA-GM-A2DI | 52 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 7.09 | LumA | European | TCGA.GM.A2DI.01A.31R.A18M.07 |
| TCGA-B6-A401 | 47 | female | Black or African American | Primary solid Tumor | unknown | IDC | positive | positive | negative | NA | NA | alive | 7.11 | LumA | African_admix | TCGA.B6.A401.01A.11R.A239.07 |
| TCGA-GM-A2DO | 54 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 7.11 | LumB | African | TCGA.GM.A2DO.01A.11R.A18M.07 |
| TCGA-AR-A254 | 50 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | positive | NA | NA | alive | 7.13 | Her2 | European | TCGA.AR.A254.01A.21R.A169.07 |
| TCGA-BH-A0BS | 55 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not available | NA | NA | alive | 7.15 | LumA | European | TCGA.BH.A0BS.01A.11R.A12P.07 |
| TCGA-BH-A0BS | 55 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | not available | NA | NA | alive | 7.15 | LumA | European | TCGA.BH.A0BS.11A.11R.A12P.07 |
| TCGA-AR-A1AO | 47 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 7.17 | Normal | European | TCGA.AR.A1AO.01A.11R.A12P.07 |
| TCGA-AR-A1AX | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 7.2 | LumA | European | TCGA.AR.A1AX.01A.11R.A12P.07 |
| TCGA-AR-A1AW | 65 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 7.21 | LumB | European | TCGA.AR.A1AW.01A.21R.A12P.07 |
| TCGA-AR-A2LJ | 40 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | positive | NA | NA | alive | 7.21 | NA | European | TCGA.AR.A2LJ.01A.12R.A19W.07 |
| TCGA-GM-A2DK | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 7.24 | LumA | European | TCGA.GM.A2DK.01A.21R.A180.07 |
| TCGA-PE-A5DE | 41 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 7.24 | LumA | European | TCGA.PE.A5DE.01A.11R.A27Q.07 |
| TCGA-AC-A2FK | 45 | female | White | Primary solid Tumor | not available | ILC | positive | positive | not evaluated | NA | NA | alive | 7.26 | Normal | American | TCGA.AC.A2FK.01A.12R.A180.07 |
| TCGA-E2-A1B1 | 45 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 7.26 | LumA | European | TCGA.E2.A1B1.01A.21R.A12P.07 |
| TCGA-A2-A0CQ | 62 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 7.38 | LumA | African_admix | TCGA.A2.A0CQ.01A.21R.A034.07 |
| TCGA-AR-A250 | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 7.41 | LumB | European | TCGA.AR.A250.01A.31R.A169.07 |
| TCGA-BH-A0C3 | 47 | female | White | Primary solid Tumor | premenopausal | with IDC/ILC phenotypes | positive | negative | negative | metastasis | bone | alive | 7.42 | NA | European | TCGA.BH.A0C3.01A.21R.A12P.07 |
| TCGA-BH-A0C3 | 47 | female | White | Solid Tissue Normal | premenopausal | with IDC/ILC phenotypes | positive | negative | negative | metastasis | bone | alive | 7.42 | NA | European | TCGA.BH.A0C3.11A.23R.A12P.07 |
| TCGA-B6-A0RT | 39 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | NA | NA | alive | 7.45 | Basal | European | TCGA.B6.A0RT.01A.21R.A084.07 |
| TCGA-AC-A2FF | 40 | female | Asian | Primary solid Tumor | not available | ILC | positive | positive | not evaluated | NA | NA | alive | 7.55 | LumA | South Asian_admix | TCGA.AC.A2FF.01A.11R.A17B.07 |
| TCGA-AC-A2FF | 40 | female | Asian | Solid Tissue Normal | not available | ILC | positive | positive | not evaluated | NA | NA | alive | 7.55 | LumA | South Asian_admix | TCGA.AC.A2FF.11A.13R.A17B.07 |
| TCGA-BH-A0C7 | 48 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | negative | not available | NA | NA | alive | 7.58 | LumB | European | TCGA.BH.A0C7.01B.11R.A115.07 |
| TCGA-A2-A3XT | 45 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 7.58 | Basal | African | TCGA.A2.A3XT.01A.11R.A22U.07 |
| TCGA-A2-A0CP | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 7.7 | LumA | European | TCGA.A2.A0CP.01A.11R.A034.07 |
| TCGA-AR-A252 | 50 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 7.77 | LumA | European | TCGA.AR.A252.01A.11R.A169.07 |
| TCGA-AR-A1AP | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 7.82 | LumA | European | TCGA.AR.A1AP.01A.11R.A12P.07 |
| TCGA-AR-A1AU | 39 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 7.85 | LumA | European | TCGA.AR.A1AU.01A.11R.A12P.07 |
| TCGA-AR-A1AN | 46 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 7.99 | LumA | European | TCGA.AR.A1AN.01A.11R.A12P.07 |
| TCGA-AO-A1KP | 77 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.08 | LumB | European | TCGA.AO.A1KP.01A.11R.A13Q.07 |
| TCGA-AR-A1AL | 60 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 8.13 | LumA | European | TCGA.AR.A1AL.01A.21R.A12P.07 |
| TCGA-AR-A24S | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.15 | LumB | European | TCGA.AR.A24S.01A.11R.A169.07 |
| TCGA-AR-A0TQ | 27 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 8.19 | LumB | European | TCGA.AR.A0TQ.01A.11R.A084.07 |
| TCGA-AR-A1AM | 52 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 8.19 | NA | European | TCGA.AR.A1AM.01A.41R.A22K.07 |
| TCGA-AR-A24Z | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.22 | LumB | European | TCGA.AR.A24Z.01A.11R.A169.07 |
| TCGA-AR-A24X | 52 | female | White | Primary solid Tumor | premenopausal | IDC/ILC | positive | positive | equivocal | NA | NA | alive | 8.22 | NA | European | TCGA.AR.A24X.01A.11R.A169.07 |
| TCGA-A2-A0CV | 41 | female | Asian | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.24 | LumA | East Asian | TCGA.A2.A0CV.01A.31R.A115.07 |
| TCGA-A2-A0CL | 37 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.25 | Normal | African | TCGA.A2.A0CL.01A.11R.A115.07 |
| TCGA-A2-A0ST | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 8.26 | Basal | European | TCGA.A2.A0ST.01A.12R.A084.07 |
| TCGA-AR-A1AQ | 49 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 8.27 | Basal | European | TCGA.AR.A1AQ.01A.11R.A12P.07 |
| TCGA-AC-A2BM | 41 | female | Black or African American | Primary solid Tumor | not available | IDC | positive | positive | not evaluated | NA | NA | alive | 8.27 | LumB | African | TCGA.AC.A2BM.01A.11R.A21T.07 |
| TCGA-AR-A251 | 51 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | equivocal | NA | NA | alive | 8.3 | Basal | European | TCGA.AR.A251.01A.12R.A169.07 |
| TCGA-AR-A24N | 54 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 8.31 | LumB | European | TCGA.AR.A24N.01A.11R.A169.07 |
| TCGA-B6-A1KF | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 8.45 | Basal | European | TCGA.B6.A1KF.01A.11R.A13Q.07 |
| TCGA-GM-A2DN | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.46 | LumA | European | TCGA.GM.A2DN.01A.11R.A180.07 |
| TCGA-A2-A0EM | 73 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 8.47 | LumA | European | TCGA.A2.A0EM.01A.11R.A034.07 |
| TCGA-A2-A04W | 50 | female | White | Primary solid Tumor | premenopausal | apocrine | negative | negative | positive | NA | NA | alive | 8.49 | NA | European | TCGA.A2.A04W.01A.31R.A115.07 |
| TCGA-AO-A12A | 47 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.52 | LumA | European | TCGA.AO.A12A.01A.21R.A115.07 |
| TCGA-E2-A1LI | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | NA | NA | alive | 8.54 | Basal | European | TCGA.E2.A1LI.01A.12R.A157.07 |
| TCGA-AR-A24U | 47 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | positive | NA | NA | alive | 8.56 | Her2 | European | TCGA.AR.A24U.01A.11R.A169.07 |
| TCGA-B6-A40B | 76 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 8.63 | LumA | European | TCGA.B6.A40B.01A.11R.A239.07 |
| TCGA-AR-A1AK | 70 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 8.65 | LumA | European | TCGA.AR.A1AK.01A.21R.A12P.07 |
| TCGA-AR-A24Q | 49 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 8.68 | Basal | European | TCGA.AR.A24Q.01A.12R.A169.07 |
| TCGA-AR-A24T | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 8.77 | LumA | European | TCGA.AR.A24T.01A.11R.A169.07 |
| TCGA-AR-A24V | 52 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.77 | LumA | European | TCGA.AR.A24V.01A.21R.A169.07 |
| TCGA-A2-A25E | 34 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | locoregional recurrence | chest wall | alive | 8.77 | LumB | African | TCGA.A2.A25E.01A.11R.A169.07 |
| TCGA-GM-A2DM | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 8.83 | LumA | American | TCGA.GM.A2DM.01A.11R.A180.07 |
| TCGA-E2-A1LH | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 8.89 | Basal | European | TCGA.E2.A1LH.01A.11R.A14D.07 |
| TCGA-E2-A1LH | 59 | female | White | Solid Tissue Normal | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 8.89 | Basal | European | TCGA.E2.A1LH.11A.22R.A14D.07 |
| TCGA-AO-A128 | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | alive | 8.89 | Basal | European | TCGA.AO.A128.01A.11R.A10J.07 |
| TCGA-Z7-A8R6 | 46 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | NA | NA | alive | 8.91 | LumB | European | TCGA.Z7.A8R6.01A.11R.A41B.07 |
| TCGA-AR-A0U4 | 54 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 8.93 | Basal | European | TCGA.AR.A0U4.01A.11R.A109.07 |
| TCGA-A2-A25A | 44 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 8.97 | Normal | European | TCGA.A2.A25A.01A.12R.A16F.07 |
| TCGA-A2-A0CR | 54 | female | Asian | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 8.99 | LumA | East Asian | TCGA.A2.A0CR.01A.11R.A22K.07 |
| TCGA-A2-A0CW | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 8.99 | LumB | European | TCGA.A2.A0CW.01A.21R.A115.07 |
| TCGA-AO-A129 | 29 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | alive | 9.0 | Basal | European | TCGA.AO.A129.01A.21R.A10J.07 |
| TCGA-Z7-A8R5 | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | locoregional recurrence | recur>bone | alive | 9.0 | LumA | European | TCGA.Z7.A8R5.01A.42R.A41B.07 |
| TCGA-AR-A1AI | 47 | female | White | Primary solid Tumor | postmenopausal | medullary carcinoma | negative | negative | equivocal | NA | NA | alive | 9.02 | Basal | European | TCGA.AR.A1AI.01A.11R.A12P.07 |
| TCGA-AO-A126 | 39 | female | Asian | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | locoregional recurrence | NA | alive | 9.05 | LumA | East Asian | TCGA.AO.A126.01A.11R.A10J.07 |
| TCGA-AR-A0TT | 53 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 9.08 | LumB | African_admix | TCGA.AR.A0TT.01A.31R.A084.07 |
| TCGA-GM-A3NW | 63 | female | White | Primary solid Tumor | postmenopausal | ILC | negative | positive | equivocal | NA | NA | alive | 9.2 | LumA | European | TCGA.GM.A3NW.01A.21R.A22K.07 |
| TCGA-BH-A42U | 80 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | negative | negative | negative | NA | NA | alive | 9.21 | Normal | African | TCGA.BH.A42U.01A.12R.A24H.07 |
| TCGA-AR-A24R | 45 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | alive | 9.39 | LumB | European | TCGA.AR.A24R.01A.11R.A169.07 |
| TCGA-AO-A125 | 72 | female | Black or African American | Primary solid Tumor | postmenopausal | papillary carcinoma | positive | positive | negative | NA | NA | alive | 9.46 | NA | African | TCGA.AO.A125.01A.11R.A10J.07 |
| TCGA-AO-A124 | 38 | female | White | Primary solid Tumor | premenopausal | mucinous/ductal | negative | negative | negative | NA | NA | alive | 9.6 | NA | European | TCGA.AO.A124.01A.11R.A10J.07 |
| TCGA-GM-A2DL | 50 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | positive | negative | NA | NA | alive | 9.63 | LumA | European | TCGA.GM.A2DL.01A.11R.A18M.07 |
| TCGA-A2-A0EP | 56 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | alive | 9.86 | LumA | European | TCGA.A2.A0EP.01A.52R.A22U.07 |
| TCGA-AR-A24O | 43 | female | White | Primary solid Tumor | premenopausal | ILC with ductal features | positive | positive | negative | not available | not available | alive | 9.88 | NA | European | TCGA.AR.A24O.01A.11R.A169.07 |
| TCGA-AR-A24M | 38 | female | White | Primary solid Tumor | premenopausal | IDC/ILC | positive | positive | negative | NA | NA | alive | 10.02 | NA | European | TCGA.AR.A24M.01A.11R.A169.07 |
| TCGA-A2-A04R | 36 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | alive | 10.15 | LumB | African_admix | TCGA.A2.A04R.01A.41R.A109.07 |
| TCGA-AR-A1AH | 51 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | alive | 10.42 | Basal | European | TCGA.AR.A1AH.01A.11R.A12D.07 |
| TCGA-AQ-A04L | 48 | female | White | Primary solid Tumor | perimenopausal | IDC | positive | negative | positive | NA | NA | alive | 10.83 | NA | European | TCGA.AQ.A04L.01B.21R.A10J.07 |
| TCGA-3C-AALI | 50 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | alive | 10.97 | Her2 | African | TCGA.3C.AALI.01A.11R.A41B.07 |
| TCGA-3C-AAAU | 55 | female | White | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | metastasis | lung | alive | 11.08 | LumA | European | TCGA.3C.AAAU.01A.11R.A41B.07 |
| TCGA-AR-A0U3 | 59 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | alive | 11.17 | LumA | European | TCGA.AR.A0U3.01A.11R.A109.07 |
| TCGA-A2-A0EN | 70 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | alive | 11.19 | LumA | European | TCGA.A2.A0EN.01A.13R.A084.07 |
| TCGA-A2-A0CK | 60 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | new primary | contralateral | alive | 11.39 | LumA | European | TCGA.A2.A0CK.01A.11R.A22K.07 |
| TCGA-B6-A1KN | 57 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 11.59 | LumB | European | TCGA.B6.A1KN.01A.11R.A13Q.07 |
| TCGA-AR-A0TP | 43 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | negative | NA | NA | alive | 11.7 | Basal | European | TCGA.AR.A0TP.01A.11R.A084.07 |
| TCGA-B6-A0IQ | 40 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | NA | NA | alive | 11.73 | Basal | European | TCGA.B6.A0IQ.01A.11R.A034.07 |
| TCGA-A2-A04N | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 11.92 | LumA | European | TCGA.A2.A04N.01A.11R.A115.07 |
| TCGA-B6-A0I2 | 45 | female | White | Primary solid Tumor | indeterminate | IDC | not evaluated | not evaluated | not evaluated | NA | NA | alive | 11.94 | Basal | European | TCGA.B6.A0I2.01A.11R.A034.07 |
| TCGA-AR-A24H | 65 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | alive | 13.4 | LumB | European | TCGA.AR.A24H.01A.11R.A169.07 |
| TCGA-B6-A0RO | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | alive | 13.49 | LumA | European | TCGA.B6.A0RO.01A.22R.A084.07 |
| TCGA-B6-A0IO | 66 | female | White | Primary solid Tumor | indeterminate | IDC | positive | Indeterminate | not evaluated | NA | NA | alive | 13.8 | LumA | European | TCGA.B6.A0IO.01A.11R.A034.07 |
| TCGA-AR-A2LE | 69 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | not evaluated | new primary | endoometrium | alive | 13.86 | LumA | European | TCGA.AR.A2LE.01A.11R.A180.07 |
| TCGA-B6-A0RV | 42 | female | White | Primary solid Tumor | indeterminate | IDC/ILC | positive | positive | not evaluated | NA | NA | alive | 14.12 | NA | European | TCGA.B6.A0RV.01A.11R.A084.07 |
| TCGA-B6-A0WT | 61 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | new primary | contralateral | alive | 15.71 | LumA | European | TCGA.B6.A0WT.01A.11R.A109.07 |
| TCGA-B6-A0IJ | 42 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | NA | NA | alive | 19.46 | Basal | African | TCGA.B6.A0IJ.01A.11R.A034.07 |
| TCGA-B6-A0RI | 44 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | locoregional disease | chest wall | alive | 19.51 | LumA | European | TCGA.B6.A0RI.01A.11R.A056.07 |
| TCGA-B6-A0RE | 61 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | NA | NA | alive | 21.29 | Basal | African_admix | TCGA.B6.A0RE.01A.11R.A056.07 |
| TCGA-B6-A0RN | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | alive | 21.92 | LumA | European | TCGA.B6.A0RN.01A.12R.A084.07 |
| TCGA-B6-A0IA | 51 | female | White | Primary solid Tumor | indeterminate | ductal/cribiform | positive | positive | not evaluated | NA | NA | alive | 22.97 | NA | European | TCGA.B6.A0IA.01A.11R.A034.07 |
| TCGA-B6-A0I5 | 49 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | NA | NA | alive | 23.43 | LumA | European | TCGA.B6.A0I5.01A.11R.A034.07 |
| TCGA-B6-A0RU | 40 | female | White | Primary solid Tumor | indeterminate | ductal/metaplastic | negative | negative | not evaluated | NA | NA | alive | 23.56 | NA | European | TCGA.B6.A0RU.01A.11R.A084.07 |
| TCGA-AC-A23H | 90 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | dead | NA | Her2 | European | TCGA.AC.A23H.01A.11R.A157.07 |
| TCGA-AC-A23H | 90 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | negative | positive | NA | NA | dead | NA | Her2 | European | TCGA.AC.A23H.11A.12R.A157.07 |
| TCGA-E9-A1N6 | 52 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | metastasis | bone>recur>liver | dead | NA | NA | European | TCGA.E9.A1N6.01A.11R.A144.07 |
| TCGA-E9-A1N6 | 52 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | positive | metastasis | bone>recur>liver | dead | NA | NA | European | TCGA.E9.A1N6.11A.32R.A144.07 |
| TCGA-E9-A1NG | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | NA | LumA | European | TCGA.E9.A1NG.01A.21R.A14M.07 |
| TCGA-E9-A1NG | 62 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | NA | LumA | European | TCGA.E9.A1NG.11A.52R.A14M.07 |
| TCGA-E9-A1NF | 60 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | negative | NA | NA | dead | NA | NA | European | TCGA.E9.A1NF.01A.11R.A14D.07 |
| TCGA-E9-A1NF | 60 | female | White | Solid Tissue Normal | postmenopausal | IDC/ILC | positive | positive | negative | NA | NA | dead | NA | NA | European | TCGA.E9.A1NF.11A.73R.A14D.07 |
| TCGA-C8-A3M7 | 60 | female | Asian | Primary solid Tumor | postmenopausal | ILC | negative | negative | negative | locoregional recurrence | NA | dead | 0.0 | LumA | East Asian | TCGA.C8.A3M7.01A.12R.A21T.07 |
| TCGA-AC-A62V | 58 | male | Black or African American | Primary solid Tumor | not applicable | IDC | positive | positive | not evaluated | metastasis | bone | dead | 0.01 | NA | African | TCGA.AC.A62V.01A.11R.A31O.07 |
| TCGA-C8-A12Q | 78 | female | Asian | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | metastasis | liver | dead | 0.01 | Her2 | East Asian | TCGA.C8.A12Q.01A.11R.A115.07 |
| TCGA-E9-A2JS | 72 | female | White | Primary solid Tumor | postmenopausal | ILC | not evaluated | not evaluated | not evaluated | metastasis | bone|liver | dead | 0.04 | LumB | European | TCGA.E9.A2JS.01A.11R.A180.07 |
| TCGA-E9-A226 | 45 | female | White | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | metastasis | bone|liver | dead | 0.04 | LumB | European | TCGA.E9.A226.01A.21R.A157.07 |
| TCGA-AC-A3EH | 79 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | negative | negative | NA | NA | dead | 0.05 | NA | European | TCGA.AC.A3EH.01A.22R.A22K.07 |
| TCGA-E9-A1RB | 40 | female | White | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 0.06 | LumB | European | TCGA.E9.A1RB.01A.11R.A157.07 |
| TCGA-E9-A1RB | 40 | female | White | Solid Tissue Normal | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 0.06 | LumB | European | TCGA.E9.A1RB.11A.33R.A157.07 |
| TCGA-E9-A245 | 47 | female | White | Primary solid Tumor | premenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 0.07 | LumA | European | TCGA.E9.A245.01A.22R.A16F.07 |
| TCGA-A8-A08L | 89 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | dead | 0.08 | Her2 | European | TCGA.A8.A08L.01A.11R.A00Z.07 |
| TCGA-BH-A42T | 75 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | dead | 0.88 | NA | African_admix | TCGA.BH.A42T.01A.11R.A24H.07 |
| TCGA-AC-A2QJ | 48 | female | White | Primary solid Tumor | perimenopausal | metaplastic carcinoma | negative | negative | negative | metastasis | bone | dead | 1.22 | NA | American | TCGA.AC.A2QJ.01A.12R.A19W.07 |
| TCGA-D8-A1XC | 85 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | metastasis | bone | dead | 1.03 | NA | European | TCGA.D8.A1XC.01A.11R.A14D.07 |
| TCGA-D8-A1Y1 | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 0.83 | LumB | European | TCGA.D8.A1Y1.01A.21R.A14M.07 |
| TCGA-LL-A73Z | 55 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | metastasis | skin | dead | 0.62 | Normal | African | TCGA.LL.A73Z.01A.11R.A32P.07 |
| TCGA-A2-A0CU | 73 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | dead | 0.43 | LumA | European | TCGA.A2.A0CU.01A.12R.A034.07 |
| TCGA-E2-A15M | 66 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | dead | 0.92 | LumA | European | TCGA.E2.A15M.01A.11R.A12D.07 |
| TCGA-E2-A15M | 66 | female | White | Solid Tissue Normal | postmenopausal | ILC | positive | positive | negative | NA | NA | dead | 0.92 | LumA | European | TCGA.E2.A15M.11A.22R.A12D.07 |
| TCGA-D8-A73W | 79 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | negative | negative | metastasis | lung|bone | dead | 1.05 | NA | European | TCGA.D8.A73W.01A.22R.A352.07 |
| TCGA-A2-A0T2 | 66 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | metastasis | liver|abdomen | dead | 0.7 | Basal | European | TCGA.A2.A0T2.01A.11R.A084.07 |
| TCGA-AQ-A7U7 | 55 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | dead | 1.6 | LumA | European | TCGA.AQ.A7U7.01A.22R.A352.07 |
| TCGA-E2-A2P5 | 78 | female | Black or African American | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | metastasis | bone | dead | 2.25 | NA | admix | TCGA.E2.A2P5.01A.11R.A19W.07 |
| TCGA-OL-A5D6 | 71 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | NA | NA | dead | 3.02 | Normal | African_admix | TCGA.OL.A5D6.01A.21R.A27Q.07 |
| TCGA-E2-A14Z | 64 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | metastasis | bone | dead | 1.54 | LumA | European | TCGA.E2.A14Z.01A.11R.A115.07 |
| TCGA-A2-A04P | 36 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | not evaluated | metastasis | bone>axilla recur|lung>liver | dead | 1.5 | Basal | African | TCGA.A2.A04P.01A.31R.A034.07 |
| TCGA-A7-A13E | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | equivocal | metastasis | lung|bone|liver|brain|skin | dead | 1.68 | Basal | European | TCGA.A7.A13E.01A.11R.A12P.07 |
| TCGA-A7-A13E | 62 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | negative | equivocal | metastasis | lung|bone|liver|brain|skin | dead | 1.68 | Basal | European | TCGA.A7.A13E.11A.61R.A12P.07 |
| TCGA-A2-A0YT | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | not evaluated | NA | NA | dead | 1.98 | LumB | European | TCGA.A2.A0YT.01A.11R.A109.07 |
| TCGA-AO-A0J5 | 48 | female | White | Primary solid Tumor | premenopausal | ductal/micropapillary | positive | negative | equivocal | metastasis | lung|bone|liver | dead | 2.17 | NA | European | TCGA.AO.A0J5.01A.11R.A034.07 |
| TCGA-A2-A0CM | 40 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | dead | 2.06 | Basal | African_admix | TCGA.A2.A0CM.01A.31R.A034.07 |
| TCGA-A2-A0EW | 53 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | metastasis | bone | dead | 5.16 | LumA | European | TCGA.A2.A0EW.01A.21R.A115.07 |
| TCGA-BH-A0BF | 56 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 3.62 | LumB | European | TCGA.BH.A0BF.01A.21R.A12P.07 |
| TCGA-A2-A3XY | 49 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | metastasis | lung>lymph nodes>brain | dead | 2.99 | NA | African | TCGA.A2.A3XY.01A.11R.A239.07 |
| TCGA-AC-A2FE | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | bone>liver | dead | 7.22 | NA | European | TCGA.AC.A2FE.01A.11R.A19W.07 |
| TCGA-A2-A0SV | 63 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | metastasis | bone | dead | 2.26 | LumB | European | TCGA.A2.A0SV.01A.11R.A084.07 |
| TCGA-A8-A06U | 80 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | 2.42 | LumA | European | TCGA.A8.A06U.01A.11R.A00Z.07 |
| TCGA-E2-A1B4 | 74 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 2.75 | LumA | European | TCGA.E2.A1B4.01A.11R.A12P.07 |
| TCGA-A2-A3XU | 35 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | metastasis | bone>breast recur|chest wall | dead | 2.5 | Basal | African_admix | TCGA.A2.A3XU.01A.12R.A22U.07 |
| TCGA-A8-A06X | 77 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | positive | NA | NA | dead | 2.58 | LumB | European | TCGA.A8.A06X.01A.21R.A00Z.07 |
| TCGA-A1-A0SK | 54 | female | Asian | Primary solid Tumor | indeterminate | \neuroendocrine carcinoma, large-cell type, high-grade\"" | negative | negative | negative | NA | NA | dead | 2.65 | NA | East Asian | TCGA.A1.A0SK.01A.12R.A084.07 |
| TCGA-OL-A66K | 72 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | NA | NA | dead | 3.49 | LumA | European | TCGA.OL.A66K.01A.11R.A29R.07 |
| TCGA-A2-A3XS | 62 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | metastasis | lung | dead | 2.83 | NA | African_admix | TCGA.A2.A3XS.01A.11R.A22U.07 |
| TCGA-A8-A08J | 52 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | NA | NA | dead | 3.09 | Her2 | European | TCGA.A8.A08J.01A.11R.A00Z.07 |
| TCGA-B6-A3ZX | 50 | female | Black or African American | Primary solid Tumor | unknown | IDC/ILC | negative | negative | negative | metastasis | bone | dead | 3.15 | NA | African | TCGA.B6.A3ZX.01A.11R.A239.07 |
| TCGA-A2-A3XX | 49 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | NA | NA | dead | 3.94 | Basal | African | TCGA.A2.A3XX.01A.21R.A239.07 |
| TCGA-AR-A2LK | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | equivocal | metastasis | bone | dead | 4.51 | LumB | European | TCGA.AR.A2LK.01A.11R.A180.07 |
| TCGA-BH-A0C1 | 61 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | metastasis | bone | dead | 3.86 | LumA | European | TCGA.BH.A0C1.01B.11R.A12D.07 |
| TCGA-A2-A0SW | 82 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | not evaluated | metastasis | liver | dead | 3.74 | LumB | European | TCGA.A2.A0SW.01A.11R.A084.07 |
| TCGA-A2-A0CO | 85 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | dead | 4.02 | NA | European | TCGA.A2.A0CO.01A.13R.A22K.07 |
| TCGA-BH-A0BP | 76 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 6.29 | LumA | European | TCGA.BH.A0BP.01A.11R.A115.07 |
| TCGA-HN-A2OB | 45 | female | not available | Primary solid Tumor | premenopausal | ILC | positive | positive | negative | metastasis | bone|omentum | dead | 5.2 | LumA | European | TCGA.HN.A2OB.01A.21R.A27Q.07 |
| TCGA-A2-A04V | 39 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | dead | 5.26 | LumA | European | TCGA.A2.A04V.01A.21R.A034.07 |
| TCGA-AR-A24L | 26 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | NA | NA | dead | 7.85 | LumA | European | TCGA.AR.A24L.01A.11R.A169.07 |
| TCGA-AR-A0TZ | 43 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | equivocal | metastasis | bone | dead | 8.93 | LumA | European | TCGA.AR.A0TZ.01A.12R.A084.07 |
| TCGA-A2-A0CS | 73 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | metastasis | ovary | dead | 6.43 | LumA | European | TCGA.A2.A0CS.01A.11R.A115.07 |
| TCGA-AO-A03P | 54 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | metastasis | liver | dead | 7.97 | LumB | African | TCGA.AO.A03P.01A.11R.A00Z.07 |
| TCGA-B6-A0IP | 74 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | dead | 10.75 | LumA | European | TCGA.B6.A0IP.01A.11R.A034.07 |
| TCGA-A8-A08T | 64 | female | not available | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | not available | not available | dead | 9.33 | LumA | European | TCGA.A8.A08T.01A.21R.A00Z.07 |
| TCGA-B6-A0IM | 75 | female | Black or African American | Primary solid Tumor | postmenopausal | ductal/cribiform | positive | positive | not evaluated | NA | NA | dead | 10.6 | NA | African | TCGA.B6.A0IM.01A.11R.A034.07 |
| TCGA-B6-A0X1 | 48 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | NA | NA | dead | 20.41 | Basal | European | TCGA.B6.A0X1.01A.11R.A109.07 |
| TCGA-B6-A0RH | 51 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | NA | NA | dead | 17.68 | Her2 | African | TCGA.B6.A0RH.01A.21R.A115.07 |
| TCGA-GM-A2DA | 46 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | metastasis | bone>liver>lymph node>brain | dead | 18.05 | LumA | European | TCGA.GM.A2DA.01A.11R.A18M.07 |
| TCGA-B6-A0IC | 90 | female | White | Primary solid Tumor | postmenopausal | invasive papillary | positive | positive | not evaluated | NA | NA | dead | NA | NA | European | TCGA.B6.A0IC.01A.11R.A034.07 |
| TCGA-BH-A1F8 | 90 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | NA | LumB | European | TCGA.BH.A1F8.01A.11R.A13Q.07 |
| TCGA-BH-A1F8 | 90 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | NA | LumB | European | TCGA.BH.A1F8.11B.21R.A13Q.07 |
| TCGA-UU-A93S | 63 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | metastasis | bone|liver | dead | 0.32 | Her2 | African_admix | TCGA.UU.A93S.01A.21R.A41B.07 |
| TCGA-AR-A0TR | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | equivocal | NA | NA | dead | 0.44 | LumA | European | TCGA.AR.A0TR.01A.11R.A084.07 |
| TCGA-AQ-A0Y5 | 70 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | 0.47 | LumA | European | TCGA.AQ.A0Y5.01A.11R.A14M.07 |
| TCGA-BH-A18T | 70 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | dead | 0.61 | Basal | European | TCGA.BH.A18T.01A.11R.A12D.07 |
| TCGA-EW-A1P8 | 58 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | metastasis | lung|bone|liver|skin | dead | 0.65 | Basal | European | TCGA.EW.A1P8.01A.11R.A144.07 |
| TCGA-E2-A1LK | 84 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | equivocal | locoregional recurrence | axilla | dead | 0.73 | Basal | African_admix | TCGA.E2.A1LK.01A.21R.A14D.07 |
| TCGA-BH-A8FY | 87 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | negative | NA | NA | dead | 0.81 | LumA | European | TCGA.BH.A8FY.01A.11R.A36F.07 |
| TCGA-AR-A5QQ | 68 | female | White | Primary solid Tumor | postmenopausal | squamous (metaplastic) carcinoma | negative | negative | negative | locoregional recurrence | chest wall|lung|liver|bone|adrenal glands | dead | 0.88 | NA | European | TCGA.AR.A5QQ.01A.11R.A28M.07 |
| TCGA-B6-A0I9 | 62 | female | White | Primary solid Tumor | indeterminate | IDC | Indeterminate | positive | not evaluated | metastasis | bone | dead | 0.99 | Her2 | European | TCGA.B6.A0I9.01A.11R.A034.07 |
| TCGA-BH-A1EV | 45 | female | White | Primary solid Tumor | not available | IDC | positive | positive | positive | NA | NA | dead | 1.0 | Her2 | European | TCGA.BH.A1EV.01A.11R.A137.07 |
| TCGA-BH-A1EV | 45 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | positive | NA | NA | dead | 1.0 | Her2 | European | TCGA.BH.A1EV.11A.24R.A137.07 |
| TCGA-A8-A09X | 62 | female | not available | Primary solid Tumor | postmenopausal | ILC | negative | negative | negative | NA | NA | dead | 1.17 | Her2 | European | TCGA.A8.A09X.01A.11R.A00Z.07 |
| TCGA-BH-A18N | 88 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | dead | 1.28 | LumA | European | TCGA.BH.A18N.01A.11R.A12D.07 |
| TCGA-BH-A18N | 88 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | NA | NA | dead | 1.28 | LumA | European | TCGA.BH.A18N.11A.43R.A12D.07 |
| TCGA-AR-A1AR | 50 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | negative | new primary | contralateral | dead | 1.43 | Basal | European | TCGA.AR.A1AR.01A.31R.A137.07 |
| TCGA-BH-A1EY | 79 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | metastasis | lung|liver | dead | 1.47 | LumA | European | TCGA.BH.A1EY.01A.11R.A13Q.07 |
| TCGA-B6-A0WW | 58 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | metastasis | brain | dead | 1.53 | LumB | African | TCGA.B6.A0WW.01A.11R.A109.07 |
| TCGA-B6-A0IK | 63 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | metastasis | lung | dead | 1.56 | Her2 | European | TCGA.B6.A0IK.01A.12R.A056.07 |
| TCGA-B6-A409 | 44 | female | Black or African American | Primary solid Tumor | premenopausal | IDC | negative | negative | equivocal | metastasis | lung | dead | 1.57 | Basal | African | TCGA.B6.A409.01A.11R.A24H.07 |
| TCGA-BH-A1FG | 88 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 1.58 | LumA | European | TCGA.BH.A1FG.01A.11R.A13Q.07 |
| TCGA-BH-A1FG | 88 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 1.58 | LumA | European | TCGA.BH.A1FG.11B.12R.A13Q.07 |
| TCGA-BH-A18J | 56 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | metastasis | bone | dead | 1.68 | LumA | European | TCGA.BH.A18J.01A.11R.A12D.07 |
| TCGA-BH-A18J | 56 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | metastasis | bone | dead | 1.68 | LumA | European | TCGA.BH.A18J.11A.31R.A12D.07 |
| TCGA-AR-A2LH | 55 | female | White | Primary solid Tumor | postmenopausal | ILC | negative | negative | equivocal | metastasis | bone|liver | dead | 1.69 | Normal | European | TCGA.AR.A2LH.01A.31R.A18M.07 |
| TCGA-B6-A0WX | 40 | female | Black or African American | Primary solid Tumor | premenopausal | pleomorphic/lobular | negative | negative | not evaluated | metastasis | bone | dead | 1.75 | NA | African | TCGA.B6.A0WX.01A.11R.A109.07 |
| TCGA-B6-A0I8 | 46 | female | White | Primary solid Tumor | indeterminate | IDC | not evaluated | not evaluated | not evaluated | locoregional disease | pectoral muscle | dead | 2.05 | NA | European | TCGA.B6.A0I8.01A.11R.A034.07 |
| TCGA-BH-A1F0 | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | Indeterminate | negative | NA | NA | dead | 2.15 | Basal | European | TCGA.BH.A1F0.01A.11R.A137.07 |
| TCGA-BH-A1F0 | 80 | female | White | Solid Tissue Normal | postmenopausal | IDC | negative | Indeterminate | negative | NA | NA | dead | 2.15 | Basal | European | TCGA.BH.A1F0.11B.23R.A137.07 |
| TCGA-AC-A2FM | 87 | female | White | Primary solid Tumor | postmenopausal | ILC | not evaluated | not evaluated | not evaluated | metastasis | bone marrow | dead | 2.17 | NA | European | TCGA.AC.A2FM.01A.11R.A19W.07 |
| TCGA-AC-A2FM | 87 | female | White | Solid Tissue Normal | postmenopausal | ILC | not evaluated | not evaluated | not evaluated | metastasis | bone marrow | dead | 2.17 | NA | European | TCGA.AC.A2FM.11B.32R.A19W.07 |
| TCGA-BH-A18L | 50 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | dead | 2.22 | LumB | European | TCGA.BH.A18L.01A.32R.A12D.07 |
| TCGA-BH-A18L | 50 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | NA | NA | dead | 2.22 | LumB | European | TCGA.BH.A18L.11A.42R.A12D.07 |
| TCGA-B6-A0X4 | 62 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | metastasis | bone | dead | 2.35 | LumA | European | TCGA.B6.A0X4.01A.11R.A109.07 |
| TCGA-E2-A1LE | 71 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | metastasis | lung | dead | 2.41 | NA | European | TCGA.E2.A1LE.01A.12R.A19W.07 |
| TCGA-BH-A18P | 60 | female | White | Primary solid Tumor | not available | IDC | positive | negative | positive | NA | NA | dead | 2.52 | Her2 | European | TCGA.BH.A18P.01A.11R.A12D.07 |
| TCGA-BH-A18P | 60 | female | White | Solid Tissue Normal | not available | IDC | positive | negative | positive | NA | NA | dead | 2.52 | Her2 | European | TCGA.BH.A18P.11A.43R.A12D.07 |
| TCGA-BH-A1F2 | 53 | female | White | Primary solid Tumor | not available | IDC | positive | positive | positive | NA | NA | dead | 2.63 | LumB | European | TCGA.BH.A1F2.01A.31R.A13Q.07 |
| TCGA-BH-A1F2 | 53 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | positive | NA | NA | dead | 2.63 | LumB | European | TCGA.BH.A1F2.11A.32R.A13Q.07 |
| TCGA-B6-A0I6 | 49 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | metastasis | bone|skin | dead | 2.71 | NA | African | TCGA.B6.A0I6.01A.11R.A034.07 |
| TCGA-BH-A0EA | 72 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 2.71 | LumA | European | TCGA.BH.A0EA.01A.11R.A115.07 |
| TCGA-BH-A1FD | 68 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 2.76 | LumB | European | TCGA.BH.A1FD.01A.11R.A13Q.07 |
| TCGA-BH-A1FD | 68 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 2.76 | LumB | European | TCGA.BH.A1FD.11B.21R.A13Q.07 |
| TCGA-BH-A1FH | 47 | female | White | Primary solid Tumor | not available | IDC | positive | negative | not evaluated | metastasis | bone | dead | 2.83 | LumA | European | TCGA.BH.A1FH.01A.12R.A13Q.07 |
| TCGA-BH-A1FH | 47 | female | White | Solid Tissue Normal | not available | IDC | positive | negative | not evaluated | metastasis | bone | dead | 2.83 | LumA | European | TCGA.BH.A1FH.11B.42R.A13Q.07 |
| TCGA-BH-A18R | 50 | female | White | Primary solid Tumor | not available | IDC | Indeterminate | negative | positive | NA | NA | dead | 3.13 | Her2 | European | TCGA.BH.A18R.01A.11R.A12D.07 |
| TCGA-BH-A18R | 50 | female | White | Solid Tissue Normal | not available | IDC | Indeterminate | negative | positive | NA | NA | dead | 3.13 | Her2 | European | TCGA.BH.A18R.11A.42R.A12D.07 |
| TCGA-BH-A203 | 78 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 3.21 | Her2 | European | TCGA.BH.A203.01A.12R.A169.07 |
| TCGA-BH-A203 | 78 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 3.21 | Her2 | European | TCGA.BH.A203.11A.42R.A169.07 |
| TCGA-AR-A1AT | 62 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | dead | 3.48 | NA | European | TCGA.AR.A1AT.01A.11R.A12P.07 |
| TCGA-BH-A1EU | 83 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 3.52 | LumA | European | TCGA.BH.A1EU.01A.11R.A137.07 |
| TCGA-BH-A1EU | 83 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 3.52 | LumA | European | TCGA.BH.A1EU.11A.23R.A137.07 |
| TCGA-BH-A1FM | 44 | female | White | Primary solid Tumor | not available | IDC | positive | negative | not evaluated | NA | NA | dead | 3.8 | LumB | European | TCGA.BH.A1FM.01A.11R.A13Q.07 |
| TCGA-BH-A1FM | 44 | female | White | Solid Tissue Normal | not available | IDC | positive | negative | not evaluated | NA | NA | dead | 3.8 | LumB | European | TCGA.BH.A1FM.11B.23R.A13Q.07 |
| TCGA-PE-A5DC | 72 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | positive | NA | NA | dead | 3.92 | LumA | European | TCGA.PE.A5DC.01A.12R.A27Q.07 |
| TCGA-BH-A1EX | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | 4.13 | LumA | East Asian | TCGA.BH.A1EX.01A.11R.A13Q.07 |
| TCGA-BH-A18U | 72 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | 4.28 | LumB | European | TCGA.BH.A18U.01A.21R.A12D.07 |
| TCGA-BH-A18U | 72 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | positive | NA | NA | dead | 4.28 | LumB | European | TCGA.BH.A18U.11A.23R.A12D.07 |
| TCGA-BH-A1FR | 73 | female | White | Primary solid Tumor | not available | IDC/mucinous | positive | positive | not evaluated | NA | NA | dead | 4.5 | NA | European | TCGA.BH.A1FR.01A.11R.A13Q.07 |
| TCGA-BH-A1FR | 73 | female | White | Solid Tissue Normal | not available | IDC/mucinous | positive | positive | not evaluated | NA | NA | dead | 4.5 | NA | European | TCGA.BH.A1FR.11B.42R.A13Q.07 |
| TCGA-BH-A1FL | 69 | female | White | Primary solid Tumor | not available | IDC | positive | positive | not evaluated | NA | NA | dead | 4.58 | LumA | European | TCGA.BH.A1FL.01A.11R.A13Q.07 |
| TCGA-BH-A1FU | 44 | female | White | Primary solid Tumor | not available | IDC | negative | negative | not evaluated | NA | NA | dead | 4.62 | Normal | European | TCGA.BH.A1FU.01A.11R.A14D.07 |
| TCGA-BH-A1FU | 44 | female | White | Solid Tissue Normal | not available | IDC | negative | negative | not evaluated | NA | NA | dead | 4.62 | Normal | European | TCGA.BH.A1FU.11A.23R.A14D.07 |
| TCGA-BH-A18Q | 56 | female | White | Primary solid Tumor | not available | IDC | negative | negative | positive | NA | NA | dead | 4.63 | Basal | European | TCGA.BH.A18Q.01A.12R.A12D.07 |
| TCGA-BH-A18Q | 56 | female | White | Solid Tissue Normal | not available | IDC | negative | negative | positive | NA | NA | dead | 4.63 | Basal | European | TCGA.BH.A18Q.11A.34R.A12D.07 |
| TCGA-BH-A1EW | 38 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | NA | NA | dead | 4.64 | LumA | European | TCGA.BH.A1EW.01A.11R.A137.07 |
| TCGA-BH-A1EW | 38 | female | White | Solid Tissue Normal | premenopausal | IDC | negative | negative | negative | NA | NA | dead | 4.64 | LumA | European | TCGA.BH.A1EW.11B.33R.A137.07 |
| TCGA-AR-A0TY | 54 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | negative | negative | metastasis | bone | dead | 4.65 | LumB | European | TCGA.AR.A0TY.01A.12R.A115.07 |
| TCGA-BH-A208 | 48 | female | White | Primary solid Tumor | not available | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 4.82 | Normal | European | TCGA.BH.A208.01A.11R.A157.07 |
| TCGA-BH-A208 | 48 | female | White | Solid Tissue Normal | not available | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 4.82 | Normal | European | TCGA.BH.A208.11A.51R.A157.07 |
| TCGA-B6-A0X7 | 62 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | not evaluated | new primary | colon | dead | 4.88 | NA | European | TCGA.B6.A0X7.01A.11R.A10J.07 |
| TCGA-AO-A03U | 31 | female | White | Primary solid Tumor | premenopausal | secretory | negative | negative | negative | NA | NA | dead | 4.91 | NA | European | TCGA.AO.A03U.01B.21R.A10J.07 |
| TCGA-GM-A2D9 | 69 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | metastasis | bone>lymph node|lung | dead | 4.96 | LumA | European | TCGA.GM.A2D9.01A.11R.A18M.07 |
| TCGA-BH-A1FJ | 66 | female | White | Primary solid Tumor | not available | IDC | negative | positive | not evaluated | NA | NA | dead | 5.28 | LumB | European | TCGA.BH.A1FJ.01A.11R.A13Q.07 |
| TCGA-BH-A1FJ | 66 | female | White | Solid Tissue Normal | not available | IDC | negative | positive | not evaluated | NA | NA | dead | 5.28 | LumB | European | TCGA.BH.A1FJ.11B.42R.A13Q.07 |
| TCGA-B6-A0IE | 38 | female | Black or African American | Primary solid Tumor | premenopausal | IDC/ILC | negative | negative | not evaluated | metastasis | bone | dead | 5.46 | NA | African_admix | TCGA.B6.A0IE.01A.11R.A034.07 |
| TCGA-BH-A18S | 79 | female | White | Primary solid Tumor | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | dead | 5.5 | NA | European | TCGA.BH.A18S.01A.11R.A12D.07 |
| TCGA-BH-A18S | 79 | female | White | Solid Tissue Normal | postmenopausal | mucinous carcinoma | positive | positive | negative | NA | NA | dead | 5.5 | NA | European | TCGA.BH.A18S.11A.43R.A12D.07 |
| TCGA-B6-A0X5 | 61 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | metastasis | bone|liver|pleura | dead | 5.74 | LumB | African_admix | TCGA.B6.A0X5.01A.21R.A109.07 |
| TCGA-BH-A1EN | 78 | female | White | Primary solid Tumor | postmenopausal | IDC | negative | negative | positive | NA | NA | dead | 5.82 | Her2 | European | TCGA.BH.A1EN.01A.11R.A13Q.07 |
| TCGA-BH-A1EN | 78 | female | White | Solid Tissue Normal | postmenopausal | IDC | negative | negative | positive | NA | NA | dead | 5.82 | Her2 | European | TCGA.BH.A1EN.11A.23R.A13Q.07 |
| TCGA-BH-A1FN | 34 | female | White | Primary solid Tumor | not available | IDC | positive | positive | not evaluated | NA | NA | dead | 6.0 | LumB | European | TCGA.BH.A1FN.01A.11R.A13Q.07 |
| TCGA-BH-A1FN | 34 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | not evaluated | NA | NA | dead | 6.0 | LumB | European | TCGA.BH.A1FN.11A.34R.A13Q.07 |
| TCGA-BH-A18M | 39 | female | White | Primary solid Tumor | not available | IDC | positive | positive | positive | NA | NA | dead | 6.04 | LumA | European | TCGA.BH.A18M.01A.11R.A12D.07 |
| TCGA-BH-A18M | 39 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | positive | NA | NA | dead | 6.04 | LumA | European | TCGA.BH.A18M.11A.33R.A12D.07 |
| TCGA-BH-A1FE | 31 | female | White | Primary solid Tumor | not available | IDC | positive | positive | not evaluated | NA | NA | dead | 6.22 | LumA | European | TCGA.BH.A1FE.01A.11R.A13Q.07 |
| TCGA-BH-A1FE | 31 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | not evaluated | NA | NA | dead | 6.22 | LumA | European | TCGA.BH.A1FE.11B.14R.A13Q.07 |
| TCGA-B6-A0I1 | 73 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | negative | negative | not evaluated | metastasis | lung | dead | 6.46 | Basal | African_admix | TCGA.B6.A0I1.01A.11R.A21T.07 |
| TCGA-B6-A0RM | 57 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | NA | NA | dead | 6.5 | LumA | African_admix | TCGA.B6.A0RM.01A.11R.A084.07 |
| TCGA-B6-A0WV | 67 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | not evaluated | NA | NA | dead | 6.62 | LumB | European | TCGA.B6.A0WV.01A.11R.A109.07 |
| TCGA-B6-A0RL | 60 | female | Black or African American | Primary solid Tumor | not available | IDC | positive | positive | not evaluated | NA | NA | dead | 6.76 | LumB | African | TCGA.B6.A0RL.01A.11R.A084.07 |
| TCGA-AO-A03O | 69 | female | Black or African American | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 6.8 | LumB | African_admix | TCGA.AO.A03O.01A.11R.A00Z.07 |
| TCGA-BH-A1ET | 55 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | dead | 6.9 | LumA | European | TCGA.BH.A1ET.01A.11R.A137.07 |
| TCGA-BH-A1ET | 55 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | NA | NA | dead | 6.9 | LumA | European | TCGA.BH.A1ET.11B.23R.A137.07 |
| TCGA-BH-A204 | 80 | female | White | Primary solid Tumor | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 6.94 | LumB | European | TCGA.BH.A204.01A.11R.A157.07 |
| TCGA-BH-A204 | 80 | female | White | Solid Tissue Normal | postmenopausal | IDC | not evaluated | not evaluated | not evaluated | NA | NA | dead | 6.94 | LumB | European | TCGA.BH.A204.11A.53R.A157.07 |
| TCGA-AR-A0U2 | 47 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | metastasis | bone|liver | dead | 6.98 | LumB | European | TCGA.AR.A0U2.01A.11R.A109.07 |
| TCGA-B6-A0IN | 45 | female | White | Primary solid Tumor | indeterminate | IDC with mucinous features | positive | negative | not evaluated | metastasis | bone|brain | dead | 7.04 | NA | European | TCGA.B6.A0IN.01A.11R.A034.07 |
| TCGA-BH-A1F5 | 62 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | dead | 7.43 | NA | European | TCGA.BH.A1F5.01A.12R.A13Q.07 |
| TCGA-BH-A18K | 46 | female | White | Primary solid Tumor | not available | IDC | positive | positive | negative | NA | NA | dead | 7.56 | LumA | European | TCGA.BH.A18K.01A.11R.A12D.07 |
| TCGA-BH-A18K | 46 | female | White | Solid Tissue Normal | not available | IDC | positive | positive | negative | NA | NA | dead | 7.56 | LumA | European | TCGA.BH.A18K.11A.13R.A12D.07 |
| TCGA-BH-A1EO | 68 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC features | positive | positive | negative | NA | NA | dead | 7.66 | NA | European | TCGA.BH.A1EO.01A.11R.A137.07 |
| TCGA-BH-A1EO | 68 | female | White | Solid Tissue Normal | postmenopausal | IDC/ILC features | positive | positive | negative | NA | NA | dead | 7.66 | NA | European | TCGA.BH.A1EO.11A.31R.A137.07 |
| TCGA-AR-A256 | 45 | female | White | Primary solid Tumor | premenopausal | IDC | negative | negative | negative | locoregional disease | NA | dead | 7.81 | Basal | European | TCGA.AR.A256.01A.11R.A169.07 |
| TCGA-B6-A0IH | 81 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | dead | 8.12 | LumA | European | TCGA.B6.A0IH.01A.11R.A115.07 |
| TCGA-B6-A0WS | 58 | female | Black or African American | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | NA | NA | dead | 8.12 | LumA | African_admix | TCGA.B6.A0WS.01A.11R.A115.07 |
| TCGA-BH-A1F6 | 51 | female | White | Primary solid Tumor | not available | IDC | negative | negative | negative | NA | NA | dead | 8.12 | Basal | European | TCGA.BH.A1F6.01A.11R.A13Q.07 |
| TCGA-BH-A1F6 | 51 | female | White | Solid Tissue Normal | not available | IDC | negative | negative | negative | NA | NA | dead | 8.12 | Basal | European | TCGA.BH.A1F6.11B.94R.A13Q.07 |
| TCGA-B6-A0RS | 38 | female | White | Primary solid Tumor | indeterminate | IDC | negative | negative | not evaluated | new primary | contralateral | dead | 8.39 | Her2 | European | TCGA.B6.A0RS.01A.11R.A084.07 |
| TCGA-B6-A0RP | 73 | female | White | Primary solid Tumor | postmenopausal | IDC/ILC | positive | positive | not evaluated | metastasis | bone | dead | 8.56 | NA | European | TCGA.B6.A0RP.01A.21R.A084.07 |
| TCGA-B6-A0WY | 40 | female | White | Primary solid Tumor | premenopausal | IDC | positive | negative | not evaluated | metastasis | bone | dead | 9.48 | LumA | European | TCGA.B6.A0WY.01A.11R.A109.07 |
| TCGA-BH-A1ES | 35 | female | White | Primary solid Tumor | premenopausal | IDC | positive | positive | negative | NA | NA | dead | 9.48 | NA | European | TCGA.BH.A1ES.01A.11R.A137.07 |
| TCGA-BH-A1FC | 78 | female | Black or African American | Primary solid Tumor | postmenopausal | medullary carcinoma | negative | negative | negative | NA | NA | dead | 9.51 | Basal | African | TCGA.BH.A1FC.01A.11R.A13Q.07 |
| TCGA-BH-A1FC | 78 | female | Black or African American | Solid Tissue Normal | postmenopausal | medullary carcinoma | negative | negative | negative | NA | NA | dead | 9.51 | Basal | African | TCGA.BH.A1FC.11A.32R.A13Q.07 |
| TCGA-BH-A1FB | 60 | female | White | Primary solid Tumor | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 10.05 | NA | European | TCGA.BH.A1FB.01A.11R.A13Q.07 |
| TCGA-BH-A1FB | 60 | female | White | Solid Tissue Normal | postmenopausal | IDC | positive | positive | negative | NA | NA | dead | 10.05 | NA | European | TCGA.BH.A1FB.11A.33R.A13Q.07 |
| TCGA-B6-A0IB | 64 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | metastasis | skin>lung|bone|liver | dead | 10.79 | LumB | European | TCGA.B6.A0IB.01A.11R.A034.07 |
| TCGA-B6-A0X0 | 54 | female | White | Primary solid Tumor | indeterminate | cribiform | positive | positive | not evaluated | NA | NA | dead | 10.8 | NA | European | TCGA.B6.A0X0.01A.21R.A115.07 |
| TCGA-BH-A209 | 77 | female | Black or African American | Primary solid Tumor | postmenopausal | medullary carcinoma | positive | positive | not evaluated | NA | NA | dead | 10.84 | LumB | African | TCGA.BH.A209.01A.11R.A157.07 |
| TCGA-BH-A209 | 77 | female | Black or African American | Solid Tissue Normal | postmenopausal | medullary carcinoma | positive | positive | not evaluated | NA | NA | dead | 10.84 | LumB | African | TCGA.BH.A209.11A.42R.A157.07 |
| TCGA-B6-A0RQ | 68 | female | White | Primary solid Tumor | postmenopausal | ILC | positive | positive | not evaluated | NA | NA | dead | 11.68 | Normal | European | TCGA.B6.A0RQ.01A.11R.A115.07 |
| TCGA-B6-A0IG | 50 | female | White | Primary solid Tumor | indeterminate | IDC | positive | positive | not evaluated | NA | NA | dead | 12.2 | LumA | European | TCGA.B6.A0IG.01A.11R.A034.07 |